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A relationship between latent viral infections and drug hypersensitivity reactions (HSR) has 
been observed in several clinical situations. Abacavir hypersensitivity has been shown by 
several groups to be an HLA-B*57:01 restricted CD8+ T cell dependent process. Although 
compelling evidence suggests that carriage of HLA-B*57:01 is necessary, it is not sufficient 
for abacavir hypersensitivity. Based on previous structural and functional studies, it was 
hypothesised that heterologous immune responses of the pre-existing anti-viral T cell responses 
mediate abacavir hypersensitivity. Human herpesviruses (HHV) have been posited to be 
associated with the development of HSR because they have co-evolved with the human major 
histocompatibility complex and they persist in most people as lifelong latent, asymptomatic 
infections. In addition, they are reactivated in immunocompromised individuals and have been 
implicated in drug-viral interactions such as associated with Epstein-Barr virus (EBV). EBV is 
the most common HHV infecting more than 95% of the world’s population. The EBV genome 
is approximately 172 kb in length and encodes 89 proteins. However, the extent to which these 
proteins are surveyed by host-derived T cells has not been fully explored. The objective of this 
body of work was to generate ORFeome-wide map of memory CD8+ T cell responses for the 
identification of HLA-B*57:01 restricted antigens which could be involved in the cross-
reactivity of abacavir drug hypersensitivity. Mapping revealed 14 novel HLA-B*57:01 
restricted EBV antigens and confirmed the previously identified epitopes EBNA3B 
(VSFIEFVGW), EBNA2 (LASAMRML), and LMP1 (IALYLQQNW). A novel 
immunodominant epitope was detected in EBNA3C (QSRGDENRGW). To identify cross-
reactive anti-viral T cell receptors, single cells specific for the immunodominant epitopes of 
EBNA3B (VSF) and EBNA3C (QSR) were sorted based on tetramer staining. Antigen-specific 
T cells were sequenced for the T cell receptors cloned into Jurkat cells. A modified 
heterologous T cell receptor reporter assay was developed to study the T cell responses against 
HLA-B*57:01 restricted EBV immunodominant epitopes. Dose-dependent T cell responses 
were detected against each EBV epitope, however, the TCRs were not cross-reactive to 
abacavir plus self-peptide presented in the context of HLA-B*57:01. The presence of abacavir 
was shown to modulate the EBV-specific TCR responses to the two EBV epitopes, which suggested 
the non-covalent binding of abacavir to HLA-B*57:01 may have down modulated the TCR responses. 
Although unable to demonstrate cross-reactivity of the EBV-specific TCRs with the abacavir plus 
self-peptide, this work has provided a road map for future experiments to elucidate the role of 
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heterologous immunity in the immunopathogenesis of drug hypersensitivity and other aberrant 
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1.1 Human herpesviruses (Family: Herpesviridae) 
The Herpesviridae is a large family of double-stranded DNA viruses that cause infections in a 
wide range of hosts including humans. Although more than 100 known herpesviruses exist, 
eight members of the family commonly infect humans, and nearly 100% of the adult population 
is infected with at least one of these viruses (Grinde, 2013). The eight members include herpes 
simplex virus types 1 and 2 (HSV1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), 
human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), Epstein-Barr virus (EBV), and 
Kaposi's sarcoma-associated herpesvirus (KSHV). All herpesviruses are ubiquitous and remain 
latent for lifelong in their hosts.  
Human herpesviruses are subdivided into three subfamilies: alpha-, beta-, and gamma-
herpesviruses. Alpha herpesviruses include HSV1, HSV2 and VZV. They mainly target 
neurons for long-term latency, but they can also replicate in mucoepithelia (Grinde, 2013). Beta 
herpesviruses have the largest genome among herpesviruses and include CMV, HHV6, and 
HHV7. They prefer monocytes and lymphocytes for long term latency, but most of them can 
also infect epithelial cells (Grinde, 2013). Gamma herpesviruses include EBV, also called 
HHV4, and KSHV. The gamma herpesvirus subfamily is further divided into 
lymphocryptovirus and rhadinoviruses. The EBV is a member of the lymphocryptovirus genus. 
An overview of the key features of human herpesviruses is shown in Table 1.1.
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Table 1.1. Key features of the herpesviruses that infect humans 
Source of the table from (Grinde, 2013). 
Subfamily Common Name Another name Primary target cells Latency sites 
Alpha 
Herpes simplex virus type 1 Human herpesvirus 1 Mucoepithelia Sensory and cranial nerve ganglia 
Herpes simplex virus type 2 Human herpesvirus 2 Mucoepithelia Sensory and cranial nerve ganglia 
Varicella-zoster virus Human herpesvirus 3 Mucoepithelia Sensory and cranial nerve ganglia 
Beta 
Cytomegalovirus Human herpesvirus 5 Monocytes, lymphocytes and epithelia Monocytes, lymphocytes 
Human herpesvirus 6   T cells Various leukocytes 
Human herpesvirus 7   T cells T cells, epithelia 
Gamma 
Epstein-Barr virus Human herpesvirus 4 Epithelia and B cells Memory B cells 
Kaposi sarcoma-associated herpesvirus Human herpesvirus 8 Probably lymphocytes and epithelia B cells 
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1.2 Epstein-Barr virus 
In 1958, Denis Burkitt first reported a specific type of jaw cancer affecting young children in 
East Africa (Burkitt, 1958), later named after him as Burkitt’s lymphoma (BL). In 1964, EBV 
was isolated and documented by Epstein, Achong and Barr from the cell lines derived from 
Burkitt lymphoma (Epstein et al., 1964). However, the mere presence of the intact virus alone 
was not enough to conclude that it was involved in the pathogenesis of BL. Later, Werner and 
Gertrude Henle demonstrated that cocultivation of irradiated BL cells with healthy control 
peripheral leukocytes could lead to the outgrowth of the cell line (Henle, 1968; Henle et al., 
1967). Since its discovery, EBV has been implicated in the development of several human non-
malignant and malignant diseases of both lymphoid (Burkitt's lymphoma, Hodgkin's disease, 
post-transplantation/human immunodeficiency virus-associated lymphoproliferative disease, 
and some T cell lymphomas) and epithelial origin (nasopharyngeal carcinoma and gastric 
carcinoma) (Young and Rickinson, 2004). 
Currently, two major types of EBV have been described; EBV type 1 (EBV-1) and EBV type 
2 (EBV-2). EBV-1 and EBV-2 vary in the gene sequences that code for the EBV nuclear 
antigens (EBNA-2, EBNA-3A, EBNA-3B, and EBNA-3C) (Sample et al., 1990). The two 
EBV types are widely distributed and differ in the transformation efficiency of B lymphocytes 
in vitro, EBV-1 immortalizes B lymphocytes more efficiently than EBV-2. This difference in 
the growth transformation of the EBV subtypes may relate to differential gene regulation by 
type 1 and type 2 EBNA-2 (Lucchesi et al., 2008). Besides type-specific variation, DNA 
sequence heterogeneity was observed in EBV genomes isolated from different geographic 
regions or even from the same region (Correia et al., 2018; Palser et al., 2015). These variations 
define different viral strains within EBV-1 and EBV-2 types. 
 
1.3 EBV structure and genome 
Like other herpesviruses, a mature EBV virion has a protein nucleocapsid with icosahedral 
symmetry that contains the viral genome. The capsid is surrounded by tegument, composed of 
globular proteins, which in turn is surrounded by an envelope containing both lipids and surface 
glycoproteins projections (Epstein et al., 1965). The EBV genome was sequenced first from 
the infectious mononucleosis-derived B95-8 strain, cloned as a BamHI fragment library (Baer 
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et al., 1984); (Accession number V01555). This prototype B95-8 strain is different from many 
isolates as it is missing an 11.8 kb fragment of the genome. Hence, to present a sequence that 
would represent the majority of the isolates, an 11.8 kb sequence derived from Raji strain of 
EBV (Parker et al., 1990) has been inserted into the B95-8 sequence (accession number 
NC_007605).  
The EBV genome is composed of linear double-stranded DNA (dsDNA) of about 172 kilobase 
pairs (kb) in length, encoding 43 “core” genes, which are common to all herpesviruses and 46 
“noncore” genes (Calderwood et al., 2007). The physical genome map of EBV was shown in 





Figure 1.1. Genetic map of EBV 
All ORFs in the genome have been marked, and the orientation of the arrows shows their 




1.4 EBV lifecycle 
In general, EBV is transmitted from the carrier through the saliva containing infectious virions 
and enters the host via the oropharynx region. The virus can also be spread by blood or through 
transplanted allogeneic hematopoietic cells or solid donor organs (Nijland et al., 2015). B cells 
are the main targets of EBV infection, mainly because of their complement receptor 2 (CR2; 
also known as CD21) expression, which interacts with the major EBV glycoprotein gp350. 
EBV can also infect epithelial cells directly or by transfer infection from infected B cells 
(Shannon-Lowe and Rowe, 2011). This leads to initiation of the lytic replication, making viral 
progeny that spreads cell to cell and allows the transmission to new hosts. In the new host, 
EBV replicates in the epithelial cells and disseminates to naïve B cells. Infected B cells 
proliferate into latently infected blasting B cells, expressing all latency associated EBV 
proteins. Although many of the infected proliferating cells are cleared by immune responses, 
some of the EBV infected B cells differentiate into memory B cells, the long-term reservoir of 
EBV and the expression of latent EBV proteins are continually reduced finally reaching a 
quiescent stage where no EBV proteins are expressed (Latency 0). Intermittently, a small subset 
of latently infected memory B cells may become reactivated from latency to lytic replication 
through physiologic events, such as antigen stimulation and receipt of a plasma cell 
differentiation signal mechanisms (Hislop et al., 2007b). The life cycle of EBV was 




Figure 1.2. The lifecycle of Epstein-Barr virus (EBV)  
The primary mode of transmission of EBV from the carrier is through saliva and invades the 
host via the oropharynx and infects B cells. The infected B cells proliferate and spread through 
the B cell compartment. The B cell proliferation is mostly controlled by the EBV-specific 
cytotoxic T cells, and some EBV-infected B cells with limited antigen presentation constitute 
the long-term viral reservoir. Intermittently, a subset of resting B cells may lead to the 
reactivation of the virus releasing infectious virions that may be amplified through infection of 
the epithelium and ultimately infecting new naïve B cells. Figure from (Odumade et al., 2011).
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Like all herpesviruses, latent and lytic cycles are two distinct stages in the EBV life cycle. 
During the latent phase, EBV expresses a limited set of viral gene products, which are involved 
in stimulating EBV infected B cell proliferation, inhibiting viral lytic replication, affecting 
apoptosis, and maintenance of the EBV genome (Kieff, 2001; Rickinson and Kieff., 2001). 
However, during the lytic phase of EBV, many viral gene products that are involved in the 
replication of viral DNA and viral particle synthesis are expressed. 
 
1.4.1 Latent cycle 
EBV-immortalised B lymphoblasts express nine EBV encoded latent antigens, including six 
nuclear antigens (EBNA 1–6), three latent membrane proteins (LMP1, 2A and 2B), two non-
coding RNAs (EBERs) and non-translated viral miRNAs. Based on the differential expression 
of the latent genes in infected B cells, the latent phase is divided into three stages, including 
latency I-III (Rowe et al., 1992). After infection, the resting naïve B cell enters latency III with 
the expression of EBNA1, EBNA2, EBNA3 (A-C), EBNA-LP, LMP1, and LMP2. Later, the 
virus limits its gene expression and enters latency II with the expression of EBNA1 and LMP1. 
Finally, EBV restricts gene expression more and enters latency I with the expression of EBNA1 
only. The fourth form of latency known as latency 0 has been described in quiescent memory 
B cells, where no EBV genes are expressed, with the possible exception of LMP2 (Babcock et 
al., 2000). 
EBNA1 is the only EBV protein that is expressed in three types of latency stages (I, II and III) 
and lytic modes of EBV infection. It is required for the efficient transformation of primary B 
cells and persistence of EBV genomes (Frappier, 2012). EBNA2 is one of the first viral genes 
expressed after EBV infection of B cells and is required for cell transformation. EBNA2 is a 
transcriptional activator of viral genes including LMP1 and LMP2 (Abbot et al., 1990), and 
also of certain cellular genes such as CD23 and CD21 that are B cell activation antigens 
(Cordier et al., 1990). EBNA2 sequence diverges more extensively between type1 and type 2 
strains of EBV. EBNA3 is a family of 3 latency associated proteins including EBNA3A, 3B 
and 3C, also known as EBNA3, 4 and 6 that are encoded by three adjacent genes on the genome 
and have similar exon structure. EBNA3A and 3C are essential for B cell growth 
transformation and maintenance in vitro (Tomkinson et al., 1993). EBNA5, also known as 
EBNA-LP, is one of the first detectable virus-encoded proteins along with EBNA2 (Alfieri et 
al., 1991). The EBNA5 protein contains multiple copies of a 66 amino acid repeat domain. This 
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protein is essential for the recruitment of viral transcription factors and for the survival of EBV-
infected naïve B cells (Szymula et al., 2018).  
LMP1 is a key oncogene essential for B cell transformation and is associated with EBV-related 
malignancies. LMP1 is an integral membrane protein that behaves like a constitutively 
activated member of the tumour necrosis factor receptor family, activating several signalling 
pathways in a ligand-independent manner (Gires et al., 1997). LMP2A is a functional 
homologue of B cell receptor (BCR) that can provide a survival signal for the EBV-infected B 
cells and also regulates the lytic cycle (Schaadt et al., 2005). The exact function of LMP2B is 
not known, although it has been reported that it can regulate the activity of LMP2A (Rovedo 
and Longnecker, 2007).  
EBV encoded non-coding RNAs, EBER1 and EBER2, play a role in EBV mediated B cell 
transformation and are used as markers for the detection of EBV. EBV encodes 44 mature 
microRNAs in two gene clusters, BHRF1 (miR-BHRF1) and BART (miR-BART) (Navari et 
al., 2018). miR-BHRF1 is expressed during latency III, and miR-BART is expressed during 
the latency types I and II, with decreased or no expression in latency type III (Navari et al., 
2018). 
 
1.4.2 Lytic cycle 
During latent infection, a constant copy number of the genome is maintained, and only a limited 
number of genes are expressed. However, in the lytic cycle, viral DNA is amplified, and a 
variety of lytic genes are expressed prior to virion maturation (Khanna et al., 1995). Almost 80 
lytic genes that are involved in viral DNA replication and viral protein synthesis are expressed. 
Lytic proteins are grouped into immediate early (IE), early (E) and late antigens (L). The latent 
to the lytic transition is activated by expression of two immediate-early proteins, BZLF1 and 
BRLF1. Both BZLF1 and BRLF1 serve as transcriptional activators and initiate early lytic gene 
expression. BZLF1 is a master regulator of the transition from latent to lytic replication, while 
the BRLF1 gene product accelerates the expression of the BZLF1 gene (Feederle et al., 2000; 
Ragoczy et al., 1998). 
In addition to the two IE proteins, two EBV early proteins – BMLF1 and BMRF1, transactivate 
other E genes. EBV late antigens encode the structural components that are required for 
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successful packaging of viral DNA into virions. They include the viral capsid antigen (BNRF1) 
and the membrane antigen complex containing three major EBV-induced glycoproteins, gp350 
(BLLF1), gp110 (BALF4) and gp85 (BXLF2) (Khanna et al., 1995). 
 
1.5 EBV-associated diseases 
EBV is a highly prevalent virus infecting more than 95% of the population around the world. 
Primary infection with EBV during early childhood is largely asymptomatic or cause 
nonspecific symptoms, whereas infection of adolescents may lead to infectious mononucleosis 
(IM). Despite this typically benign nature, the virus is linked to multiple malignancies 
including; Burkitt’s lymphoma (BL), Hodgkin’s lymphoma (HL), post-transplant 
lymphoproliferative disorder (PTLD), T cell and natural killer (NK) cell lymphomas, 
lymphoepithelioma-like gastric carcinomas and nasopharyngeal carcinoma (NPC).  
In healthy people, EBV is controlled by strong immunological responses to EBV, specifically 
mediated by T cells, and the virus-induced malignancies are comparatively sporadic. However, 
immunocompromised individuals or whose immunological responses are greatly suppressed 
show a rising frequency of EBV-associated malignancies and these malignancies can be 
controlled by the restoration of the T cell compartment in at least some cases (Hislop and 
Taylor, 2015). 
 
1.6 Immune evasion 
Viruses have developed various strategies that enable them to evade immunity during acute or 
chronic infection. Similarly, to avoid the host’s immune defence, EBV has acquired numerous 
immune evasion mechanisms. EBV evasion programs are mainly classified into three groups, 
those that control: 1) immune cell function, 2) antigen presentation pathways or 3) apoptotic 
pathways (Hatton et al., 2014). During EBV infection, EBV modulates immune cell function 
by inhibiting the production of IFN-γ, IL-2 and IL-6 by CD4+ T cells through the lytic cycle 
protein BCRF1 (Jochum et al., 2012). Another lytic protein of EBV, BARF1 indirectly inhibits 
the production of the IFN-α by mononuclear cells through binding to colony stimulating factor 
(CSF-1) receptor and reducing the effect of CSF-1 on the proliferation of macrophages (Cohen 
and Lekstrom, 1999). 
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EBV express a variety of proteins that target antigen processing and presentation. EBNA1, a 
latent protein contains a glycine-alanine repeat that inhibits its own proteasomal degradation 
and presentation by HLA class I (Blake et al., 1997; Tellam et al., 2004; Voo et al., 2004; Yin 
et al., 2003). Another EBV protein, BNLF2a interferes with antigen presentation by targeting 
the transporter associated with antigen processing (TAP) complex (Croft et al., 2009; Hislop 
et al., 2007a; Horst et al., 2011). EBV-encoded BGLF5, an exonuclease blocks the synthesis 
of cellular proteins including those for HLA molecules (Rowe et al., 2007; Zuo et al., 2008); 
and BILF1, downregulates the cell surface expression of HLA class I molecules by binding to 
the molecule and internalising them for lysosomal degradation (Zuo et al., 2009; Zuo et al., 
2011). 
EBV has developed several strategies to prevent apoptosis of the infected cell and to enhance 
viral persistence (Hatton et al., 2014). EBV encodes two anti-apoptotic viral Bcl-2 homolog 
proteins, BHRF1 and BALF1, which are expressed during the early stages of infection and 
during lytic replication. These proteins can block apoptosis by binding to the pro-apoptotic 
Bim protein (Altmann and Hammerschmidt, 2005; Desbien et al., 2009; Henderson et al., 1993; 
Marshall et al., 1999). Similarly, LMP1, a functional homologue of CD40 (Rastelli et al., 
2008), can promote cell growth and prevents apoptosis in collaboration with LMP2A, which 
mimics BCR signalling, to infected B cells that would otherwise undergo programmed cell 
death in the absence of antigen-specific stimulation (Mancao and Hammerschmidt, 2007). 
EBV-encoded microRNAs (miRNAs), act as immune modulators by interfering with the 
expression of host miRNAs and viral genes (LMP1 and LMP2A) (Lo et al., 2007; Lung et al., 
2009). In addition, non-coding EBV encoded RNAs (EBER) confer resistance to IFN-α 
induced apoptosis by binding to protein kinase R and inhibiting its phosphorylation, which 
facilitates the transformation of B cells (Nanbo et al., 2002). These are the various immune 
evasion strategies employed by EBV to modulate host immune responses and to ensure its 
survival within the host. 
 
1.7 Immune responses to EBV 
EBV can establish either latent or lytic infection in cells, and the replication cycle oscillates 
between the two phases. EBV latent infection occurs in infected B cells within lymphoid tissue, 
while lytic replication occurs in epithelial cells of the oropharynx. These differential cellular 
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backgrounds and anatomical locations influence the functional and antigen-specific responses 
of viral-specific T cells (Hislop and Taylor, 2015). 
 
1.7.1 CD8+ T cell responses during primary infection 
Although primary infection with EBV is typically acquired asymptomatically in childhood, 
when delayed until adolescence it may lead to the clinical disease infectious mononucleosis 
(IM), which is characterised clinically by fever, pharyngitis, lymphadenopathy and 
sometimes hepatosplenomegaly. In the peripheral blood, atypical lymophocytosis is present, 
and there is a large expansion of activated EBV-specific CD8+ T cells (Callan et al., 1996). 
Studies based on HLA class I tetramer staining mapped the most abundant primary responses 
to peptides derived from EBV lytic cycle proteins, with vastly reduced responses directed 
against latent protein epitopes (Callan et al., 1998; Hislop et al., 2002). CD8+ T cell responses 
are skewed toward epitopes derived from the immediate early (IE) gene products, with lesser 
but substantial frequencies to some early (E) gene products and with only occasional 
responses to late (L) gene products, displaying the hierarchy of immunodominace among 
lytic proteins (Pudney et al., 2005). The responses to individual lytic epitopes responses can 
account between 1%-50% of the total CD8+ T cell population in the peripheral circulation 
(Hislop et al., 2005). Compared to lytic epitope-specific T cells, latent antigen-specific 
responses represent from 0.1 to 5 % of the peripheral CD8+ T cell population (Hislop et al., 
2007b). 
 
1.7.2 CD8+ T cell responses in established infection 
Although immune responses measured during IM provide a guide to EBV-specific T cells 
responses, it does not typify most infections, which are asymptomatic. In healthy donors, CD8+ 
T cell responses directed toward lytic antigens account for 0.2%-2% of the CD8+ population, 
while latent antigens account for 0.05%-1% of the CD8+ population (Hislop et al., 2007b). 
Similar to IM patients, the EBV lytic antigens displayed a hierarchy of immunodominance, in 
the order IE > E ≫ L. CD8+ responses to latent antigens were mostly made to EBNA3 family 
of proteins and to a lesser extent LMP2, EBNA1 and EBNA2, whereas sporadic responses 
were detected against EBNA-LP and LMP1 (Khanna et al., 1992; Murray et al., 1992).  
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In most of the healthy carriers, the memory T cell pool specific for EBV epitopes is highly 
stable with occasional fluctuations of virus specific CD8+ T cells, suggesting subclinical 
reactivation (Crough et al., 2005). However, there is evidence for an age-related disruption of 
this balance of CD8+ T cell pool. In older healthy individuals over 60 years of age, elevated 
virus loads and CD8+ T cell responses accounting up to 14% of the total CD8+ T cell 
population have been observed (Hislop et al., 2007b). Remarkably, these inflated responses 
in elderly donors depend upon the donor’s CMV serological status. In individuals carrying 
both EBV and CMV, dramatic expansions of CMV-specific CD8+ T cells are seen, but EBV-
specific responses are stable. This suggests the presence of one virus-specific population may 
suppress immunity to another virus during aging (Khan et al., 2004). 
 
1.7.3 CD8+ T cell responses in patients with EBV-associated 
malignancies 
EBV-specific cytotoxic T cell responses are required to control EBV mediated growth 
transformation of B cells for the lifetime of the host. However, loss of immune responses in 
immunosuppressed individuals results in malignancies of B cell origin lymphomas such as 
Hodgkin lymphoma, Burkitt lymphoma and diffuse large B cell lymphoma and some cases 
of non-B cell origin such as extranodal NK/T cell lymphoma. EBV is also linked to tumours 
of epithelial origin such as nasopharyngeal carcinoma and gastric carcinomas (Hislop and 
Taylor, 2015).  
EBV-associated malignancies include expression of distinct patterns of EBV antigens (Table 
1.2). In Burkitt lymphoma cells, only EBNA1 latent antigen is expressed. However, in these 
patients, EBV evades the immune responses by preventing proteasome-dependent processing 
of EBNA1 for MHC class I presentation. Studies have shown that EBNA1 is not presented to 
CD8+ because of its internal glycine-alanine repeat domain that blocks antigen processing 
(Levitskaya et al., 1995; Tellam et al., 2004). In NPC and HL, the tumours express LMP1 and 
LMP2, as well as EBNA1 proteins. In contrast to BL, NPC cells display normal antigen 
processing of EBV proteins, and the peptides are efficiently recognized by HLA class I 
restricted, EBV-specific CTLs (Khanna et al., 1998). 
Many studies have reported a link between human leukocyte antigen (HLA) polymorphism 
and the risk of developing different EBV-associated malignancies. For Hodgkin lymphoma, 
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individuals carrying HLA-A*01 are more susceptible to developing EBV+ HL, while those 
carrying HLA-A*02 have a reduced risk of developing EBV+ HL (Niens et al., 2007). 
Similarly, for NPC, HLA-A*02:07 is a risk allele, whereas HLA-A*11:01 is a protective allele 
(Su et al., 2013). The HLA-A*02:07 subtype is very common in the Chinese population and is 
associated with increased risk of the disease (Huang et al., 2012). Much less is known about 
the EBV-specific immune response in patients with other EBV malignancies.
31 
 
Table 1.2. Overview of EBV-associated malignancies and EBV antigens expressed 









EBNA1 Sporadic 15-85 
AIDS-related 30–40 
T/NK Lymphoma Extranodal  100 EBNA1, LMP2B 
Diffuse large B cell 
lymphoma (DLBCL) 
Late PT-DLBCL >50 
EBNA1, LMP1, 
LMP2 
Elderly DLBCL >50 
AIDS-related ~50 
Hodgkin lymphoma 
Classical 30 EBNA1, LMP1, 
LMP2 AIDS-related 100 
PTLD-like lymphoma 









Non-keratinizing 100 EBNA1, LMP1, 
LMP2 Keratinizing 30-100 
Gastric carcinoma 








1.8 Role of viral infections in drug allergy 
Several clinical observations have indicated a relationship between viral infections and the 
development of allergic drug symptoms. For example, ampicillin-induced exanthema in 
patients with EBV-associated IM (Coskey and Paul, 1969). Although exanthematous eruptions 
in mononucleosis patients are relatively uncommon (rate: 10%), once treated with antibiotics 
such as ampicillin, an extensive maculopapular rash can develop in the second week after the 
administration of the drug (100% of children, 70% of adults) (Michels and Ostrov, 2015). 
Similarly, the occurrence of co-trimoxazole-induced adverse drug reactions is high in HIV 
seropositive patients, whereas, in the general population, the reactions are rare (Michels and 
Ostrov, 2015).  
Some studies provided evidence to indicate a strong relationship between the reactivation of 
herpesviruses and the development of adverse responses to certain drugs. The well-known 
example is drug-induced hypersensitivity syndrome (DIHS)/ drug reaction with eosinophilia 
and systemic symptoms (DRESS) due to some drugs such as anti-epileptics and sulfa 
antibiotics is associated with the reactivation of HHV-6 infection (Ichiche et al., 2003; 
Tohyama et al., 2007). This reactivation is associated with relapse of one or more 
DIHS/DRESS symptoms and slow recovery (Aihara et al., 2003). Such findings have prompted 
scientists to examine whether viral infections, particularly HHV infections, could be involved 
in the immunopathogenesis of adverse drug reactions (Sousa-Pinto et al., 2016). 
 
1.9 Adverse drug reactions 
Adverse drug reaction (ADR) is any response to a drug which is harmful and unintended. ADRs 
are common and can cause significant economic burden, and patient morbidity and mortality. 
They are classified into two types, on-target or off-target reactions (Garon et al., 2017). The 
on-target ADRs are the most common and are caused by the pharmacological properties of a 
drug, which are predictable and can occur in anyone. However, up to 20 % of all ADRs are not 
readily anticipated based on the drug's pharmacological activity alone and were considered 
"idiopathic" and "unpredictable" until recently (White et al., 2015). It is now known that these 
reactions are caused by specific off-target drug activity and include immune-mediated ADRs 
(IM-ADRs) and pharmacological drug effects. IM-ADRs can be further classified based on the 
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type of primary immune cell involvement, including B cell and antibody-mediated (Gell and 
Coombs Type I-III), and purely T cell-mediated reactions (Gell and Coombs Type IV) (Gell 
and Coombs, 1963). Type IV reactions are delayed hypersensitivity reactions (DHR) and are 
mediated by drug-reactive T lymphocytes. DHRs are important clinically because they can be 
fatal and often have long-term severe sequelae.  
 
1.10 Delayed drug hypersensitivity 
Delayed-type reactions typically manifest several days after drug exposure. These reactions 
range from mild exanthema to a life-threatening severe cutaneous adverse reaction (SCAR). 
SCAR includes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute 
generalised exanthematous pustulosis (AGEP) and DRESS (also called DIHS or 
hypersensitivity syndrome (HSS)) (Chen et al., 2018). In addition, delayed hypersensitivity 
reactions can manifest as single organ involvement pathologies such as drug-induced liver 
injury (DILI) with pancreatitis and tubulointerstitial nephritis (Pavlos et al., 2015). Finally, 
abacavir hypersensitivity syndrome is a distinct form of a drug hypersensitivity reaction that 
has not been seen with other drugs to-date and is characterised by fever, malaise, 
gastrointestinal and respiratory symptoms with only 70% of patients developing a skin rash 
(Pavlos et al., 2015). Abacavir hypersensitivity has a rapid on and off effect such that symptoms 
and signs will rapidly disappear within 2-3 days of cessations and unlike DRESS/DIHS relapse 
of symptoms following discontinuation of the drug and viral reactivation has not been 
described. 
 
1.11 Mechanisms of delayed drug hypersensitivity  
1.11.1 Human leukocyte antigens 
The key proteins that mediate T cell immune responses are the HLA molecules encoded by the 
major histocompatibility complex (MHC) located on the short arm of chromosome 6 (Fig. 1.3). 
The HLA molecules are mainly classified into two classes, class I and class II. The HLA class 
I molecules are present on the surface of all nucleated cells. Their main function is to present 
endogenously processed self and foreign peptides to CD8+ T cells. MHC class II molecules are 
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present on professional antigen presenting cells (APC) such as dendritic cells, macrophages 
and B cells and present exogenous peptides to CD4+ T cells. 
The class I molecule consists of two peptide chains; the invariant light chain or β-2- 
microglobulin (β2m), and the heavy chain (α- chain) (Bjorkman and Parham, 1990), which is 
polymorphic and encodes three classical HLA genes, namely HLA-A, -B and -C. Genes 
encoding HLA class I α-chain have a characteristic structure in which various protein domains 
are encoded by various exons. The leader protein encodes exon 1, which initiates transcription. 
The class I heavy chain has three extracellular domains (α1, α2, and α3), which are encoded by 
exons 2, 3, and 4, respectively. A peptide binding groove, which determines the antigenic 
specificities of the HLA class I molecules is formed by the α1 and α2 domains. The α3 and 
β2m domains together form immunoglobulin constant domain-like folds (Choo, 2007). 
Typically, the peptide binding groove of HLA class I molecules accommodate peptides of 
approximately 8-10 amino acids in length but predominantly nonamers (Choo, 2007). 
The HLA class II molecules consist of two amino acid chains, α and β chains of equal size. 
The class II molecules are encoded by three classical MHC gene loci, namely HLA-DP, -DQ 
and -DR. The peptide binding groove of MHC class II molecules is more open and presents 
peptides in the order of 11-15 amino acids in length. The HLA genes are highly polymorphic 
and more than 15,000 different classical HLA class I and II alleles have been recognised 
(Dendrou et al., 2018). This huge HLA allelic polymorphism is a key factor determining 
alloreactivity. One of the clinical consequences of HLA polymorphism is that numerous 
diseases are associated with particular HLA alleles and haplotypes. In addition, several 
phenotypically distinct T cell mediated ADRs have been strongly associated with the carriage 




Figure 1.3. A simplified map of HLA class I and II loci on the short arm of chromosome6  
The HLA complex in humans resides on chromosome 6 and encodes proteins critical for the 
regulation of the immune system in humans. The HLA molecules are broadly classified into 
two classes, class I and class II. HLA class I region includes classic loci A, B, C and HLA class 




1.11.2 HLA alleles and drug-induced toxicity 
The risk of T cell mediated DHR in a certain population is often associated with variations in 
HLA alleles (Pavlos et al., 2015). For example, drug hypersensitivity reactions associated with 
the use of abacavir is associated with the allele, HLA-B∗57:01. Due to various HLA allele 
frequencies in different ethnicities, the occurrence of abacavir hypersensitivity in Caucasians 
is much higher compared to other populations (Fan et al., 2017). In addition, severe cutaneous 
adverse drug reactions, such as SJS/TEN induced by carbamazepine have been associated with 
HLA-B∗15:02 allele. While a strong association between HLA-B*15:02 and SJS/TEN has been 
demonstrated in Han Chinese (Chung et al., 2004) and Thai populations (Locharernkul et al., 
2008), no such relationship has been observed in Caucasians (Alfirevic et al., 2006). Similarly, 
several alleles of HLA genes have been proposed to have an association with ADRs caused by 
different drugs in different populations (Table 1.3) (Fan et al., 2017). Evidently, the ability of 
a drug/metabolites to bind with a specific HLA allele plays a primary role in determining ADRs 
in a population carrying that particular HLA allele (Van Den Driessche and Fourches, 2017). 
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Table 1.3. Drug-induced ADRs associated with various HLA alleles  
Source of the table from (Fan et al., 2017). 
Drug HLA allele Phenotype Population 
Abacavir B∗57:01 HSS Australian Caucasian 
    African American 
    Brazilian 
    British 
    Indian 
    Iranian 
Flucloxacillin B∗57:01 DILI Caucasian 
Carbamazepine B∗15:02 SJS/TEN Taiwanese 
    Han Chinese 
    Thai 
    Malaysian 
    Asian 
  A∗31:01 MPE, HSS, SJS/TEN Han Chinese 
    Caucasian 
    Japanese 
  B∗15:11 SJS/TEN Japanese 
Phenytoin B∗15:02 SJS/TEN Han Chinese 
    Thai 
Lamotrigine A∗31:01 HSS British 
  B∗15:02 SJS/TEN Han Chinese 
Allopurinol B∗58:01 SJS/TEN Han Chinese 
    Caucasian 
    Thai 
    Japanese 
   SCARS Taiwanese 
Nevirapine DRB1∗01:01 DRESS Hispanics, African 
Lumiracoxib DRB1∗15:01 DILI Not available 
Ticlopidine A∗33:03 DILI Japanese 
Antithyroid drugs B∗38:02-DRB1∗08:03 Agranulocytosis Taiwanese 
  B∗14:02 HSS Sardinian 
Sulphamethoxazole B∗38 SJS/TEN European 
Methazolamide B∗59:01, CW∗01:02 SJS/TEN Korean and Japanese 




1.11.3 T cell receptor (TCR) 
Human T cells play an important role in the adaptive immune response to pathogens. Each T 
cell expresses a unique TCR, which recognise antigens in the form of peptides presented on 
the surface of antigen-presenting cells by MHC molecules. The TCR is a heterodimer, 
composed of two protein chains. In humans, the dominant type of TCR which is associated 
with the two main T cell populations, CD4+ helper T cells and CD8+ cytotoxic T cells consists 
of an alpha (α) chain and a beta (β) chain encoded by TRA and TRB, respectively (Nash et al., 
2015). Effective T cell response relies on highly diverse αβ TCR repertoire. 
Somatic assembly of TCR genes through site specific DNA recombination reactions generates 
a diverse T cell repertoire (Krangel, 2009). TCR diversity is a result of the random 
recombination of variable (V), diversity (D) and joining (J) gene segments in the case of TCR 
β, and unique V and J segments for TCRα, by the recombination-activating genes RAG1 and 
RAG2 (Bassing et al., 2002). The most variable part of both the TCR α-chain and β-chain is 
complementarity determining regions (CDR), which complement an antigen-MHC complex’s 
shape (Toor et al., 2016). Each chain has three CDRs, CDR1-3. CDR1 and CDR2 are coded 
for entirely by the V segment, whereas CDR3 incorporates some of V segment and all the D 
and J segments for TCRβ and parts of the V and J segments for TCRα. CDR3 is the main CDR 
responsible for recognizing the processed antigen lodged in the antigen binding groove of the 
HLA molecule of an antigen presenting cell (Danska et al., 1990; Toor et al., 2016). 
 
1.11.4 Models of drug hypersensitivity reactions 
The mechanism by which small drug molecules elicit T cell responses remains incompletely 
understood. However, several hypotheses have been proposed to explain how drug activates 
the immune system, namely (1) the hapten/prohapten model, (2) the pharmacological 
interaction with immune receptors (p-i) model, and (3) the altered peptide repertoire model 
(Fig. 1.4). 
The hapten/pro-hapten theory states that a drug or drug-metabolites covalently binds to self-
proteins leading to form an antigenic hapten-carrier complex, which is then processed and 
loaded into HLA molecules for presentation and activation of antigen-specific T cells (Griem 
et al., 1998; Pichler et al., 2002; Weltzien et al., 1996). For example, allergy to penicillin and 
reactive metabolites of sulfamethoxazole (nitroso-sulfamethoxazole) was explained through 
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this model (Naisbitt et al., 2001; Padovan et al., 1996). The p-i concept model postulates that 
the offending drug or its reactive metabolite bind non-covalently by van der Waals and 
electrostatic interactions to T cell receptors or HLA-peptide complexes without the 
involvement of antigen processing and presentation (Pichler et al., 2006). The p-i stimulated T 
cells are believed to be recruited from the effector or memory T cell pool. The altered peptide 
model proposes that a drug could strongly bind a specific site within the peptide binding groove 
of HLA, which alters the structure of the antigen binding cleft and therefore the repertoire of 
peptide ligands that can be bound and presented to T cells. Consequently, the self-peptides 
presented because of altered binding specificity are recognised as neo-antigens and result in a 
T cell response (Illing et al., 2012; Ostrov et al., 2012). Some studies from independent groups 
have demonstrated that this model may be key in the pathogenesis of abacavir hypersensitivity 
syndrome (Illing et al., 2012; Norcross et al., 2012; Ostrov et al., 2012) and the crystal structure 
of abacavir bound to HLA-B*57:01, self or synthetic peptide was solved (Illing et al., 2012; 










Figure 1.4. Models of drug hypersensitivity to explain T cell stimulation by small 
pharmaceutical molecules  
The hapten/prohapten model states that a drug or drug-metabolites covalently bind to a self-
protein, leading to neo-antigen formation, which is then processed and loaded into HLA 
molecules for presentation and activation of antigen-specific T cells. The p-i model proposes 
drugs or metabolites bind non-covalently to HLA-peptide complexes or T cell receptor to 
directly stimulate T cells. The altered peptide model states that a drug binds to a specific site 
within the antigen-binding groove of MHC, which alters the repertoire of self-peptide ligands 
that can be bound and presented to T cells. Figure from (White et al., 2015). 
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1.12 Abacavir hypersensitivity 
Abacavir (ABC) is a guanosine analogue widely used in the treatment of HIV-1 infection as a 
part of combination antiretroviral therapy. ABC can cause hypersensitivity responses in 5-8% 
of treated patients (Cutrell et al., 2004). Abacavir hypersensitivity is characterised by fever, 
malaise, gastrointestinal symptoms and rash in 70%. (Phillips and Mallal, 2009). These 
symptoms appear within the first days or weeks of treatment and require the immediate 
cessation of the medication. Re-exposure of the drug can cause a rapid, severe, and even life-
threatening recurrence (Hetherington et al., 2001).  
Abacavir hypersensitivity is restricted to individuals carrying the HLA risk allele, HLA-
B*57:01 (100% negative predictive value, NPV). Patients carrying related B17 serotype alleles 
such as HLA-B*58:01 and HLA-B*57:03 are tolerant of abacavir. However, only 55% of 
individuals carrying HLA-B*57:01 develop hypersensitivity when exposed to the drug (55% 
positive predictive value, PPV) (Mallal et al., 2008). In vitro studies have shown that abacavir 
reactive CD8+ T cells can be expanded uniformly following culture from 100% of HLA-
B*57:01 positive unexposed donors but not from HLA-B*57:01 negative donors (Lucas et al., 
2015). These findings are in agreement with 100% NPV of the test but not the 55% PPV. 
The structural basis of the restriction of abacavir hypersensitivity reactions to HLA-B*57:01 
revealed that abacavir binds non-covalently within the hydrophobic F-pocket of the HLA-
B*57:01 peptide binding groove. This affects the shape and chemistry of the antigen binding 
groove and subsequently inducing a preference for smaller amino acid residues (valine, 
isoleucine, or leucine) (Illing et al., 2012; Ostrov et al., 2012). This alters the repertoire of 
HLA-B*57:01 restricted peptides presented to CD8+ T cells, allowing for the presentation of 
novel self-peptides, which would not bind to HLA-B*57:01 in the absence of abacavir. This 
mechanism is termed as ‘altered peptide repertoire model'. Abacavir-HLA-B*57:01 specificity 
was explained by the sensitivity of the F pocket of HLA-B*57:01, namely to its Ser116 residue, 
which is absent in similar allotypes (HLA-B*58:01, and HLA-B*57:03). This explains why 
abacavir specific T cells are not activated by the closely related allotypes (Illing et al., 2012). 
Moreover, to understand abacavir specific activation of CD8+ T cells, Adam et al (2012) 
generated abacavir specific T cell clones from HLA‐B*57:01+ donors and analysed their 
specific reactivity patterns with varying abacavir concentrations. The study clearly showed that 
the reactivity patterns of abacavir specific T cell clones were not exclusively dependent on the 
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T cell clone itself but were also based on different TCR avidities for abacavir. This implies a 
potential role of drug concentrations in vivo for drug hyper‐sensitivity (Adam et al., 2012).  
However, these studies do not explain why only 55% of patients carrying HLA-B*57:01 allele 
will develop drug hypersensitivity. HLA-B*57:01 is necessary but not sufficient for the 
development of abacavir hypersensitivity. Hence, identifying other factors that account for the 
“PPV” gap will be necessary to improve current mechanistic models of the pathogenesis of the 
syndrome. 
 
1.13 Heterologous immunity 
The phenomenon by which memory T cells of one pathogen are reactivated in response to a 
second, unrelated viral infection is termed as heterologous immunity (Rehermann and Shin, 
2005). This phenomenon can be either beneficial or harmful to the host. Several drug-induced 
hypersensitivity reactions and HLA allele associations occur in individuals infected with 
viruses (Michels and Ostrov, 2015). The mechanistic roles of viruses in the initiation or 
preservation of T cell-mediated ADRs are complex and have been proposed that pathogen-
specific effector memory T cells can cross-react with the neo-antigen created by drug exposure 
presented in the context of HLA risk allele thus causing hypersensitivity reactions (the 
heterologous immunity model). 
This model would posit, for instance that in abacavir hypersensitivity, pre-formed anti-viral 
memory T cells cross-react with an abacavir-HLA-B*57:01-altered self-peptide ligand 
complex and cause drug hypersensitivity (Lucas et al., 2015). CD8+ T cells isolated from 
abacavir-hypersensitive patients are activated following exposure to abacavir-stimulated HLA-
B*57:01 expressing APCs (Adam et al., 2012). In addition, CD8+ T cells derived from 
abacavir-naive, HLA-B*57:01+ individuals are also activated in response to abacavir (Adam et 
al., 2014; Chessman et al., 2008). Therefore, abacavir specific CD8+ T cells derived from both 
memory and naive T cell populations and do not require costimulatory signals or CD4+ T cell 
help (Adam et al., 2014; Lucas et al., 2015; White et al., 2015). Thus, drug hypersensitivity in 
an individual with a risk-conferring HLA allele could be determined by the presence or absence 
of pre-existing memory responses (Pavlos et al., 2015). A heterologous immunity model would 
predict that the history of pathogen exposure would therefore predict or drive the risk of an 
ADR. In the case of abacavir, the presence of pre-existing memory T cells in abacavir naïve 
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patients and the rapid onset of the reaction (as quick as 1.5 days following first exposure) would 
support this hypothesis. 
White et al. (2015) proposed a heterologous model in which the pathogenesis of a T cell-
mediated ADR are summarised as follows (Fig. 1.5) 
i. T cell-mediated ADR requires the presence of the HLA risk allele; but which alone is 
insufficient for the reaction.  
ii. When the subject gets primary infection by HHV (or other pathogen); HHV peptides 
are presented in the context of the HLA risk allele, and the virus is attacked by 
polyclonal CD8+ T cell responses. Then the HHV enters into latency and the T cell 
response contracts.  
iii. Memory T cells remain at the site of antigen encounter and are intermittently stimulated 
by viral antigens during viral reactivation. Activation of effector memory T cells forces 
the virus back into latency. 
iv. When the subject is exposed to the offending drug, the drug interacts with the risk HLA 
protein and results in either neo-antigen formation or presentation of an altered 
repertoire of endogenous peptides.  
v. TCR that was initially primed against HHV peptide recognises the peptide-MHC 
complex either through molecular mimicry or through an alternate binding strategy, 





Figure 1.5. Timeline of the generation of T cell-mediated adverse drug reactions  
According to the heterologous immunity model, the cross-reactive T cells specific for HHV (or 
another pathogen), sensitised much earlier cross-recognise the drug-induced self-peptides 





1.14 EBV and heterologous immunity 
The model of heterologous immunity provides a novel explanation for the drug mediated 
responses through cross-reactive T cell responses. HHVs are the likely microbial pathogens 
that could lead to heterologous immune responses because of their persistent infection and 
generation of long-lasting cross-reactive T cells (White et al., 2015). Among HHV, EBV is a 
widely spread member of the Herpesviridae family, gammaherpesviridae subfamily, whose 
prevalence exceeds 95% of the adult human population and persist for life. 
EBV plays an important role in the pathogenesis of various T cell mediated autoimmune 
diseases such as multiple sclerosis (MS), for which molecular mimicry is a likely mechanism 
(Libbey et al., 2014). Molecular mimicry is a cross-reactive mechanism in which pathogenic 
antigens that are structurally similar to the proteins of the host generate an immune response. 
A well-known study of molecular mimicry is that a TCR from an MS patient cross-recognised 
both a DRB1* 15:01-restricted myelin basic protein (MBP) and DRB5*01:01-restricted EBV 
peptide (Lang et al., 2002). Likewise, another study confirmed the natural presentation of a 
self-peptide on human cells cross-recognised by EBV-specific CD8+ T cells, for which the 
presenting HLA allele for the EBV and self-peptide is the same (Rist et al., 2015). The study 
showed that the self-peptide-HLA-B*18:01 complex is a structural mimic of the EBV peptide- 
HLA-B*18:01 complex. This shows that EBV-reactive T cells could be involved in 
autoimmune reactions via molecular mimicry. 
Similarly, in organ transplantation rejection, the characterisation of the cross-reactivity 
between an HLA-B8-restricted CD8+ T cell response to the EBV epitope FLR and HLA-
B*44:02 supports the model of heterologous immunity (D'Orsogna et al., 2012). In addition, 
the evidence of EBV reactivation along with the other herpesviruses such as HHV-6/7 and 
CMV, in various immune-mediated drug allergies suggests a possible role in most but not all 
drugs implicated in DRESS/DIHS/HSS (Aihara et al., 2001; Descamps et al., 2003; Picard et 
al., 2010).  
Structural studies have found that the abacavir binds non-covalently to HLA-B*57:01 molecule 
and alters the repertoire of peptides presented by the HLA molecule (Illing et al., 2012; 
Norcross et al., 2012; Ostrov et al., 2012). Functional studies have indicated that CD8+ T cells 
derived from both abacavir hypersensitive patients and abacavir-naïve, HLA-B*57:01 positive 
individuals were activated following the addition of abacavir (Adam et al., 2012; Adam et al., 
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2014; Chessman et al., 2008). These studies indicate that some of the altered peptides may 
restimulate the pre-existing memory cells against some of the latently infected viruses through 
heterologous immunity and cause hypersensitivity reactions. Among latently infected viruses, 
EBV is the most widely distributed human herpesviruses and the cellular responses make up a 
significant proportion of the memory pool (Hislop et al., 2007b). Hence, studying the responses 
of CD8+ T cell to this virus and characterising any cross-reactive TCR in the presence of 
abacavir may help in the advancement of the study. 
 
1.15 Aims and scope of thesis 
The objective of this research project was to investigate whether pre-existing memory T-cell 
responses to EBV contribute to heterologous immune responses in the presence of abacavir 
and cause hypersensitivity reactions to the drug. These reactions are known to occur only in 
individuals carrying HLA-B*57:01 allele. However, only 55% of HLA-B*57:01+ patients 
develop abacavir hypersensitivity, meaning that this risk allele is necessary but not sufficient 
for disease. Previous studies found a relationship between drug hypersensitivity reactions and 
latent viral infections. This observation suggests that the risk of abacavir hypersensitivity may 
be modulated by certain pathogen infections, but this idea has not been proven experimentally. 
The overall aim of the study was to evaluate this hypothesis by studying the CD8+ T cell 
responses to the widely distributed human herpesvirus, EBV and thus contribute to the 
understanding of the mechanism(s) responsible for drug hypersensitivity reactions, which 
could have important clinical implications. 
Hypothesis 1: Genome-wide mapping of EBV has the potential to reveal novel candidate CD8+ 
T cell antigens, whose responses maybe implicated in the heterologous immune model of 
abacavir hypersensitivity (AHS). 
Aim 1: Comprehensive mapping of CD8+ T cell responses to the EBV ORFeome in HLA-
B*57:01, EBV seropositive individuals. 
Hypothesis 2: There are additional undescribed and novel HLA-B*57:01 restricted EBV 
epitopes. 
Aim 2: To determine novel HLA-B*57:01 restricted EBV epitopes in the candidate antigens. 
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Hypothesis 3: EBV-specific T cells cross-recognise HLA-B*57:01 presented abacavir plus 
self-peptide. 
Aim 3: To sequence and clone EBV-specific T cell receptors and investigate TCR cross-
reactivity to “altered-self”. 
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2.1.1 Reagent list 
12-O-Tetradecanoylphorbol 13-acetate (TPA) Sigma-Aldrich, USA 
3,3′,5,5′-Tetramethylbenzidine (TMB)  Sigma-Aldrich, USA 
Agarose (molecular biology grade) Invitrogen, USA 
Ampicillin Sigma-Aldrich, USA 
BD Cytofix/Cytoperm™  BD Biosciences, USA 
BD GolgiPlug™  BD Biosciences, USA 
BD Perm/Wash™Buffer  BD Biosciences, USA 
BigDye Terminator v3.1 Cycle Sequencing kit Applied Biosystems, USA 
Bovine Serum Albumin (BSA) Invitrogen, USA 
Bright-Glo™ Luciferase Assay System  Promega, USA 
Cyclosporin A (CSA) Sigma-Aldrich, USA 
Deoxynucleotide triphosphates (dNTPs) New England Biolabs, USA 
Dimethyl sulphoxide (DMSO) Chem supply Pty Ltd, Australia 
Dulbecco’s Modified Eagles Media (DMEM) Gibco, Life Technologies, USA 
Ethylenediaminetetraacetic acid (EDTA) BDH, Australia 
Ethanol Rowe Scientific, Australia 
Foetal bovine serum (FBS) Serana, Australia 
Formaldehyde Sigma-Aldrich, USA 
FuGENE6 Promega, USA 
Gateway® BP Clonase® II Enzyme mix  Invitrogen, USA 
Gateway® LR Clonase® II Enzyme mix  Invitrogen, USA 
Geneticin (G418 sulphate) Gibco, Life Technologies, USA 
Glycerol MP Biomedical, USA 
Granulocyte-macrophage colony-stimulating factor (GM-CSF)  PeproTech, Australia 
Human IFN gamma recombinant protein Thermofisher Scientific, USA 
Human recombinant IL-2  PeproTech, USA 
Human serum Sigma-Aldrich, USA 
Hydrochloric acid (HCl) Sigma-Aldrich, USA 
Immunoglobulin-Inhibiting Reagent (IIR) Bioreclamation, USA 
Interleukin-4 (IL-4)  PeproTech, Australia 
Ionomycin  Sigma-Aldrich, USA 
Isopropanol Sigma-Aldrich, USA 
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Kanamycin  Sigma-Aldrich, USA 
Luciferin Bright Glo Promega, USA 
Luria Bertani (LB) agar powder Invitrogen, USA 
Luria Bertani (LB) broth powder Invitrogen, USA 
Magnesium chloride BDH, Australia 
Molecular size DNA ladder (1kb+) Invitrogen, USA 
Natural IL-2 Lonza, Köln, Germany 
Opti-MEM  Gibco, Life Technologies, USA 
Penicillin Streptomycin L-Glutamine (PSG) Invitrogen, USA 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, USA 
Phosphate buffered saline (PBS) tablets Sigma-Aldrich, USA 
Phosphate Buffered Saline (PBS), Ca and Mg free Gibco, Life Technologies, USA 
Phosphoric acid Sigma-Aldrich, USA 
Phytohaemagglutinin P (PHA-P)  Sigma-Aldrich, USA 
Platinum Taq polymerase HiFi and 10 X Buffer Invitrogen, USA 
Potassium chloride (KCl) BDH, Australia 
Restriction endonucleases and respective 10 X buffers New England Biolabs, USA 
RNase outTM recombinant Ribonuclease Inhibitor Invitrogen, USA 
Roswell Park Memorial Institute medium (RPMI)  Gibco, Life Technologies, USA 
RPMI with no phenol red Gibco, Life Technologies, USA 
Sodium bicarbonate (NaHCO3) Chem supply Pty Ltd, Australia 
Sodium butyrate (NaB) Sigma-Aldrich, USA 
Sodium carbonate (Na2CO3) Chem supply Pty Ltd, Australia 
Sodium chloride Chem supply Pty Ltd, Australia 
Steady-Glo® Luciferase  Promega, USA 
Streptavidin- horse radish peroxidase (Strep-HRP) Mabtech, Sweden 
TMB substrate (ELISpot) Mabtech, Sweden 
Trizma® base Sigma-Aldrich, USA 
Trypsin-EDTA Sigma-Aldrich, USA 
Tween-20 Sigma-Aldrich, USA 






2.1.2.1 Flow cytometry antibodies 
Specificity Supplier Clone Fluorophore 
Volume per test in 
100 µL total reaction 
Cell viability BD Biosciences - 
7-aminoactinomycin D 
(7-AAD) 2.5 µL 
CD137 BD Biosciences 4B4-1 Allophycocyanin (APC) 3 µL 
CD3  BD Horizon UCHT1 AF700 2.5 µL 
CD3  BD Biosciences UCHT1 PE 1 µL 
CD8  BioLegend RPA-T8 
Allophycocyanin-Fire 
750 0.1 µL 
CD8  BD Biosciences RPA-T8 BB515 2.5 µL 
CD8  Invitrogen 3B5 FITC 2.5 µL 
Cell viability BD Biosciences - 
fixable viability stain 
(FVS) 510 0.1 µL 
Cell viability BD Biosciences - FVS620 0.1 µL 
IFN-γ BD Biosciences 4S.B3 
phycoerythrin-Cy7  
(PE-cy7) 1 µL 
 
2.1.2.2 ELISA and ELISpot antibodies 
Antibody Supplier  Clone 
Mouse IgG1 recombinant human IFN-γ (2G1) Thermofisher Scientific, USA 2G1 
Mouse IgG1 recombinant human IFN-γ Biotin conjugate (B133.5) Thermofisher Scientific, USA B133.5 
Mouse IgG1 recombinant human IFN-γ (1-D1K) MABTECH, Sweden 1-D1K 
Mouse IgG1 recombinant human IFN-γ Biotin conjugate (7-B6-1) MABTECH, Sweden 7-B6-1 
Mouse IgG2a anti-human CD3-2 monoclonal antibody  MABTECH, Sweden CD3-2 
 
2.1.3 Bacterial strains 
2.1.3.1 DH10B 
The DH10B E. coli bacterial strain was used to propagate all plasmids and ligation reactions 





The DB3.1 E. coli bacterial strain was used to propagate all plasmids and ligation reactions 




The Gateway® entry vector, pDONR201 (Invitrogen) was used to clone the EBV open reading 
frame (ORF) PCR products flanked by Gateway® attB recombination sites. The plasmid 
encodes a kanamycin resistance (KnR) gene. 
 
2.1.4.2 pDEST103 
The plasmid pDEST103 (Jing et al., 2012) is an expression plasmid that accepts DNA from 
either pDONR201 (Invitrogen) or pDONR223 (Invitrogen). In this project, all the EBV ORFs 




The plasmid pSELECT-GFPzeo-mcs (InvivoGen) was used to construct pAR100 Jurkat assay 
plasmid. This plasmid is an expression plasmid which contains GFP:zeo, a fusion gene that 




The plasmid pORF9-hCD8Aa (InvivoGen) is an expression plasmid containing a human 
CD8A (isoform 1) open reading frame. The CD8A open reading frame was excised from this 
plasmid and cloned into the plasmid pSELECT-GFPzeo-mcs (InvivoGen). 
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2.1.4.5 pGL3-NFAT luciferase 
The plasmid pGL3-NFAT (Addgene) contains an NFAT binding sequence upstream of a 
luciferase reporter. This plasmid was used to construct the pAR100 plasmid. 
 
2.1.4.6 pcDNA3.1 (+) 
The plasmid pcDNA3.1(+) (Invitrogen) was used as an intermediary plasmid in the 
construction of pAR100 and pAR101 Jurkat assay plasmids. This plasmid contains an 
ampicillin resistance gene. 
 
2.1.4.7 EBV ORF entry plasmids 
A library representing 85 EBV ORFs in Gateway® entry clones, pENTR series were kindly 
provided by Mike Calderwood (The Channing Laboratory, Harvard Medical School and 
Brigham and Women’s Hospital, Boston, MA 02115). All the ORFs were cloned into the entry 
vector pDONR223 (Invitrogen). These plasmids contain spectinomycin resistance gene.  
 
2.1.5 Culture media 
2.1.5.1 Tissue culture media 
2.1.5.1.1 Heat inactivated foetal bovine serum (FBS) 
FBS was heat inactivated at 56°C for 30 minutes, aliquoted and stored at -20oC for later use. 
Heat inactivated FBS was used in all media unless otherwise stated. 
 
2.1.5.1.2 Roswell Park Memorial Institute medium (RPMI) media-1640 
Before use, FBS was added to RPMI-1640 as required and supplemented with 1% Penicillin 




2.1.5.1.3 T cell media (TCM) 
TCM was made by supplementing RPMI-1640 with 5% human serum, 5% FBS and 1% PSG. 
 
2.1.5.1.4 Dulbecco’s Modified Eagles Media (DMEM)  
Before use, 10% FBS was added to DMEM and the media was supplemented with 1% PSG. 
 
2.1.5.2 Bacterial culture media 
2.1.5.2.1 Luria-Bertani (LB) agar media 
LB agar powder  32 g 
Sterile water 1 L  
LB agar powder was dissolved in sterile water and autoclave sterilised. Selection antibiotics 
were added when the molten agar was at 60oC. Agar was poured into 85mm petri dishes and 
used after setting at room temperature for 30 minutes. 
 
2.1.5.2.2 LB broth media 
LB broth powder  20 g 
Sterile water 1 L  
LB broth powder was dissolved in sterile water and autoclave sterilised. Selection antibiotics 
were added immediately before use. 
 
2.1.6 Buffers and solutions 
2.1.6.1 Fluorescence-activated cell sorting (FACS) buffer 
FACS buffer was made with 1 X phosphate-buffered saline (PBS), pH 7.2, supplemented with 




2.1.6.2 Magnetic-activated cell sorting (MACS) buffer 
MACS buffer was made with 1 X PBS, pH 7.2 supplemented with 0.5% bovine serum albumin 
(BSA), and 2 mM ethylenediaminetetraacetic acid (EDTA). 
 
2.1.6.3 10 X PBS 
10 X PBS was made by dissolving 50 tablets of PBS in 1 litre of sterile water and filter 
sterilised. Before use, 1 X PBS was made by adding the appropriate amount of sterile water. 
 
2.1.6.4 1 X PBS-Tween-20 buffer (PBS-T) 
1 X PBS 1 L  
Tween-20 2 mL 
The solution was made by adding 2 mL of Tween-20 to 1 litre of 1 X PBS and used for washing 
ELISA plates. 
 
2.1.6.5 0.2 M Sodium carbonate buffer  
Sodium carbonate 21.2 g 
Sterile water 1 L 
0.2 M sodium carbonate buffer was made, and autoclave sterilised. 
 
2.1.6.6 0.2 M Sodium bicarbonate buffer  
Sodium bicarbonate 16.8 g 
Sterile water 1 L 




2.1.6.7 0.1 M Sodium carbonate buffer (Coating buffer) (pH9.6) 
0.2 M Sodium carbonate 16 mL 
0.2 M Sodium bicarbonate 34 mL 
Coating buffer was made by mixing the above volumes of the two buffers with the final volume 
adjusted to 200 mL with sterile water. The pH was adjusted to 9.6 using the stock solutions. 
 
2.1.6.8 3 M HCl 
HCl 62.6 mL 
Sterile water was added to the acid and the volume adjusted to 250 mL. 
 
2.1.6.9 10 X Tris-buffered saline (TBS) buffer 
Sodium chloride 80 g 
Potassium chloride 2 g 
Trizma® base  30 g 
Buffer was made with sterile water and the pH was adjusted to 7.4 with 3 M HCl. The final 
volume was adjusted to 1 L and autoclave sterilised. 
 
2.1.6.10 Blocking buffer 
Blocking buffer was made by supplementing 1 X TBS with 1% BSA. 
 
2.1.6.11 1 X TBS-T 
1 X TBS-T buffer was made by adding 0.05% Tween-20 to 1 X TBS. 
 
2.1.6.12 Sample buffer 




2.1.6.13 1 M H3PO4 (Stop solution) 
H3PO4 33.75 mL 
Sterile water was added to the acid and adjusted to a volume of 500 mL. 
 
2.1.7 Primers 
Primers were designed from the appropriate sequences using Primer 3 (version 0.4.0) and 
purchased from Integrated DNA Technologies, Singapore. 
 
Table 2.1. Primers used to amplify EBV ORFs 











Table 2.2. Primers used to construct and sequence pAR100 and pAR101 plasmids 
Primer name Primer sequence (5' - 3') 
CD8_F aagtccACCGGTGCCACCATGGCCTTACCAGTGACCG 
CD8_R atcgatCTTAAGGACGTATCTCGCCGAAAGG 
























2.1.8 Cell lines 
2.1.8.1 B95-8 
The marmoset B cell line, B95-8, is an EBV producing cell line containing EBV in the 
supernatant and was used for human B cell transformation. The B95-8 cell line was maintained 
in RPMI-1640 supplemented with 10% FBS in tissue culture dishes at 37°C and 5% CO2. 
 
2.1.8.2 Cos7  
Cos7 is an adherent, primate kidney epithelial cell line. Cells were cultured in DMEM media 
supplemented with 10% FBS and 1% PSG in tissue culture dishes at 37°C and 5% CO2.  
 
2.1.8.3 K562-B*57:01 cell line 
K562-B*57:01 is a stable single antigen-expressing cell line generated by transfecting human 
leukocyte antigen (HLA) B*57:01 sequence into a K562 cell line. The cells were maintained 
in RPMI-1640 supplemented with 10% FBS, 1% PSG and 0.5 mg/mL Geneticin G418 at 37°C 
and 5% CO2. 
 
2.1.8.4 Jurkat (E6.1) cell line 
Jurkat (E6.1) is a human T lymphoblastoid cell line derived from an acute T cell leukemia. The 





2.1.9 Donor samples 
Peripheral blood mononuclear cells (PBMCs) from healthy donors (Australian Bone Marrow 
Donor Registry) carrying the HLA-B*57:01 allele and positive for EBV which were stored 
cryopreserved at the Institute for Immunology and Infectious Diseases (IIID), Murdoch, Perth, 
Western Australia, were utilised for this research. HLA typing was carried out by the accredited 
staff at IIID, an ASHI accredited lab. The donors used in the present study and their HLA 
typing is listed in Table 2.3. 
 
Table 2.3. List of donors used in this study 
Donor ID 
HLA type           Serology     
A1 A2 B1 B2 DRB11 DRB12 CMV EBV *VSFIEFVGW 
Donor 1 02:AMAY  NA 57:01 35:03 13:03 14:JCJ Negative IgG positive Positive  
Donor 2 31:01 32:01 57:01 35:03 NA NA Negative IgG positive Positive  
Donor 3 29:02 68:02 57:01 44:03 NA NA Positive NA Positive 
Donor 4 01 02 57:01 07:02 NA NA NA NA  Positive 
Donor 5 01CRY 03:01 57:01 07:02 NA NA NA NA Positive 
Donor 6 01 03:01 57:01 14:02 NA NA NA NA Positive 
Donor 7 01 32 57:01 40 NA NA Negative NA Positive 
Donor 8 01CRY 02BDDU 57:01 44WRJ NA NA Negative NA Positive 
Donor 9 01 02 57:01 0702 NA NA NA NA Positive 
*All donors were tested with EBV epitope (VSFIEFVGW) to confirm the donors were positive 
to EBV; NA-information not available 
 
2.1.10 Human ethics approval 
Ethics approval for the conduct of this research project was obtained from Murdoch University 






2.2.1 Bacterial techniques 
2.2.1.1 Generation of electrocompetent bacterial cells 
Frozen glycerol stocks of bacterial cells (DH10B and DB3.1) were streak plated onto LB agar 
plates with no antibiotics and incubated overnight at 37oC. A single colony was selected and 
inoculated into 10 mL of LB media. Liquid cultures were incubated overnight at 37oC with 
shaking (200 rpm). The next day, 1 litre of LB media was inoculated with 10 mL of starter 
culture and returned to the 37°C shaker. To monitor the bacterial growth phase, the optical 
density (OD600) was measured every hour, followed by every 15-20 minutes when the OD600 
was above 0.2 until the OD600 reached log phase (0.4-0.6). After cells reached log phase, they 
were kept at 4°C for the remainder of the procedure. Cells were pelleted by centrifugation at 
5000  g and 2C for 10 minutes, the supernatant decanted, and resuspended in ice cold sterile 
water. After a second wash with ice cold sterile water, the cells were washed with 10% glycerol. 
Finally, the bacterial pellet was resuspended in the pellet volume of 10% glycerol. The cells 
were aliquoted into sterile pre-cooled 1.5 mL microfuge tubes at 25 L and immediately stored 
at -80C. 
 
2.2.1.2 Ligation and bacterial transformation 
DNA was ligated using 1U of T4 DNA ligase (New England Biolabs) at 16oC overnight 
following manufacturer’s instructions. All ligations were transformed into appropriate 
electrocompetent cells following the Gene Pulser Xcell (Bio-rad) electroporation protocol. 
Briefly, 1 µL of the ligation reaction was mixed with 25 µL of electrocompetent E.coli and 
transferred to an ice-cold, 1 mm gap electroporation cuvette (Bio-Rad) and pulsed on a Gene 
Pulser Xcell electroporation unit (Bio-Rad) at 1.8 kV, 25 µF, and 200 Ω. Immediately after 
electroporation, the cells were mixed with LB media and incubated at 37oC for 1 hour with 
shaking at 200 rpm. Transformed bacteria were selected by plating on LB agar plates 
containing the appropriate antibiotic. The plates were incubated overnight at 37oC. Antibiotics 




2.2.1.3 Creating Gateway® entry clones 
To create a Gateway® entry clone, the EBV-ORF PCR products flanked with attB sites were 
transferred into attP containing pDONOR201 plasmid with BP Clonase II (Invitrogen) 
following the manufacturer's instructions. The BP reactions were then transformed into DH10B 
electrocompetent E. coli strain and selected on kanamycin (50 µg/mL) antibiotic LB agar 
plates. 
 
2.2.1.4 Cloning of entry clones into pDEST103 expression plasmid 
The EBV ORFs were transferred from entry clones into an expression vector, pDEST103 (Jing 
et al., 2012) with LR Clonase II (Invitrogen) according to the manufacturer's instructions. The 
LR reactions were transformed into DH10B electrocompetent E. coli strain and selected on 
ampicillin (100 µg/mL) antibiotic LB agar plates. 
 
2.2.1.5 Plasmid DNA extraction (miniprep) 
Single colonies were picked and cultured overnight in 5 mL of LB broth containing the 
appropriate antibiotic at 37oC with shaking (200 rpm). From the liquid cultures, plasmid DNA 
was extracted using the Nucleospin® Plasmid (NoLid) kit (Macherey-Nagel) according to the 
manufacturer’s instructions.  
 
2.2.1.6 Plasmid DNA extraction (midiprep) 
Single colonies were picked and cultured overnight in 100 mL of LB broth containing the 
appropriate antibiotic at 37oC with shaking (200 rpm). Plasmid DNA was extracted from the 
cultures using the NucleoBond® Xtra Midi EF kit (Macherey-Nagel) according to the 




2.2.2 Molecular techniques 
2.2.2.1 RNA extraction and cDNA conversion 
Total RNA extraction was performed using the Qiagen RNeasy mini kit (QIAGEN®), as per 
manufacturer’s instructions. The cDNA conversion from total RNA was performed using the 
Superscript III™ first strand synthesis system (Invitrogen), as per manufacturer’s instructions. 
 
2.2.2.2 Polymerase chain reaction 
EBV open reading frames (ORFs) were amplified using high fidelity Platinum Taq polymerase. 
The reaction conditions were as described below. 
Reagent Volume 
10 X HIFI PCR Buffer 2.5 μL 
50 mM MgSO4 1 µL 
10 mM dNTPs 1 µL 
25 µM Forward Primer 1 µL 
25 µM Reverse Primer 1 µL 
Template DNA 2 µL 
HIFI Platinum Taq 0.5 µL 
Nuclease-free water 16 µL 
Total volume 25 µL 
 
Denaturation (×1) 95°C  5 minutes 
Cycles (×35) 95°C  1 minute 
 
60°C 30 seconds 
 
72°C 30 seconds 
Final extension 72°C 10 minutes 




2.2.2.3 Agarose gel electrophoresis 
Restriction enzyme digested DNA samples, PCR products, and 1 Kb+ DNA ladder were mixed 
with 2 X loading dye and loaded on a 0.7%-2% agarose gel in 1 X TAE buffer and run at 100 
V for 30 minutes. DNA bands were visualised and photographed using the Bio-Rad 
ChemiDOC XRS transilluminator (Bio-Rad). 
 
2.2.2.4 Sanger sequencing 
Sequencing of the EBV ORFs and the plasmid system was carried out using an ABI 3730XL 
Genetic Analyser at IIID, Murdoch University. The sequencing reaction was set up as below 
and the sequencing products were purified using Agencourt CleanSEQ beads (Beckman 
Coulter), as per manufacturer’s instructions. Sequences were assembled and compared to the 
reference sequence using CLC Main Workbench v7.6 (QIAGEN). 
Reagent Concentration Volume  
2.5 X Sequencing Buffer 2.5 X 7.5 µL 
BDT   0.5 µL 
Primer 1 pmol/uL 2 µL 
Template 200-400 ng/uL 2 µL 
Nuclease free water   8 µL 
TOTAL   20 µL 
 
2.2.3 Cellular techniques 
2.2.3.1 Sub-culture of adherent cells  
Cos7 and B95-8 cell lines grow adherently to the culture flasks. To detach the cells, Trypsin-
EDTA was used as described. The growth media was removed, and the cells were rinsed with 
1 X PBS to remove any traces of media containing FBS. For a T75 flask, 2 mL of 1 X Trypsin-
EDTA was added and incubated at 37oC and 5% CO2 for 5 minutes. The detached cells were 
neutralised with the complete media containing 10% FBS and centrifuged at 400 g for 10 




2.2.3.2 EBV stock preparation 
EBV stock was made from supernatants of B95-8 cultures as described previously (Oh et al., 
2003). The B95-8 cells were grown in complete RPMI-1640 media supplemented with 10% 
heat inactivated FBS at 37°C and 5% CO2. The cells were maintained at 2-5 × 10
5 cells/mL for 
10-15 days. Cells were removed by centrifugation at 600 g for 5 minutes and the supernatant 
was filtered through a 0.45 µm membrane (Millipore, Bedford, MA, USA), aliquoted and 
stored at -80°C overnight. Aliquots were transferred to liquid nitrogen for long term storage 
the following day. 
 
2.2.3.3 Generation of B-lymphoblastoid cell lines (B-LCL) 
EBV-transformed lymphoblastoid B cell lines were generated from PBMCs by infection with 
EBV virus stock as described previously (Oh et al., 2003). Briefly, 1 mL of EBV stock was 
added to 1-3 × 106 PBMCs in 3 mL of RPMI-1640 media supplemented with non-heat 
inactivated 20% FBS, and 2 µg/mL CSA and incubated at 37°C and 5% CO2 in a T25 flask. 
Each week, half of the supernatant was replaced by fresh medium containing 1 µg/mL CSA 
for 2-3 weeks. Once clustering of cells was seen, fresh media with no CSA was added and the 
cells continued to grow until the desired number of cells were obtained. 
 
2.2.3.4 Chemical induction of lytic phase in LCLs 
LCLs were seeded at 1 × 106 cells/ml in a 6 well plate and treated with 20 ng/mL of 12-
tetradecanoylphorbol 13-acetate (TPA) and 3mM, the final concentration of sodium butyrate 
(NaB) for 24 hours to induce the cells into lytic phase. After 24 hours, the LCLs were washed 
thrice in R10 and used in antigen presentation assays. 
 
2.2.3.5 Preparation of monocyte-derived dendritic cells (moDC) 
Monocyte-derived dendritic cells were cultured in vitro from PBMCs based on plastic 
adherence in the presence of GM-CSF and IL-4 for 6 days as described previously (Hosken et 
al., 2006). Briefly, frozen PBMCs were thawed, added to 10 mL of RPMI-1640 and centrifuged 
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at 400 g for 10 minutes. Later, 5-8 × 106 PBMCs were resuspended in RPMI-1640 media 
supplemented with 1% human serum and 1% FBS and allowed to adhere to the wells of a six-
well polystyrene tissue culture plate (Flacon®, Becton Dickinson Lab ware) for 4 hours at 37°C 
and 5% CO2. Non-adherent PBMCs were gently washed away prior to the addition of 6 mL of 
TCM containing 10 ng/mL IL-4 and 10 ng/mL GM-CSF. After 3 days, the media was replaced 
with fresh TCM media containing 10 ng/mL IL-4, and 10 ng/mL GM-CSF and incubated at 
37°C and 5% CO2 for a further 3-4 days. After 6-7 days, moDCs were harvested. To harvest 
mature moDCs, the medium was removed from wells into a 50 mL falcon tube and the adherent 
moDCs in the wells were treated with 1 mL of 20 nM EDTA. After incubation at 37°C for 5 
minutes, moDCs were scrapped with a cell scrapper and harvested into a 50 mL falcon tube. 
Cells were centrifuged and resuspended in TCM and used as antigen-presenting cells. 
 
2.2.3.6 CD8+ T cell isolation 
CD8+ T cells were isolated by negative selection using the MACS CD8+ T cell isolation kit 
(Miltenyi Biotec, Australia) according to the manufacturer’s instructions. Briefly, 10 × 107 
PBMCs were resuspended in 400 µL of MACS buffer. Cells were then stained with 100 µL of 
CD8+ T cell biotin-antibody cocktail for 5 minutes at 4°C. Later, 300 µL of MACS buffer was 
added and stained with 200 µL of CD8+ T cell microbead cocktail for 10 minutes at 4°C. Cells 
were then passed through LD™ separation columns where unwanted cells were allowed to 
bind to the magnet and the unlabelled CD8+ T cells passed through the columns and were 
collected. These collected CD8+ T cells were washed 2-3 times in TCM, counted using the 
Countess™ automated cell counter (Invitrogen, USA) and resuspended in TCM at 5 × 106 
cells/mL. 
 
2.2.3.7 Antigen presentation through moDC plus LCL 
For in vitro antigen presentation through moDC plus LCL, mature moDCs were resuspended 
at 1 × 106 cells/mL in TCM and plated at 200 µL/well in a 24-well polystyrene tissue culture 
plate (Flacon®, Becton Dickinson Labware). Similarly, LCLs were resuspended at 1 × 106 
cells/mL in TCM and gamma irradiated at 8000 cGy (Gammacell 3000 Elan; MDS Nordian). 
Gamma irradiated LCLs were added to the moDC seeded wells at 200 µL/well (equivalent to 
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2 ×105 cells/well) and incubated at 37°C and 5% CO2 to settle until the isolation of CD8
+ T 
cells. Finally, 400 µL of CD8+ T cells (2 × 106 cells/well) were added to the antigen-loaded 
moDCs for a responder/DC ratio of 10:1 in a final volume of 800 µL and incubated at 37°C 
and 5% CO2 overnight. 
 
2.2.3.8 Antigen presentation through LCL 
For antigen presentation through LCL, gamma irradiated LCLs were seeded at 200 µL/well 
(equivalent to 2 × 105 cells/well) and 200 μL of TCM was added to each well to equalise the 
volumes of the two assays. Finally, 400 µL of CD8+ T cells (2 × 106 cells/well) were added and 
incubated at 37°C and 5% CO2 overnight. 
 
2.2.3.9 EBV reactive CD8+ T cell sorting 
After stimulation of CD8+ T cells with either moDCs plus LCLs or LCLs alone for 20 hours, 
the cells were stained with 7-AAD, anti-CD3-PE, anti-CD8α-FITC, and anti-CD137-APC for 
30 minutes at room temperature in 100 μL TCM as described previously (Jing et al., 2012). 
After 2-3 washes in TCM, cells were resuspended in 500 µL of TCM and strained using a 
polystyrene tube with a cell strainer cap (In Vitro Technologies, Australia). All available 
CD8+CD137+ T cells and a fraction of CD8+CD137- cells were collected in a microfuge tube 
using a FACSAria II (BD Biosciences).  
 
2.2.3.10 EBV-specific CD8+ T cell expansion 
Sorted cells were centrifuged at 400 g for 3 minutes with half of the top media removed and 
replaced with fresh TCM. Cells were then plated in bulk in a 96-well U-bottom plate (Flacon®, 
Becton Dickinson Lab ware) with 1.5 × 105 allogeneic and gamma irradiated (3,300 CGy, 
Gammacell 3000 Elan; MDS Nordian) PBMCs and 1.6 μg/mL PHA-P in 200 μL of TCM and 
incubated at 37°C and 5% CO2. On day 2, 32 U/mL of natural human IL-2 was added to the 
cells and maintained for 14 days by removing 100 μL of media and replacing with 100 μL of 
fresh TCM with natural human IL-2 every two days.  
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A small portion of the first expansion was further expanded as described previously (Koelle et 
al., 2001). Briefly, 5 × 104 cells from the first expansion were mixed with 2.5 × 107 cells of 
gamma irradiated allogeneic PBMCs (3300 CGy, Gammacell 3000 Elan; MDS Nordian), 5 × 
106 gamma irradiated allogeneic LCLs (8000 rad, Gammacell 3000 Elan; MDS Nordian), and 
30 ng/mL anti-CD3 mAb in a total of 25mL of TCM. After 24 hours, fresh media supplemented 
with 50 U/mL of human recombinant IL-2 (r-IL2) was added. After every 3 days, fresh media 
with r-IL2 was added until day 14 where the cells were split as needed with the cell 
concentration maintained under 2 ×106 cells/mL. 
 
2.2.3.11 EBV ORFeome screening 
Cos-7 cells were plated at 1 × 104 cells/well in 96-well flat bottom plates (Flacon®, Becton 
Dickinson Lab ware) in 200 μL of DMEM as described previously (Koelle et al., 2001). After 
24 hours, Cos7 cells were co-transfected with 75 ng of HLA-B*57:01 plasmid DNA and 150 
ng of pDEST103-EBV ORF per well using FuGENE 6. Each EBV ORF was tested in duplicate 
transfection experiments. Cos7 cells transfected with a pDEST103 empty plasmid was used as 
a negative control. After 72 hours, Cos7 cell media was removed and bulk EBV-specific CD8+ 
T cells were added at 5-10 × 104 cells/well in 100-200 μL fresh TCM. After 48 hours, 
supernatants were collected and stored at -20°C. T cell activation was identified by supernatant 
ELISA for IFN-γ. 
 
2.2.3.12 Enzyme linked immunosorbent assay (ELISA) 
T cell activation was detected by supernatant ELISA for IFN-γ as described previously (Koelle 
et al., 2001). Briefly, clear flat-bottom 96-well Maxisorp Nunc-immuno nonsterile plates 
(ThermoFisher Scientific, Australia) were coated with 100 μL of 1 μg/mL of mouse IgG1 
recombinant human IFN-γ (2G1) diluted in 0.1 M sodium carbonate (pH 9.6) buffer overnight 
at 4°C. After washing the wells three times with PBS-T, plates were blocked with 200 μL of 
blocking buffer for 1 hour at room temperature. After blocking and washing three times, 100 
μL of supernatants from EBV ORFeome screening were added. For standards, human 
recombinant IFN-γ ELISA standard serially diluted from 800 pg/mL to 12.5 pg/mL in sample 
buffer were added and incubated for 2 hours with shaking at room temperature. Plates were 
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washed five times and 100 μL of mouse IgG1 recombinant human IFN-γ biotin conjugate 
(B133.5), diluted to 100 ng/mL in sample buffer was added for 1 hour with shaking at room 
temperature. After five washes, 100 μL of streptavidin-horseradish peroxide (HRP), diluted 
1:1000 in TBS-T buffer, was added for 30 minutes. Later, ready to use 3,3′,5,5′-TMB substrate 
was added for 10 minutes and the reactions were stopped with 1 M phosphoric acid. The optical 
density was read at 450 nm wavelength using a DTX 880 multimode detector (Beckman 
Coulter, Canada, Mississauga, ON). Standard curves were constructed using GraphPad Prism® 
Version 5 Software (GraphPad Software Inc., San Diego, Calif, U.S.A.). Standard curves were 
created from serial dilutions of the human recombinant IFN-γ ELISA standard starting from 
800 pg/mL to 12.5 pg/mL and subtracting the mean absorbance value of the blank wells 
as shown in representative Figure B.1 (Appendix B). Sample concentrations were calculated 
using the standard curves in GraphPad Prism® Version 5 Software GraphPad. 
 
2.2.3.13 Enzyme linked immunosorbent spot (ELISpot) 
ELISpot assays were used to detect IFN-γ release by activated CD8+ T cells. A 96-well, 
multiScreen-IP filter ELISpot plate (Merck Millipore, Australia) was coated with 100 μL of 
mouse IgG1 recombinant human IFN-γ (1-D1K) at 2 µg/mL in PBS and incubated overnight 
at 4°C. Polyclonal CD8+ T cells (responder cells) and K562-HLA-B*57:01 single antigen cell 
lines (stimulator cells)  were thawed and resuspended in RPMI-1640 supplemented with 10% 
FBS were rested at 37oC and 5% CO2 overnight. Next day, coated plates were washed 6 times 
with PBS and then blocked with 100 µL of RPMI-1640 supplemented with 10% FBS at room 
temperature for 30 minutes-2 hours. Following blocking, peptides and rested cells at a 
responder/stimulator cell ratio of 10:1 in a total of 100 uL were added to duplicate wells and 
incubated overnight at 37°C and 5% CO2. The responder/stimulator cells with no peptide 
stimulation were also included in duplicate wells as negative controls. The following day, 
plates were washed 6 times with PBS prior to the addition of 100 uL of mouse IgG1 
recombinant human IFN-γ biotin conjugate (7-B6-1), diluted to a final concentration of 1 
μg/mL in sterile PBS and incubated for 2 hours at room temperature, followed by 6 washes 
with PBS. After washing, 100 uL of Streptavidin HRP diluted in 0.5% FCS and supplemented 
with PBS was added to each well at 1 μg/mL final concentration and incubated at RT for 1 
hour. Following the Streptavidin-HRP incubation, the ELISpot plates were washed 6 times in 
PBS and 100 uL of filtered TMB substrate was added to each well. Individual cytokine 
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producing cells were detected as dark spots after a 12-minute reaction with filtered TMB 
substrate. Reactions were stopped by washing the plate with water. The spots were counted 
with an automated imaging device, AID ELISpot analyser (AID GmbH, Strassberg, Germany) 
after air drying the plate overnight. Results from IFN-γ-ELISpot assays were expressed as spot 
forming cells (SFC) per 106 cells after subtracting the average background counts from 
unstimulated negative controls.  
 
2.2.3.14 Intracellular cytokine staining (ICS) 
The frequency of EBV-reactive antigen-specific CD8+ T cells was determined using ICS as 
described previously (Kuzushima et al., 1999). Briefly, bulk expanded CD8+ T cells were 
resuspended at a concentration of 2 × 106 cells/mL in TCM. Autologous LCLs were 
resuspended at a concentration of 1 × 106 cells/mL in TCM. Aliquots of the responder CD8+ T 
cells (0.5 mL) and LCLs (0.5 mL) were mixed in a 24-well plate in the presence of 1 μL of BD 
GolgiPlug™ and were incubated at 37°C and 5% CO2 for 5 hours. As a negative control, the 
same number of CD8+ T cells and LCLs were separately incubated in the presence of the BD 
GolgiPlug™ and combined later. As a positive control, responder CD8+ T cells were stimulated 
with phorbol myristate acetate (50 ng/mL) and ionomycin (500 ng/mL). The cells were surface 
stained with FVS 510, CD3-AF700 and CD8-BB515. Cells were fixed with BD 
Cytofix/Cytoperm™ and permeabilized with BD Perm/Wash™ Buffer. Finally, intracellular 
cytokine staining was performed with IFN-γ-PE-Cy7. Stained cells fluorescence was measured 
on a Beckman Coulter Gallios (Beckman Coulter, Miami Lakes, FL) flow cytometer and the 
data was analysed using Kaluza software (Beckman Coulter, Australia). 
 
2.2.4 Peptides and tetramers 
2.2.4.1 Synthetic peptides 
All peptides were synthesized by Mimotopes (Mimotopes Pty Ltd., Melbourne, Australia) 
with a purity of 90%-95%. The peptides were dissolved in dimethyl sulfoxide (DMSO) at 10 




2.2.4.2 HLA class I monomer complex production 
The HLA class I monomer complexes for EBV peptides complexed with HLA-B*57:01 were 
kindly made by Dr Celestine N Wanjalla (Vanderbilt University, Nashville, Tennessee). 
 
2.2.4.3 HLA class I tetramer production 
For tetramer production, monomer complexes were passed through a 0.5 mL centrifugal 100 
K membrane filter (Amicon® Ultra, Millipore, Australia) and centrifuged at 15,000 g for 1-5 
minutes. The complexes in the spin through, approximately 150 µL, were collected and ⅓ of 
the calculated streptavidin-PE volume (Table 2.4) was mixed and incubated for 15 minutes at 
4°C. Then another ⅓ of the calculated streptavidin-PE volume was added and incubated for 15 
minutes at 4°C. Finally, the last ⅓ of the calculated streptavidin-PE volume was added and 
incubated for 15 minutes at 4°C. The final concentration of the ready to use tetramers was 95 
nM. 
 
Table 2.4. Tetramer production calculations 

























B*57:01 150 400 6E-11 2E-11 0.1 1.8E-06 8.4 95 
SA-PE, streptavidin-PE 
 
2.2.4.4 Tetramer titration and flow cytometry 
The staining intensity can vary between tetramer specificities; hence, the tetramers were titrated 
to find the optimum working dilution to use for each individual tetramer. To minimise waste 
of valuable reagent, only 10 nM and 50 nM concentrations of tetramer were tested. 
Approximately 1 × 106 cells of EBV-specific T cell lines were added to a U-shaped microtiter plate 
and centrifuged at 400 g for 7 minutes. After removing the supernatant, the cells were washed 
in 200 µL of ice-cold FACS buffer and the cell pellets were resuspended and stained with 10 
and 50 nM of tetramer in a final volume of 25 µL. Following 20 minutes incubation at room 
temperature, the cells were washed by adding 160 uL ice-cold FACS buffer and the cells were 
surface stained with CD3-AF700 and CD8-BB515 and incubated at 4oC for 30 minutes. 
Following surface staining, the cells were washed twice in FACS buffer and fixed in 1% 
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formaldehyde and a minimum of 50,000 total events were acquired on a Beckman Coulter 
Gallios (Beckman Coulter, Miami Lakes, FL). The analysis was performed using Kaluza 
software (Beckman Coulter, Australia).  
 
2.2.5 Single cell assays 
2.2.5.1 Tetramer staining and single cell sorting 
Prior to tetramer staining, 5 × 106 CD8+ T cells and 10 × 106 PBMCs were rested overnight and 
washed twice in PBS. The cells were then supplemented with 0.05 U/µL of RNase inhibitor (RNase 
outTM recombinant ribonuclease inhibitor) and stained with either PE-conjugated HLA 
B*57:01/EBNA3B278-287 (VSFIEFVGWL) or HLA B*57:01/EBNA3C60-69 (QSRGDENRGW) 
tetramer at a final concentration of 10 nM for 20 minutes at room temperature in the dark. The 
cells were pelleted by centrifugation at 400 g for 7 minutes and washed in FACS buffer, 
followed by surface staining with antibodies CD3-AF700, CD8-APC Fire 750, and FVS620 
for 30 minutes at room temperature in the dark. After washing the cells twice in FACS buffer, 
cells were resuspended in 500 µL of FACS buffer and strained using a polystyrene tube with 
cell strainer cap (In Vitro Technologies, Australia) and supplemented with 0.1 U/ µL RNase 
inhibitor. Cells were left on wet ice and protected from light until the time of sort. Finally, 
individual cells were sorted directly into each well of a 96-well plate containing 3 µL of lysis 
buffer using the FACSAria III cell sorter at Telethon Kids Institute, Perth, Australia. 
 
2.2.5.2 TCR sequencing from single cells 
TCR sequencing from single cells was carried out at IIID, Murdoch University. Briefly, the 
single cells were reverse transcribed into cDNA, during which individual cell’s cDNA products 
were barcoded and generically tagged with both 3′ oligo-dT–and 5′ biotin–labeled template 
switching oligonucleotides. The cDNA of each cell was subsequently targeted with a combination 
of nested generic tags and suitable gene-specific primers (eg, TCRa or TCRb conserved regions). 
Samples were multiplexed for next-generation library preparation and sequencing. The TCR 
sequencing data was analysed using Visual Genome Analysis Studio (VGAS) software 




2.2.5.3 TCR-α and TCR-β chain gene synthesis and cloning 
The full length TCR-α and TCR-β chain genes were custom synthesised by Integrated DNA 
Technologies (USA) in pUCIDT-Amp vector. The synthesis included the restriction enzyme, 
AflII and a self-cleaving peptide, porcine teschovirus-1 (P2A) at 5’ end followed by TCR-α and 
TCR-β chain genes linked with another P2A and SacII at 3’ end. The defined epitope specific TCR-α 
and TCR-β chain genes linked with P2A in pUCIDT-Amp plasmid were cut with AflII and SacII and 
cloned into a similarly cut pAR100 plasmid. 
 
2.2.5.4 Transfection of effector Jurkat cells 
Jurkat T cells were cultured and passaged at 0.5 × 106 cells/mL at least once before transfection. The 
cells were transfected when they were in the log phase. For transfection, cells were pelleted and 
washed once in Opti-MEM™ reduced serum media and resuspended at 5 × 107 cells/mL in Opti-
MEM™. Transfection of Jurkat cells was performed by electroporation as follows. A total of 1 × 107 
cells in 200 μL per experiment were transferred to a 0.4 cm cuvette (Bio-Rad Laboratories, 
Inc.) containing 10 μg of pAR100 plasmid and electroporated using a Gene Pulser Xcell ™ 
Electroporation System (Bio-Rad Laboratories, Inc.) using the square-wave protocol: SQR 
wave, 230V, 25ms, 1 pulse with CE module (V, % droop). After 10 minutes of recovery at 
room temperature, cells were transferred to a 6-well plate containing 5.8 mL of RPMI-1640 
with no phenol red and incubated 24 hours prior to co-culture. Transfection efficiency was 
assessed by flow cytometry to detect GFP and surface expression of CD8A with CD8 APC-
Fire 750. 
 
2.2.5.5 Co-culture and luciferase reporter assay 
For peptide and/or drug pulsing targets, K562-B*57:01 single antigen lines were resuspended 
at 1 × 106 cells/mL in RPMI-1640 with no phenol red supplemented with 10% FCS and 50,000 
cells were added to each well of a U-bottom 96-well plate. Either 10 μg/mL or 1μg/mL of 
peptide and/or 10μg/mL of abacavir were added to the corresponding wells and cells were 
incubated at 37°C and 5% CO2 for 20-24 hours. The final volume in each well was adjusted to 
70 μL with RPMI-1640 with no phenol red supplemented with 10% FCS. After 24 hours, Jurkat 
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effector cells were re-suspended at 1.65 × 106 cells/mL and 50,000 cells (30 μL) were added to 
target cells, yielding an effector to target ratio of 1:1. The total volume in each well was 100 
μL. The cells were incubated at 37°C in 5% CO2 for 6 hours. After incubation, the entire 
volume of Jurkat-K562-B*57:01 co-culture was transferred to a white Cliniplate 
(ThermoScientific) and 100 μL of Luciferin BrightGlo or Steady-Glo was added to each well. 
After incubating the plates in the dark for 10 minutes at room temperature, luciferase reporter 
was measured on a DTX 880 multimode detector (Beckman Coulter Canada, Mississauga, ON) 
using 3000 ms integration. 
 
2.2.6 Statistical analysis 
Analysis of variance (ANOVA) were done using GraphPad Prism version 5.02 (GraphPad 
software, La Jolla, CA). A p value of <0.05 was considered to be statistically significant. 
Statistical assistance in this project was provided by Prof. Ian James. 
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EBV-specific CD8+ T cell responses may be involved in the heterologous immune response to 
abacavir plus self-peptide. EBV is a large complex human herpesvirus that expresses 89 
proteins. This large number of proteins provides a significant source of potential peptides for 
CD8+ T cells. Therefore, to decode the fine specificity of CD8+ T cell response to each EBV 
antigen, the construction of the EBV ORF expression library was required. 
The common wild type B95-8 strain of EBV was chosen as the source of EBV ORFs in this 
study. The B95-8 strain of EBV is infectious mononucleosis derived isolate, which is 
biologically indistinct from other strains of EBV and transforms B cells efficiently in vitro 
(Miller and Lipman, 1973). However, this strain lacks a 12-kb genomic region (Baer et al., 
1984). The deleted region of B95-8 strain encodes four ORFs, LF1, LF2, LF3 (Kanda et al., 
2015) and RPMSI (Zhang et al., 2001). To represent the whole genome, the current study 
included the ORFs in the deleted region of B95-8, from a human Burkitt’s derived isolate, Raji 
strain. All the ORF sequences of the study were compared against the reference sequence, 
accession number NC_007605, which contains the sequences of both B95-8 and Raji strains. 
The reference sequence is approximately 172 kb in length and encodes 89 ORFs. 
This chapter describes the construction of an EBV ORFeome library that will be used to screen 
CD8+ T cell responses to EBV in Chapter 4 of the thesis. 
 
3.2 EBV ORF library construction 
3.2.1 Generation of Gateway® entry clones 
A comprehensive EBV ORF library was collected and constructed in a flexible format for 
further subcloning into a custom-made expression vector, pDEST103 (Jing et al., 2012). Table 
A.1, Appendix A; shows the list of EBV ORFs studied, their temporal phase, and the size of 
the relevant protein product. Overall the library encompassed 88 ORFs of the 89 known EBV 
proteins encoding 9 latent, 75 lytic and 4 unknown class proteins One latent protein, RPMS1, 
could not be cloned and is not present within the library. 
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A library or ORFeome representing 85 EBV proteins, was kindly provided by Dr Mike 
Calderwood (The Channing Laboratory, Harvard Medical School and Brigham and Women’s 
Hospital, Boston, MA 02115). The ORFs were supplied in a Gateway® entry vector, 
pDONR223 (Invitrogen) that allows subcloning of ORFs into other expression vectors by 
Gateway® recombinational cloning system.  
The remaining three ORFs, BCRF2/BWRF1 (homologous proteins), A73 and BVLF1 were 
PCR amplified from B95-8 cell line cDNA template using forward and reverse primers 
incorporating the attB sites (Table 2.1; Chapter 2). The PCR DNA fragments (Fig. 3.1) were 
gel purified and directly ligated into pDONR201 Gateway® entry vector which has the 
complementary attP sites utilising the Gateway technology BP® clonase II enzyme 
(Invitrogen). Following transformation into DH10B cells and selection for kanamycin 
resistance, plasmid DNA was extracted from single colonies grown overnight under antibiotic 
selection. The presence of the EBV ORF insert was confirmed by restriction enzyme digest of 
the plasmid DNA with the BsrGI restriction enzyme (Fig. 3.2). Finally, an inventory of EBV 
ORF entry clones in pDONR223 and pDONR201 vectors for flexible transfer into a destination 





Figure 3.1. PCR amplification of BCRF2, BVLF1 and A73 ORFs  
Following the synthesis of cDNA from RNA of B95.8 cell line, PCR was used to amplify gene 
fragments using forward and reverse primers incorporating the attB sites (Table 2.1; Chapter 
2). (A). Lane 1, 1 Kb plus DNA ladder; lane 2, BCRF2 gene (1149 bp); lane 3, BVLF1 gene 





Figure 3.2. Restriction enzyme digest of the plasmid DNA from each colony with BsrGI 
to confirm ORF inserts  
Plasmids that contained the insert showed a separation of insert, BCRF2(1149 bp); BVLF1(816 
bp); A73 (378 bp) and vector (2220 bp). Labels on each line correspond to different colonies 
for each construct (‘+’ represents positive for insert; ‘-’ represents no insert).
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3.2.2 Generation of expression library suitable for transfection 
in antigen presenting cells 
To facilitate the expression of the library in Cos7 cells, and to screen for antigen-specific CD8+ 
T cells, the EBV ORFs from Gateway® entry clones were then subcloned into a destination 
vector, pDEST103 (Fig. 3.3) (Jing et al., 2012). The destination clones express the ORF such 
that enhanced green fluorescent protein (EGFP)-fusion is at the N terminus of the polypeptide 
for monitoring the transfection efficiencies of the EBV ORF constructs.  
Cloning was performed with the entry clones (pDONR223/pDONR201-containing EBV ORF) 
and the destination vector (pDEST103) using LR® clonase II enzyme (Invitrogen), which 
catalyses the recombination of the gene of interest via the attL sites with the attR sites of the 
destination vector. The cloning led to the production of expression clones by transferring ORF 
sequences from the Gateway® entry clones into the custom expression vector pDEST103. 
Finally, the cloning reactions were transformed into competent E. coli strain DH10B; positive 
clones were selected by ampicillin resistance. 
The repeated domains in EBNA-LP and LF3 were deleted to reduce the size of the ORF. The 
long ORF, BPLF1 was truncated into six fragments overlapping by several hundreds of 
nucleotides. Similarly, BOLF1 was truncated into three overlapping fragments. All the 
remaining ORFs were cloned as full length ORFs except EBNA1. Many studies demonstrated 
that the glycine-alanine (GA) repeat of EBNA1 inhibits its processing and the subsequent 
association of the derived peptides with MHC-class 1 molecules, a prerequisite for recognition 
by CD8+ T cells (Murat et al., 2014; Tellam et al., 2004; Tellam et al., 2014). Thus, in the case 
of EBNA1, two small expression plasmids including the regions 1-89 AA and 379-641 AA 




Figure 3.3. Vector map of the pDEST103 expression plasmid  
Each EBV ORF was cloned into the custom made pDEST103 plasmid using standard 
Gateway® cloning procedures (Invitrogen). The expression plasmid contains an N-terminal 
EGFP reporter for the identification of transfection and ampicillin resistance gene for selection 





3.2.3 Screening of plasmid constructs to confirm the presence of 
insert 
3.2.3.1 Restriction enzyme digest screening 
After isolation of the plasmid DNA from 2-3 colonies of each ORF, each isolate was digested 
with the BsrGI restriction enzyme to confirm the presence of EBV ORF insert within the 
pDEST103 vector. The BsrGI restriction site is present on both attL1 and attL2 sides flanking 
the insert of all Gateway® ORF clones. Digested samples were analysed on 1% agarose gel 
(Fig. 3.4). Upon analysis, the digested colonies had a band that corresponded to the size of the 
pDEST103 vector and another band that corresponded to the size of EBV ORF. In some cases, 
there were multiple bands besides the vector band. This was seen when one or more BsrGI 





Figure 3.4. Confirmation of the presence of EBV ORF insert in pDEST103 using BsrGI 
restriction enzyme digestion  
Representative DNA agarose gel electrophoresis showing restriction enzyme digest of selected 
clones with BsrGI to confirm ORF inserts. Plasmids that contained the ORF insert showed a 
separation of insert (Bottom band) and vector (Top band). Multiple insert bands of EBNA3B, 
BZLF2, BRLF1, BcLF1, BARF0, BALF1 were due to one or more BsrGI recognition sites in 




3.2.3.2 Screening through Sanger sequencing 
To verify and confirm the reading frame, all ORFs were subjected to Sanger sequencing. The 
plasmids were sequenced using primers that anneal outside the coding region of the insert and 
at EGFP-ORF junctions. In some cases, where the insert size was over 1000 bp, the sequence 
of the complete insert was obtained using primer walking. The resulting sequences of all the 




Figure 3.5. Representative figure showing the EBV ORF cloned into pDEST103 plasmid 





Many studies utilised ORFeome libraries in the comprehensive analysis of virus-specific T cell 
responses (Forrest et al., 2018; Jing et al., 2012; Sylwester et al., 2005). Similarly, the aim of 
the current study was to utilise the EBV ORFeome library to evaluate CD8+ T cell responses 
in HLA-B*57:01 and EBV-positive donors. Therefore, in this chapter, a comprehensive ORF 
collection of EBV including 88 ORFs of the total 89 known EBV proteins was constructed. 
However, one EBV protein, RPMS1, which proved difficult to clone was missing in the library.  
All the ORFeome clones were maintained as homogeneous plasmid DNAs purified from single 
colonies. The identity and integrity of each ORF in the expression plasmid was confirmed by 
DNA sequencing. The important feature of the library was EGFP fusion tag at the N-terminus 
of the ORF, which helps to monitor the transfection efficiencies of the EBV constructs. 
In summary, this chapter describes the successful construction of the expression library of B95-
8 strain of EBV, which was utilized in Chapter 4, in the screening of CD8+ T cell responses to 
each ORF in a panel of six healthy HLA-B*57:01 and EBV positive donors.
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Chapter 4 Global mapping of CD8+ T cell 
responses to Epstein-Barr virus 
Hypothesis 1: Genome-wide mapping of EBV reveals novel candidate CD8+ T cell antigens, 
whose responses maybe implicated in the heterologous immune model of abacavir 
hypersensitivity (AHS). 
Aim 1: Comprehensive mapping of CD8+ T cell responses to the EBV ORFeome in HLA-
B*57:01, EBV seropositive individuals
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4.1 . Introduction 
CD8+ T cells play a critical role in controlling the primary and persistence phases of EBV 
infection (Khanna et al., 1995). EBV is a ubiquitous virus that infects 95% of the human 
population. Primary infection with EBV in adolescence can lead to infectious mononucleosis 
and persistent infection can cause life threatening infections in immunocompromised 
individuals. At the initiation of this study, there was no comprehensive mapping of CD8+ T 
cell responses to an entire EBV ORFeome. More recently, Forrest et al. (2018) explored a 
proteome-wide analysis of CD8+ T cell responses to EBV lytic antigen proteins. However, this 
study explored CD8+ T cell responses to EBV, restricted to a range of HLA alleles, but did not 
include the abacavir risk allele, HLA-B*57:01. Currently, a limited number of HLA-B*57:01 
restricted CD8+ T cell epitopes have been identified; no study has explored for the global 
genome-wide responses to EBV epitopes restricted by this risk allele.  
To study CD8+ T cell responses to EBV in healthy virus carriers, efficient stimulation of 
memory responses in vitro is essential. Conventionally, the memory CD8+ T cell responses to 
EBV is stimulated by challenging PBMCs in vitro with the autologous EBV-transformed LCLs 
(Khanna et al., 1992; Murray et al., 1992; Rickinson et al., 1981). However, LCLs are largely 
composed of latently infected cells and only a small fraction of cells enters the lytic cycle. 
Hence, the antigen-specific response is skewed towards latent proteins. Consequently, LCL 
stimulation of lymphocytes tells us less about CTL responses to virus lytic cycle antigens. 
During the lytic phase of replication, EBV exhibits a temporally regulated cascade of gene 
expression beginning with immediate early (IE) proteins followed by the early (E) proteins 
then the expression of late (L) proteins. The observation that HLA class I expression was 
downregulated at the cell surface of EBV-infected cells upon entry into lytic cycle (Keating et 
al., 2002), demonstrated increased immune evasion as the EBV replicating cells progressed 
through the lytic phase (Pudney et al., 2005). The immune evasion proteins impair the 
availability of viral peptides for presentation by MHC class I molecules on the LCL cell 
surface. Therefore, using lytic phase induced LCLs as antigen presenting cells could lead to a 
bias in the CD8+ T cell responses with IE epitopes relatively well represented followed by E 
epitopes and then lastly L phase expressed epitopes (Forrest et al., 2018). 
Some studies have used alternative APC such as monocyte derived dendritic cells (moDC), to 
stimulate HSV-1 specific CD8+ T cells (Jing et al., 2012). Recently, Forrest et al. (2018) used 
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a similar approach to avoid the phase-specific effects of evasins of EBV and present all antigens 
on the cell surface (Forrest et al., 2018). No study appears to have compared these antigen 
presenting systems side by side as a means of identifying T cells specific to all phases of EBV 
replication. In particular, this study sought to comprehensively map HLA-B*57:01 restricted 
CD8+ T cell responses to EBV and to develop an efficient protocol for the identification of 
EBV-specific CD8+ T cell responses.  
 
4.2 Results 
4.2.1 Approaches to stimulate and enrich EBV-specific CD8+ T 
cells 
In order to screen for CD8+ T cell responses against all EBV proteins, a large number of donor 
T cells are required. The precursor frequency of EBV-specific CD8+ T cells in the blood of 
healthy donors range from 0.05-2% of the total CD8+ T cell population. To identify the EBV-
specific responses that occur at lower frequencies, a large number of T cells with enriched 
specificity for CD8+ T cells is required. 
To stimulate and enrich EBV-specific CD8+ T cells from the blood of healthy virus carriers 
and to screen these T cell lines for reactivity to EBV proteins, 4 different approaches were 
developed. Comparisons between these approaches could provide a method for the 
identification of most of the CD8+ epitopes recognised by EBV-specific T cells and increase 
our understanding of T cell responses to EBV antigens.  
To detect the stimulated EBV-reactive CD8+ T cells, a similar method to that of Jing et al. 
(2012), based on activation induced expression of CD137 was used. In the present study, six 
EBV positive healthy donors (Table 2.3; Chapter 2) were recruited, in whom EBV-specific T 
cells were stimulated and isolated with the 4 approaches described below.  
 
4.2.1.1 Approach 1: stimulation with conventional LCL 
From each healthy EBV positive donor studied, LCLs were generated as described in Chapter 
2 (section 2.2.3.3). Autologous CD8+ T cells were co-cultured with gamma irradiated LCLs 
overnight as described in Chapter 2 (section 2.2.3.8). Activated CD8+ T cells were sorted based 
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on upregulation of the activation marker, CD137 and then directly expanded by non-specific 
PHA-P stimulation. After 14 days, cells were restimulated with an anti-CD3 monoclonal 
antibody (mAb) in IL-2-supplemented medium and expanded for another 2 weeks. These 
polyclonal CD8+ T cell lines, enriched for specificity to EBV, were used for immediate testing 
or were cryopreserved for future use. These EBV-specific T cell lines generated by stimulation 
with conventional LCLs are hereafter referred to as EBV-enriched cLCL. 
 
4.2.1.2 Approach 2: stimulation with lytically induced LCL 
The LCLs from each donor were chemically induced to lytic phase replication in vitro using 
12-O-tetradecanoylphorbol 13-acetate (TPA) and sodium butyrate (NaB) for 24 hours as 
described in Chapter 2 (section 2.2.3.4). Lytically induced LCLs were gamma irradiated and 
co-cultured with autologous CD8+ T cells overnight as described in Chapter 2 (section 2.2.3.8). 
Activated CD8+ T cells were sorted and expanded as described above (section 4.2.1.1). These 
EBV-enriched T cell lines, produced by stimulating with lytically induced LCLs, are hereafter 
referred to as EBV-enriched lyLCL. 
 
4.2.1.3 Approach 3: stimulation with moDC plus conventional LCL 
From each healthy donor studied, dendritic cells were generated by IL-4 and GM-CSF 
stimulation of monocytes as described in Chapter 2 (section 2.2.3.5). The monocyte derived 
dendritic cells were then exposed to gamma irradiated autologous LCLs and cocultured with 
autologous CD8+ T cells as described in Chapter 2 (section 2.2.3.7). The antigen-stimulated 
memory cells were identified and sorted through the cell surface expression of CD137. Sorted 
CD137+ T cells were then expanded twice with non-specific stimulation as described above 
(section 4.2.1.1). EBV-enriched T cell lines produced by stimulating with moDC plus 
conventional LCLs are hereafter referred to as EBV-enriched moDC+cLCL. 
 
4.2.1.4 Approach 4: stimulation with moDC plus lytically induced LCL 
The moDC derived from each donor were exposed to gamma irradiated lytically induced 
autologous LCLs and cocultured with autologous CD8+ T cells, followed by FACS sorting of 
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the activated CD8+ T cells based on the upregulation of CD137. The resultant EBV-specific 
CD8+ T cells were expanded twice with non-specific stimulation as described above (section 
4.2.1.1). EBV enriched T cell lines produced by stimulating with moDC plus lytically induced 
LCLs are hereafter referred to as EBV-enriched moDC+lyLCL. 
An overview of all EBV enriched T cell lines isolated and expanded in this study is shown in 
Table 4.1. Non-EBV-specific CD8+ T cells (CD137-) were also sorted and expanded under 




Table 4.1. List of T cell lines established from EBV-positive and HLA-B*57:01+ donors 
 
 Mode of antigen presentation 
 Conventional LCL Lytically induced LCL  
 CD137
+ T cells CD137- T cells CD137+ T cells CD137- T cells 
Donor 1 EBV-enriched cLCL1 Control cLCL1 EBV-enriched lyLCL1 Control lyLCL1 
Donor 2 EBV-enriched cLCL2 Control cLCL2 EBV-enriched lyLCL2 Control lyLCL2 
Donor 3 EBV-enriched cLCL3 Control cLCL3 EBV-enriched lyLCL3 Control lyLCL3 
Donor 4 EBV-enriched cLCL4 Control cLCL4 EBV-enriched lyLCL4 Control lyLCL4 
Donor 5 EBV-enriched cLCL5 Control cLCL5 EBV-enriched lyLCL5 Control lyLCL5 
Donor 6 EBV-enriched cLCL6 Control cLCL6 EBV-enriched lyLCL6 Control lyLCL6 
 
 Mode of antigen presentation 
 moDC+conventional LCL moDC+lytically induced LCL 
 CD137
+ T cells CD137- T cells CD137+ T cells CD137- T cells 
Donor 1 EBV-enriched moDC+cLCL1 Control moDC+cLCL1 EBV-enriched moDC+lyLCL1 Control moDC+lyLCL1 
Donor 2 EBV-enriched moDC+cLCL2 Control moDC+cLCL2 EBV-enriched moDC+lyLCL2 Control moDC+lyLCL2 
Donor 3 EBV-enriched moDC+cLCL3 Control moDC+cLCL3 EBV-enriched moDC+lyLCL3 Control moDC+lyLCL3 
Donor 4 EBV-enriched moDC+cLCL4 Control moDC+cLCL4 EBV-enriched moDC+lyLCL4 Control moDC+lyLCL4 
Donor 5 EBV-enriched moDC+cLCL5 Control moDC+cLCL5 EBV-enriched moDC+lyLCL5 Control moDC+lyLCL5 
Donor 6 EBV-enriched moDC+cLCL6 Control moDC+cLCL6 EBV-enriched moDC+lyLCL6 Control moDC+lyLCL6 
  
All EBV enriched T cell lines were isolated and expanded from 6 donors (n=6). Non-EBV-specific CD8+ T cells (CD137-) were also sorted and 
expanded under similar conditions for use as negative control lines. The lytic cycle in LCLs was induced using TPA and NaB for 24 h; TPA,12-




4.2.2 EBV-specific T cell lines maintained their antigen-
specificity 
Since EBV-specific T cell lines were produced by two rounds of non-specific stimulation, first 
PHA-P and then anti-CD3 mAb, the maintenance of EBV-specificity in these lines was 
assessed by intracellular cytokine staining (ICS). All the EBV-specific lines and control lines 
from 6 donors (Table 4.1) were stimulated with autologous LCLs and tested for IFN-γ 
expression by ICS followed by flow cytometry.  
The overall specificity of the EBV-specific T cell lines was high compared to the control lines 
(Table 4.2) A median of 4.79% of EBV-enriched with cLCL (range 1.25%-16.22%), 4.4% of 
EBV-enriched with lyLCL (range 0.82%-7.87%), 6.84% of EBV-enriched with moDC plus 
cLCL (range 1.59%-19.28%), and 3.7% of EBV-enriched with moDC plus lyLCL (range 
1.31%-14.66%) T cells were specific for EBV, as determined by IFN-γ production (all dot plots 
are shown in Appendix B; B.2). 
The data demonstrate that the sorted and expanded EBV-specific T cells retained specificity to 




Table 4.2. The expression of intracellular IFN-γ (percentage of cells) by live CD3+CD8+ EBV-enriched T cell lines and control lines after 
2 rounds of non-specific mitogen expansion by intracellular staining after exposure to autologous LCLs (all dot plots are shown in 































Donor 1 4 0.91 5 2.7 7.9 0.44 6.35 1.91
Donor 2 10.5 0.77 7.87 1.57 19.28 0.84 14.66 2.57
Donor 3 5.58 2.74 5.8 2.63 5.78 1.79 4.06 2.5
Donor 4 16.22 0.99 3.77 2.13 12.29 2.36 3.35 2.92
Donor 5 1.25 0.08 0.82 0.1 3.93 0.03 2.04 0.04
Donor 6 2.57 0.11 1.4 0.06 1.59 0.09 1.31 0.05
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4.2.3 ORFeome wide screening of EBV defined CD8+ T cell 
responses in healthy donors 
HLA-B*57:01 is a risk allele in AHS. Studies have proposed that the cross-reactivity of the 
pre-existing memory responses to common viruses such as HHV may be responsible for AHS. 
Therefore, the current study was established to map the HLA-B*57:01 restricted CD8+ T cell 
responses to the most common HHV, EBV.  
The EBV ORFeome library constructed in Chapter 3 was used to identify EBV antigen targets 
for the memory CD8+ T cells in 6 EBV positive, HLA-B*57:01 donors (Table 2.3; Chapter 2). 
The HLA-B*57:01 and other donor HLA alleles cloned in an expression vector, pcDNA3.1, 
was kindly supplied by Dr David Koelle (University of Washington, USA). Each ORF was 
tested by duplicate co-transfection studies. Positive T cell recognition of an individual EBV 
antigen was assessed by IFN-γ ELISA. IFN-γ responses to the empty vector, pDEST103, were 
subtracted from the responses to each EBV ORF. IFN-γ concentration was extrapolated from 
the standard curves as described in Chapter 2 (section 2.2.3.12). The IFN-γ standards were 
serially diluted from 800pg/mL to 12.5pg/mL. For the sake of simplicity, the responses below 
the lowest standard (12.5pg/mL) were described as zero. The IFN-γ levels were stratified into 
three groups based on the magnitude of the response, greater than 200pg/mL of IFN-γ were 
considered “high”, responses in between 50-200pg/mL were considered “medium” and the 
responses from 12.5-50pg/mL were considered as “weak”. T cell responses to each ORF were 
only considered positive if both duplicates (technical replicates) were positive. 
To assess the utility of each approach, all EBV T cell lines, from all 6 donors, were individually 




4.2.3.1 CD8+ T cell responses to EBV ORFs using EBV- enriched 
cLCL T cell lines  
Polyclonal T cell lines enriched by stimulating with conventional LCLs (section 4.2.1.1) were 
challenged against target Cos7 cells expressing individual EBV ORFs and HLA-B*57:01 
allele, with the responses across 6 donors shown in Figure 4.1. Based on levels of IFN-γ release, 
the most prominent responses were seen towards EBNA3B, EBNA3C, and LMP1. In one 
donor sample (Donor 2), responses were also detected towards BNRF1 and BGLF1, and no 











Figure 4.1. IFN-γ release by EBV-specific lines stimulated and expanded with conventional LCLs 
IFN-γ secretion was measured after co-culture of polyclonal CD8+ T cells with Cos7 cells individually expressing each EBV ORF in combination with HLA-B*57:01 allele. 
EBV ORFs were arrayed along the x-axis in the order of their location on the EBV genetic map. IFN-γ release in pg/mL was extrapolated from standard curves as described in 
Chapter 2 (section 2.2.3.12). The IFN-γ release less than the lowest IFN-γ standard used in the study, 12.5pg/mL, was graphed at 0. Blue and green bars represent IFN-γ release 
from each duplicate transfection. Data are from 6 healthy donors (n=6).  
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4.2.3.2 CD8+ T cell responses to EBV ORFs using EBV-enriched 
lyLCL T cell lines  
Polyclonal EBV-specific T cell lines produced with lytically induced LCLs (section 4.2.1.2) 
were incubated with Cos7 cells co-transfected with each EBV ORFs and HLA-B*57:01. IFN-
γ responses to each ORF are shown in Figure 4.2. The responses were high towards EBNA3B, 
EBNA3C, and BBLF2-BBLF3, followed by LMP2A and BGLF4 with medium responses, and 
weak responses towards EBNA2, BFLF2, BVRF2, and LMP1. In total, responses were 












Figure 4.2. IFN-γ release by EBV-specific T cell lines stimulated and expanded with lytically induced LCLs 
IFN-γ secretion was measured after co-culture of polyclonal CD8+ T cells with Cos7 cells individually expressing each EBV ORF in combination with HLA-B*57:01 allele. 
EBV ORFs were arrayed along the x-axis in the order of their location on the EBV genetic map. IFN γ release in pg/mL was extrapolated from standard curves as described in 
Chapter 2 (section 2.2.3.12). The IFN-γ release less than the lowest IFN γ standard used in the study, 12.5pg/mL, was graphed at 0. Red and black bars represent IFN-γ release 
from each transfection. Data are from 6 healthy donors (n=6).
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4.2.3.3 CD8+ T cell responses to EBV ORFs using EBV-enriched 
moDC plus cLCL T cell lines  
The IFN-γ secretion by EBV-enriched CD8+ T cell lines stimulated with moDC plus LCL was 
measured after co-culture with Cos7 cells individually expressing each EBV ORF antigen in 
combination with HLA-B*57:01. The responses were high towards EBNA3B, EBNA3C, and 
LMP1, followed by medium responses towards BGLF1 and weak responses towards BORF1, 











Figure 4.3. IFNγ release by EBV-specific lines stimulated and expanded with moDC plus cLCLs 
IFNγ secretion was measured after co-culture of polyclonal CD8+ T cells with Cos7 cells individually expressing each EBV ORF in combination with HLA-B*57:01 allele. EBV 
ORFs were arrayed along the x-axis in the order of their location on the EBV genetic map. IFN γ release in pg/mL was extrapolated from standard curves as described in Chapter 2 
(section 2.2.3.12). The IFNγ release less than the lowest IFN γ standard used in the study, 12.5pg/mL, was graphed at 0. Blue and green bars represent IFNγ release from each 
transfection. Data are from 6 healthy donors (n=6). 
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4.2.3.4 CD8+ T cell responses to EBV ORFs using EBV-enriched 
moDC plus lyLCL T cell lines  
The responses of EBV enriched CD8+ T cells stimulated with moDC plus lytically induced 
LCL were measured based on IFN-γ secretion after co-culture with Cos7 cells individually 
expressing each EBV ORF antigen in combination with HLA-B*57:01. The magnitude of 
CD8+ T cell responses was highest to EBNA3B, EBNA3C, and BRLF1, followed by moderate 
responses towards BORF1 and LMPl, and weak responses towards LMP2A, BLLF3, BZLF1, 
BBRF1, and BGLF4 were also noted (Fig. 4.4). In total, CD8+ T cell responses were detected 











Figure 4.4. IFN-γ release by EBV-specific lines stimulated and expanded with moDC plus lyLCLs 
IFN-γ secretion was measured after co-culture of polyclonal CD8+ T cells with Cos7 cells individually expressing each EBV ORF in combination with HLA-B*57:01 allele. 
EBV ORFs were arrayed along the x-axis in the order of their location on the EBV genetic map. IFN γ release in pg/mL was extrapolated from standard curves as described in 
Chapter 2 (section 2.2.3.12). The IFN-γ release less than the lowest IFN γ standard used in the study, 12.5pg/mL, was graphed at 0. Red and black bars represent IFN-γ release 
from each transfection. Data are from 6 healthy donors (n=6).
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4.2.3.5 Summary of HLA-B*57:01 restricted CD8+ T cell responses to 
EBV ORFs using EBV-enriched T cell lines  
The above screens (Fig. 4.1-4.4) have been combined in Table 4.3 to provide a summary of the 
accumulated data. The summary Table 4.3 represents the spectrum of positive CD8+ T cell 
responses to EBV antigens in checkerboard format distinguishing specificities of the different 
EBV-specific T cell lines across all 6 donors (section 4.2.1). Positive responses were marked 
by shaded squares, with dark green squares identifying the greatest responses (>200 pg/mL of 
IFN-γ), light shade green squares identifying moderate responses (50-200pg/mL of IFN-γ) and 
yellow shade squares identifying weak responses (12.5-50pg/ml of IFN-γ). 
Overall, the HLA-B*57:01 restricted CD8+ T cell responses were detected against 17 EBV 
ORFs. Most responses were focussed towards the 3 EBV latent antigens, EBNA3B, EBNA3C, 
and LMP1. Dominant responses in terms of the amount of IFN-γ produced were found towards 
latent proteins, including EBNA3B, EBNA3C, and LMP1 followed by subdominant responses 
to LMP2A and EBNA2. 
The responses to lytic phase proteins were identified across each temporal stages of lytic cycle 
replication, with a greater number of responses to late proteins. The capsid protein, BORF1, 
was the most frequent protein recognised among late proteins. The responses to IE proteins, 
BZLF1 were recognised by 1 donor and BRLF1 were recognised by 2 donors. The early 
protein, BBLF2-BBLF3 (primase-associated factor), was recognised by 2 donors and the 
remaining proteins, BFLF2, BLLF3 and BGLF4 by 1 donor each. It is noteworthy that 
responses to late proteins were often weak, whereas responses to latent proteins were typically 
strong. 
In regards to which antigen presentation system allowed detection of the broadest T cell 
repertoire, 5 antigen targets were detected using the EBV-enriched cLCL T cell line, 9 using 
EBV-enriched lyLCL T cell line, 7 using EBV-enriched moDC plus cLCL T cell line, and 10 
using EBV-enriched moDC plus lyLCL T cell line. It is noteworthy that the addition of DCs 
typically allowed detection of weak responses, suggesting that these cells enhanced the 
sensitivity of the antigen screen, however for immunodominant antigens the addition of DCs 
has little value.  
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Table 4.3. Summary of HLA-B*57:01 restricted responses in 6 healthy EBV positive donors (n=6) 
 
Positive ORF targets are arranged vertically in the order of their temporal phase. Individual CD8+ responses to targets expanded from different 
antigen presentation assays were marked by shaded squares, with dark green squares identifying strongest responses (>200 pg/ml of IFN-γ release), 
light shade green squares identifying medium responses (50-200pg/ml of IFN-γ release) and yellow shade squares identifying weak responses 







































































































































































4.2.3.6 CD8+ T cell responses to EBV ORFs using various donor HLA 
class I alleles 
To test if the dominance of EBNA3B, EBNA3C, and LMP1 was restricted to HLA-B*57:01 or if similar 
patterns were seen with other HLA class I alleles, CD8+ T cell responses were measured against each 
EBV ORFs with various donor HLA class I alleles using the polyclonal lines and approaches 
described above. In Table 4.4, positive responses were marked by shaded squares as described 
above (section 4.2.3.5). 
The responses to EBNA3 family antigens were detected in at least 1 donor, whereas responses 
to EBNA2 and LMP2A were observed in 2 of 4 donors. No responses were detected towards 
LMP1. In terms of frequency and size, the CD8+ T cell responses to lytic antigens displayed 
marked hierarchy in the order of IE > E > L. 
Regarding the polyclonal lines expanded from various approaches (section 4.2.1), the induction 
of lytic cycle in LCLs or the addition of moDC to LCLs added very little value in the induction 




Table 4.4. CD8+ T cell responses to EBV antigens across disparate donor HLA class I alleles 
by IFN-γ-capture ELISA in 4 healthy EBV positive donors (n=4) 
 
 
Positive ORF targets are arranged vertically in the order of their temporal phase. Individual 
CD8+ responses to targets expanded from different antigen presentation assays were marked 
by shaded squares, with dark green squares identifying strongest responses (>200 pg/ml of 
IFN-γ release), light shade green squares identifying medium responses (50-200pg/ml of IFN-
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This is the first study to screen the full range of HLA-B*57:01 restricted CD8+ responses to 
EBV. This study examined CD8+ T cell responses to the panel of 88 EBV ORFs in 6 healthy 
HLA-B*57:01+, EBV+ donors. This provided a picture of CD8+ T cell responses, with a range 
of 2 to 10 antigen-specific reactivities per donor (Table 4.3). The overall data demonstrated 
responses to 17 antigens and confirmed the previously identified HLA-B*57/58 restricted 
responses to EBNA3B (Lee et al., 2000) EBNA2 (Brooks et al., 2016), and LMP1 
(Duraiswamy et al., 2003). The identification of responses to another 14 antigens including 
LMP2A, BNRF1, BFLF2, BORF1, BLLF3, EBNA3C, BZLF1, BRLF1, BBRF1, BBLF2-
BBLF3, BGLF4, BGLF1, BcLF1 and BVRF2 are novel. 
Previous studies have shown that CD8+ T cell responses in healthy virus carriers focussed 
particularly to epitopes within EBNA3A, EBNA3B and EBNA3C, with subdominant 
responses most frequently recognising LMP2, less frequently to EBNA2, EBNA-LP and LMP1 
and very rarely if ever to EBNA1 (Khanna et al., 1992; Murray et al., 1992). The observations 
in the present study confirm this pattern of immunodominance, where the responses were 
predominantly focussed to EBNA3B and 3C. However, contrary to the previous studies the 
responses to LMP1 were frequent and observed in 6/6 donors tested using polyclonal EBV-
specific lines (Table 4.3). The responses to LMP2A and EBNA2 were observed in 1 donor 
each and no responses were observed to other latent proteins. 
Studies on lytic antigen specific CD8+ T cell responses in long-term virus carriers by Forrest 
et al. (2018) showed that late proteins were the most frequent targets of recognition by the 
CD8+ T cell response. In that study, the dominant responses were most frequently targeted 
toward the late protein, BcLF1, a major capsid protein. Other dominant responses were found 
to the IE protein BZLF1, the E proteins BALF2, BaRF1, BNLF2b and BORF2, and the L 
proteins BBRF3, BDLF1 and BNRF1. Similarly, in the present study the HLA-B*57:01 
restricted responses recognised 2 IE proteins BZLF1 and BRLF1, the 4 E proteins BFLF2, 
BLLF3, BBLF3/BBLF3 and BGLF4, and the 6 L proteins BNRF1, BORF1, BBRF1, BGLF1, 
BcLF1 and BVRF2. The structural proteins BNRF1 and BcLF1, which were the dominant 
targets in the previous study by Forrest et al. (2018) were also identified in the present study, 




This study has also tested methods for the production of EBV-specific T cell lines to determine 
if this influenced ORF recognition. Previous studies used various approaches to generate EBV-
specific T cell lines including gamma irradiated autologous LCLs (Khanna et al., 1992; Murray 
et al., 1992), LCLs containing lytically infected cells (Pudney et al., 2005), and moDC plus 
lytic cell lysate (Forrest et al., 2018). Although many approaches have been assessed for 
expanding T cell lines, no study appears to have compared these methods across the entire 
genome. Therefore, in the current study, to identify and develop a method that reliably 
stimulate and expand EBV-specific T cells in vitro, 4 approaches including; stimulation with 
cLCLs, lytically induced LCLs, moDC plus cLCLs, and moDC plus lyLCLs, were used and 
compared, by evaluating CD8+ T cell responses to EBV using polyclonal EBV-specific T cell 
lines expanded in the 4 approaches (Table 4.1). 
The EBV-specific lines stimulated using gamma irradiated cLCLs recognised 5 EBV antigens 
across 6 donors with the dominant responses to latent proteins, EBNA3B, EBNA3C and LMP1. 
However, in one donor (Donor 4) no antigens were recognised with the EBV-specific lines. 
This was not due to failure of these lines to recognise EBV because they recognised EBV 
antigens presented by other HLA alleles (Appendix B; B.2). Surprisingly, the EBV late antigen, 
BNRF1 was only recognised by T cell line produced by stimulation with cLCLs. Previously, 
this antigen was thought to be expressed exclusively in late lytic cycle, however, studies by 
Abbott et al. (2013) identified BNRF1 in latently infected, growth-transformed cells, 
suggesting that BNRF1 is also a latent antigen (Abbott et al., 2013). The responses to BNRF1 
with the T cell line produced by stimulation with cLCLs suggest the CD8+ T cells recognised 
the antigen in latently infected LCLs. However, the responses were lost with the lines generated 
by stimulation with moDC plus cLCLs. 
The lines generated using lytic phase induced LCLs had increased responses towards lytic 
proteins. However, the responses to some latent proteins were lost. For example, responses to 
EBNA3B, EBNA3C and LMP1 were lost in some donors. Interestingly, the responses to latent 
protein, LMP2A were recognised only through the lines generated with lytically induced LCLs 
and moDC+lyLCLs but not with the lines involving conventional LCLs (cLCL and 
moDC+cLCL). A previous study has shown LMP2A as an immunomodulatory protein that 
mediates partial escape of infected B cells from recognition by CD8+ T cells and maintains 
latency in LCLs (Rancan et al., 2015). In the present study, it may be due to the partial evasive 
mechanism of LMP2A, the CD8+ T cell responses to LMP2A were not recognised using the 
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lines stimulated with cLCLs or moDC plus cLCLs. However, lytic induction in LCLs 
uncovered the responses to this antigen. 
Although the addition of moDC to either conventional or lytically induced LCLs allowed the 
detection of even weak responses to lytic antigens, it suppressed some responses that were 
detected with the lines from LCLs alone. For example, the responses to BNRF1 that were seen 
with the lines stimulated and expanded with cLCL were lost with the lines from moDC plus 
cLCL. In both the systems LCLs were present, the reasons for this contradictory data are not 
clear but it appears that the DCs inhibited the system. 
In summary, the CD8+ screens described in this chapter have led to the identification of many 
novel HLA-B*57:01 restricted T cell responses to EBV. It has been shown that the three latent 
antigens, EBNA3B, EBNA3C, and LMP1 are frequent and dominant targets of the immune 
response. The comparison of approaches to generate EBV-specific lines showed the lytic 
induction in LCLs increased the detection of CD8+ T cell responses to lytic proteins, however, 
responses to latent proteins were lost in some donors. Similarly, the addition of moDC to LCLs 
has allowed the detection levels of even weak responses to lytic proteins, nonetheless, lost some 
responses that were seen with LCLs alone. It is not clear from this study that the addition of 
moDC, especially because of the large number of patient cells required for production, 




Chapter 5 Identification of HLA-B*57:01 
restricted EBV epitopes 
Hypothesis: There are additional undescribed and novel HLA-B*57:01 restricted EBV 
epitopes. 





CD8+ T cells recognise antigen in the form of short peptide fragments complexed with MHC 
class I molecules. MHC class I molecules usually accommodate peptides that are 8-10 amino 
acids in length. Each HLA allele displays a restricted set of peptides, typically defined by 
specific amino acid motifs at anchor residues within the MHC molecule (Falk et al., 1991). In 
the previous chapter, ORFeome wide screening of CD8+ T cell responses to EBV in healthy 
donors identified HLA-B*57:01 restricted responses directed mostly to three EBV genes, 
EBNA3B, EBNA3C and LMP1. Previous studies identified the dual HLA restricted (HLA-
B57/B58) epitope, IALYLQQNW (IAL) in LMP1 (Duraiswamy et al., 2003). Similarly, in 
EBNA3B, VSFIEFVGW (VSF) has been defined as an HLA-B*58:01 restricted epitope (Lee 
et al., 2000). Although, Koning et al. (Koning et al., 2013) used VSF peptide complexed with 
HLA-B*57:01 tetramers for sorting peptide specific CD8+ T cells. These data are consistent 
with the shared binding of these HLA allomorphs, which all belong to the B58 supergroup. 
The minimal HLA-B*57:01 restricted EBNA3C epitope remains unknown.  
To identify relevant T cell epitopes, direct testing of overlapping peptides or peptide libraries 
(Precopio et al., 2008; Roederer and Koup, 2003) or computer aided prediction tools (Jurtz et 
al., 2017; Nielsen and Andreatta, 2016) are commonly employed. Experimental approaches 
using overlapping peptides spanning the entire protein are expensive in terms of time, labour, 
and resource; and not suitable for studies involving large numbers of protein sequences. In 
silico prediction tools based on predicted binding affinities, reduce the number of peptides that 
need to be synthesised and tested. However, for longer sequences, synthesis of all the potential 
peptides is also expensive, with no guarantee that the predicted peptides will be recognised by 
T cell receptors 
This chapter describes the epitope screening in EBNA3C and EBNA3B using truncated 
overlapping minigenes in combination with in silico predicted peptides to identify specific 






5.2.1 In silico predictions failed to identify epitopes in EBNA3C 
Initially, to identify potential HLA-B*57:01 restricted epitopes within EBNA3C, the full-
length amino acid sequence was screened for potential T cell epitopes using NetMHCpan-3.0. 
Peptide prediction was performed by Mr Shay Leary, IIID, Murdoch University. In total, 11 
high binding affinity peptides were selected and synthesised (Table 5.1) based on predicted 
percentage rank <=0.5, which provides the relative affinity of a selected peptide compared with 
a universe of random sequences. (www.cbs.dtu.dk/services/NetMHCpan-3.0.) (Nielsen and 
Andreatta, 2016).  
All 11 peptides were tested for their ability to stimulate EBV-specific CD8+ T cells from a 
cohort of 6 EBV seropositive healthy donors (Table 2.3; Chapter 2) by IFN-γ ELISpot. 





Table 5.1. List of NetMHCpan-3.0 predicted EBNA3C epitopes 
































































5.2.2 Screening of overlapping minigenes localised the 
EBNA3C epitope in the first 125 AA  
To simplify the epitope mapping of the full length EBNA3C protein, 5 EBNA3C overlapping 
minigenes were produced and cloned into an expression plasmid, pDEST103. The plasmids 
express minigenes with an N terminal fused EGFP that allows the monitoring of transfection 
efficiency. All the plasmids were subjected to Sanger sequencing to confirm the identity and 
in-frame fusion with EGFP. 
To identify the location of the EBNA3C epitope, each minigene was co-transfected in Cos7 
cells with HLA-B*57:01 plasmid (pcDNA-B*57:01) and incubated with the EBV-specific T 
cell lines as described in Chapter 2 (Section 2.2.3.11). T cell activation was identified by 
supernatant ELISA for IFN-γ as described in Chapter 2 (section 2.2.3.12). IFN-γ responses 
were identified to minigene-1, which contains the first 1-300 AA. Responses were not detected 
to the other 4 minigenes. Because minigene 1 encodes the first 300 AA and minigene-2 encodes 
AA 125-475 of EBNA3C (Fig 5.1A), the EBNA3C epitope must be within the first 125 AA of 
the protein.  
 
5.2.3 Screening of EBNA3B minigenes confirmed the 
previously described epitope  
Like EBNA3C, EBNA3B is also a large protein and of the same size as EBNA3C. To confirm 
that responses to EBNA3B were due to the previously described epitope, VSFIEFVGWL, and 
not to epitopes elsewhere in the protein, EBNA3B was truncated similar to described for 
EBNA3C. Five EBNA3B minigenes were screened using EBV-specific T cell lines. In 
EBNA3B, positive CD8+ T cell response was observed with two minigene fragments, 1-300 
AA and 125-475 AA regions (Fig. 5.1B). These regions correspond to the location of 
VSFIEFVGWL, 278-288 AA. These data confirm previous studies (Lee et al., 2000), and 






Figure 5.1. Screening of EBNA3C and EBNA3B overlapping minigenes for CD8+ T cell recognition in ELISA assay  
Cos7 cells were transiently co-transfected with HLA-B*57:01 (pcDNA-B*57:01) and minigene plasmids, and then co-cultured with EBV-specific 
T cells. The CD8+ T cell responses to each minigene of (A) EBNA3C and (B) EBNA3B were evaluated in ELISA assay and represented as IFN-
γ release in pg/mL extrapolated from the standard curves as described in Chapter 2 (section 2.2.3.12). X-axes represent the first and last AA of the 
polypeptide sequence. EBV-specific T cell lines of three donors (Donor 1-3) expanded in Chapter 4 (EBV enriched cLCL1-3; Table 4.1) were 


























































































5.2.4 A novel CD8+ T cell epitope was identified in EBNA3C  
Since the minigene screening experiments suggested that the CD8 T cells recognised an epitope 
within the first 125 AA of EBNA3C, additional peptides predicted from this region were 
selected for further screening. In this case, peptide prediction was performed by Prof. Bjoern 
Peters, La Jolla Institute for Immunology, San Diego. In total, 3 predicted peptides (Table 5.2) 
were synthesised and tested in IFN-γ ELISpot (Fig. 5.2). The EBV-specific T cell lines were 
co-cultured with peptide pulsed K562-B*57:01 cell line using peptide concentrations from 10, 
1, 0.1, 0.01, 0.001, and 0.0001 μg/mL and IFN-γ production was measured. The data was 
represented as spot forming units (SFUs) per million cells. The SFU/million cells were 
calculated based on the original cell number input and the spots counted, minus the background 
response determined by the negative control. The peptide, VSFIEFVGW, was used as a 
positive control. 
The three peptides were tested with QSRGDENRGW giving greater responses at 10 µg/mL to 
0.0001 µg/mL peptide concentrations compared to other peptides. For the peptide, 
RGDENRGW, the IFN-γ production was similar to QSRGDENRGW at 10 µg/mL of the 
peptide. However, the IFN-γ production was reduced dramatically with 1 µg/mL of peptide 
and was undetectable with the lower peptide dilutions. No response was observed with the third 




Table 5.2. In silico predicted epitopes in the first 125 AA of EBNA3C 
Allele Start End Length Peptide Method Percentile_rank 
HLA-B*57:01 60 69 10 QSRGDENRGW Consensus (ann/smm) 0.75 
HLA-B*57:01 62 69 8 RGDENRGW ann 0.5 
HLA-B*57:01 51 58 8 YSRDQQPW ann 0.1 











































Figure 5.2. ELISpot screening of in silico predicted epitopes 
An EBV-specific T cell line (EBV-enriched cLCL1; Table 4.1; Chapter 4) was incubated with 
K562-B*57:01 plus in silico predicted peptides (QSRGDENRGW, RGDENRGW and 
YSRDQQPW) and screened for CD8+ T cell responses in an IFN-γ ELISpot. VSFIEFVGW 
was used as a positive control. Data are spot forming units (SFUs) per million cells minus the 




5.2.5 Optimal epitope EBNA3C is a 10-mer  
Further experiments sought to identify the minimal or optimal CD8+ T cell epitope in 
EBNA3C. A nested set of two peptides were synthesized by truncating and extending AA on 
either side of the QSRGDENRGW epitope, including SRGDENRGWM (10-mer), and 
SRGDENRGW (9-mer). All the peptides were initially tested for CD8+ T cell responses by 
ELISpot assays. The K562-B*57:01 cells pulsed with peptides titrated from 10 μg/mL to 
0.0001μg/mL were co-cultured with EBV-specific T cell lines (Fig. 5.3A), and the number of 
IFN-γ producing cells determined by ELISpot after subtracting the background count from 
negative control wells. The peptide, VSFIEFVGW, was used as a positive control.  
As shown in Figure 5.3A, the IFN-γ responses with 10 to 0.01 μg/mL of QSRGDENRGW 
peptide were above the assay linearity and the spot counts were higher than 600 per 
well/100,000 cells. Similarly, the response levels with SRGDENRGW at 10 μg/mL and 1 
μg/mL of the peptide were very high (>600 SFU/100,000cells) and the responses reduced with 
lower doses of the peptide. No responses were detected with the peptide, SRGDENRGWM. 
Since the responses in ELISpot assay with the peptides, QSRGDENRGW and SRGDENRG, 
were very high, the spot counts were unreliable. Therefore, the epitopes were additionally 
assessed by ELISA, as described in Chapter 2 (Section 2.2.3.12), as a complementary assay. 
The K562-B*57:01 cells pulsed with peptides titrated from 10 μg/mL to 0.0001μg/mL were 
co-cultured with EBV-specific T cell lines and the supernatants were tested by ELISA (Fig. 
5.3B). Similar to ELISpot data, the peptide, QSRGDENRGW elicited greater responses with 
10 to 0.1 μg/mL concentrations of the peptide. In contrast, the responses to SRGDENRGW 
were significantly lower and no responses were detected with the peptide, SRGDENRGWM. 
In both the experiments, QSRGDENRGW elicited a considerably higher response even at 0.1 
and 0.01 μg/mL concentrations of the peptide. This data confirmed the decamer, 











































































Figure 5.3. ELISpot and ELISA screening of minimal/optimal epitope in EBNA3C for CD8+ T cell reactivity  
An EBV-specific T cell line (EBV enriched cLCL1; Table 4.1; Chapter 4) was incubated with K562-B*57:01 plus in silico predicted peptides 
(QSRGDENRGW, SRGDENRGW and SRGDENRGWM). The peptide, VSFIEFVGW was used as a positive control. The peptide concentrations 
starting from 10 to 0.0001 µg/mL were tested. (A) The CD8+ T cell responses to peptides in ELISpot. Data are spot forming units (SFUs) per 
million cells minus the background response determined by the negative control. (B) The CD8+ T cell responses to peptides in ELISA. Data is 
represented in IFN-γ (pg/mL) extrapolated from the IFN-γ standards as described in Chapter 2 (Section 2.2.3.12).  
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5.2.6 CD8+ T cell responses to QSR within PBMC were 
relatively dominant than other peptides in donors that 
responded 
Since the CD8+  T cell responses to the QSR peptide typically induced high magnitude of IFN-
γ release from the T cell lines, the precursor memory T cells specific for QSR were tested in 
the blood of the donors to confirm the responses were not culture induced. In parallel, precursor 
frequencies of T cells specific for EBNA3B (VSF), LMP1 (IAL), EBNA2 (LAS), and EBNA1 
(LSR) were also assessed. The PBMCs from the six HLA-B*57:01 healthy EBV positive 
donors that were used for T cell expansion studies (Donor 1-6) and three other HLA-B*57:01 
healthy EBV positive donors (Donor 7-9) were screened for responses by IFN-γ ELISpot assay 
as described in Chapter 2 (Section 2.2.3.13). 
Based on the level of IFN-γ released, the responses to QSR-epitope were relatively dominant 
in each donor compared to the other epitopes, followed by VSF and IAL. At the population 
level, the responses were recognised in 65% of the donors tested, while responses to the VSF 
epitope were found in 100% donors, IAL epitope in 45%, LSR epitope in 10% and no responses 
were detected towards LAS epitope (Fig 5.4).  
The data demonstrate that similar to the responses of EBV-specific T cell lines, the precursor 





Figure 5.4. CD8+ T cell responses to HLA-B*57:01 restricted EBV epitopes within donor PBMC by IFN-γ ELISpot  
The data were represented as the mean number of spot-forming cells (SFC) per million PMBCs from replicate wells after subtraction of baseline 
reactivity to DMSO. The peptides, LSRLPFGMA (LSR), IALYLQQNW (IAL), LASAMRML (LAS), VSFIEFVGW (VSF), and 













































T cell epitopes are antigen derived peptides presented in the context of HLA molecules. The 
identification of epitopes that elicit T cell responses provides a valuable tool for the study of 
cell-mediated immune responses. In Chapter 4, comprehensive analysis of HLA-B*57:01 
restricted CD8+ T cell responses to the full range of EBV proteins found the most prominent 
responses were focussed towards EBNA3B, EBNA 3C and LMP1. In the current study, the 
candidate antigens were screened for the potential epitopes. 
Previous studies have identified HLA-B*58:01 epitope in EBNA3B (Lee et al., 2000) and 
HLA-B*58:01/57:01 restricted epitopes in LMP1 (Duraiswamy et al., 2003). The present study 
concentrated on the identification of CD8+ T cell epitopes within EBNA3C. Initial protein-
wide peptide prediction in EBNA3C with NetMHCpan 3.0, failed to identify epitopes that 
stimulated CD8+ T cell responses. Therefore, a combination of minigene and in silico 
prediction approach was followed, in which the screening was first based on overlapping 
minigenes of EBNA3C expressed in custom made pDEST103 plasmid and co-transfected in 
Cos7 cells along with HLA-B*57:01 plasmid (pcDNA-B*57:01). Secondly, peptides were 
predicted using in silico tools corresponding to positively selected regions of EBNA3C.  
In combination with the minigene approach, in silico based predicted epitope mapping defined 
a novel HLA-B*57:01 restricted epitope, QSRGDENRGW whose optimal length was mapped 
to amino acid position 60-69 of a nuclear protein, EBNA3C. Furthermore, this study confirmed 
the previously identified epitope in EBNA3B (Lee et al., 2000) as an HLA-B*57:01 restricted 
epitope (Fig. 5.1B). The QSR peptide typically induced high magnitude IFN-γ responses from 
T cell lines, suggesting high precursor frequencies of T cells. To confirm this, the PBMCs of 
healthy HLA-B*57:01+ EBV+ donors were screened for precursor memory cells specific for 
the novel epitope. In addition, for comparison, all the known HLA-B*57:01 restricted epitopes 
were also screened. The data confirmed the high magnitude IFN-γ responses to QSR epitope 
in donors responded; however, the responses were observed in 65% of the donors tested, 
suggesting it was not dominant at the population level. 
In summary, a novel HLA-B*57:01 restricted epitope, QSRGDENRGW was identified in 
EBNA3C and the precursor memory T cell frequencies to this epitope were dominant in donors 




Chapter 6 Identification and characterisation of 
VSF and QSR specific CD8+ TCR in 
an HLA-B*57:01 donor 
Hypothesis: EBV-specific T cells cross-recognise HLA-B*57:01 presented abacavir plus self-
peptide. 





The central hypothesis underlying this thesis is that AHS is due, at least in part, to cross-reactive 
memory T cells specific for common human pathogens such as the HHV, cross reacting with 
the trimolecular complex of abacavir, HLA-B*57:01 and self-peptide. This is a combination of 
the “altered-self” hypothesis proposed by (Illing et al., 2012) and a heterologous immunity 
model proposed by (White et al., 2015).  
A highly diverse T cell receptor (TCR) repertoire is linked with efficient recognition and 
control of pathogen infections (Nikolich-Žugich et al., 2004). The TCR diversity is generated 
by the random recombination of variable (V), diversity (D) and joining (J) gene segments, 
junctional variation, and differential pairing of α and β chains (Turner et al., 2006). In theory, 
potential TCR clonal diversity is estimated in the order of 1015 before thymic selection, and 
1013 after thymic selection. This stands in sharp contrast with the actual size of the TCR 
diversity in humans at a given time point, which is 2 × 107 (Nikolich-Žugich et al., 2004). As 
the number of potential foreign peptide-MHC complexes far exceeds that an actual number of 
unique TCRs, the system requires each T cell to recognize numerous peptides and thus be 
cross-reactive to achieve effective immunity. Thus, a single TCR might recognize peptides 
derived from more than one pathogen, a concept termed ‘heterologous immunity.’ Multiple 
mechanisms that explain T cell cross-reactivity have been described, such as changes in CDR 
loop conformation, altered TCR docking, and molecular mimicry (Colf et al., 2007; Garcia et 
al., 1998; Lang et al., 2002; Petrova et al., 2012; Speir et al., 1998). However, the precise 
structural features that drive cross-recognition remains unresolved. 
This study sought to test a heterologous immunity model using the EBV epitopes identified 
and/or characterised in Chapter 5. These are the novel immunodominant, HLA-B57:01 
restricted epitope, QSR from EBNA3C and the VSF peptide from EBNA3B. T cells specific 
for VSF and QSR were subjected to single cell TCR sequencing. Dominant TCR clones 
specific for each peptide were cloned and tested for specificity to their cognate ligands and then 
tested for cross reactivity to HLA-B*57:01 K562 single antigen line (SAL), plus or minus 





6.2.1 Mapping TCR diversity 
The diversity of T cells specific to VSF and QSR was determined by tetramer staining and 
single cell sorting from a single donor (Donor 1; Table 2.3; Chapter 2) who made T cell 
responses to both these epitopes. All experiments were performed with 10 uM of the tetramer, 
which provided data similar to that obtained with 50 uM tetramer (Fig. 6.1). Single T cell 
sorting was performed with a T cell line (Donor 1; EBV-enriched cLCL1; Table 4.1; Chapter 
4) and on PBMCs, the latter to determine if cloning had altered or skewed the T cell repertoire. 
High throughput sequencing of the TCRαβ CDR3 regions was carried out by pooling barcoded 
samples to form a final library and sequenced by Illumina MiSeq platform using 600v3 
reagents (Illumina) at IIID, Murdoch university, Perth. The TCR clonotypes were analysed using 




Figure 6.1. Tetramer staining of HLA-B*57:01-QSR and HLA-B*57:01-VSF via flow cytometry 
The flow plots display QSR (top row) and VSF (bottom row) tetramer responses in EBV-specific T cell lines and control lines (Donor1; EBV 
enriched cLCL1 and control cLCL1; Table 4.1; Chapter 4) stained with either 10nM or 50nM of tetramers to identify the minimal peptide used. 
The values in the quadrant represent the percentage of tetramer+ cells gated on CD8+ T cells 
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6.2.1.1 QSR specific TCR repertoire 
Deep sequencing of single CD8+ T cells specific for the QSR epitope in PBMC revealed 
diversity of T cell repertoires with a total of 7 TCR-α chains and 7 TCR-β chains. The TCRα 
repertoire was dominated by TRAV1-2 and TRAV41 and TCRβ repertoire by TRBV5-1 and 
TRBV6-1 (Fig. 6.2A; QSR-PBMC). These results demonstrate that QSR-specific T cell 
repertories harboured a few dominant clones and other less dominant clones. Next, the likely 
a/b pairing was determined using iiidVGAS (Fig. 6.2B; QSR-PBMC). The TCRαβ pairing 
present within the peripheral blood was dominated by TRAV1-2/TRBV6-1 clonotypes with a 
total number of 11 reads followed by few other sub-dominant TCRαβ-paired clonotypes (Table 
6.1).  
Similarly, analysis of TCR repertoire of QSR specific T cells isolated from EBV-specific T 
cell lines revealed 4 TCR-α chain clonotypes and 6 TCR-β clonotypes (Fig. 6.2A; QSR-T cell 
line). Within the T cell line, the dominant TCR was also TRAV1-2/TRBV6-1 (Fig. 6.2B; QSR-
T cell line) with a total number of 29 paired reads (Table 6.1). 
These data demonstrate that QSR-specific TCR repertoire in both EBV-specific T cell lines 
and PBMC share the same dominant TCR clonotype. Moreover, the subdominant TCRαβ 
clonotypes seen in QSR specific CD8+ T cells isolated from T cell lines were also observed in 
PBMC (Table 6.1). This shows the clonal hierarchy was preserved in expanded T cell lines. 
 
6.2.1.2 VSF specific TCR repertoire  
Analysis of TCR repertoire of the VSF specific T cells within EBV-specific T cell lines 
identified the TRAV and TRBV gene segments and their corresponding CDR3 (Table 6.1). In 
total, 5 TRAV and 6 TRBV clonotypes were identified. The TCRα repertoire was dominated 
by TRAV12-1 and β repertoire by TRBV20-1 (Fig. 6.2A; VSF-T cell line) with a total number 
of 14 and 37 reads respectively. The analysis of TRAV-TRBV pairing revealed the TRAV12-
1/TRBV20-1 as dominant pair (Fig. 6.2B; VSF-T cell line) with a total number of 10 reads. 
However, the subdominant TCRα clonotype, TRAV1-2, and TCRβ clonotypes, TRBV5-1, and 
TRBV6-1 were also identified in TCR repertoire specific to QSR (Fig. 6.2B; QSR-T cell line). 
This observation of same TRAV1-2/TRBV6-1 clone pair with dual specificities was tested by 
the reconstituted TCRs in Jurkat assay (section 6.2.5.1) and the TCRs showed no cross-









Figure 6.2. Circos plots showing TRAV and TRBV clonotype frequency and pairing in Donor 1 towards QSR and VSF epitopes 
(A)Each pie chart illustrates the frequency of TCRα and TCRβ sequences of sorted CD8+ tetramer specific cells from a single donor. QSR-PBMC 
represent single cells specific to QSR isolated from PBMC; QSR-T cell line represent single cells specific to QSR isolated from EBV-specific T 
cell line (EBV enriched cLCL1; Table 4.1; Chapter 4); VSF-T cell line represent single cells specific to VSF isolated from EBV-specific T cell 
line (EBV enriched cLCL1; Table 4.1; Chapter 4); Pie chart colours match clonotypes. (B) Circos plots displaying paired TRAV-TRBV clonotype 




Table 6.1. Details of the TCR clones identified in this study, including peptide reactivity and cell source, paired TCRα/β V and J gene 
usage and CDR3 sequences 
Peptide/Sorted cell source TRAV TRAJ CDR3 TRBV TRBJ CDR3 Count
TRAV1-2 TRAJ8 CAAPNTGFQKLVF TRBV6-1 TRBJ2-1 CASTGGRSSYNEQFF 11
TRAV41 TRAJ34 CAVWGRNTDKLIF 3
TRAV13-2 TRAJ49 CAATLSRNTGNQFYF 1
TRAV41 TRAJ34 CAVWGRNTDKLIF 1
TRAV16 TRAJ53 CAPPRVNSGGSNYKLTF 2
TRAV8-1 TRAJ15 CAVKRGGTALIF TRBV27 TRBJ2-1 CASSPPGRSYNEQFF 2
TRAV4 TRAJ30 CLVGSNRDDKIIF TRVB27 TRBJ2-1 CASSPPGRSYNEQFF 1
TRAV22 TRAJ30 CAVNRDDKIIF TRBV9 TRBJ2-3 CASSVVGGRAADTQYF 1
TRAV1-2 TRAJ8 CAAPNTGFQKLVF TRBV6-1 TRBJ2-1 CASTGGRSSYNEQFF 29
TRAV41 TRAJ34 CAVWGRNTDKLIF TRBV5-1 TRBJ2-3 CASRETGGRAGFADTQYF 3
TRAV41 TRAJ34 CAVWGRNTDKLIF 1
TRAV16 TRAJ53 CAPPRVNSGGSNYKLTF 1
TRAV4 TRAJ30 CLVGSNRDDKIIF TRVB27 TRBJ2-1 CASSPPGRSYNEQFF 1
TRAV12-1 TRAJ39 CVVHNAGNMLTF TRBV20-1 TRBJ1-5 CSASSPRLTSNQPQHF 10
TRAV1-2 TRAJ8 CAAPNTGFQKLVF 1
TRAV21 TRAJ30 CAVLVNRDDKIIF 1
TRAV22 TRAJ9 CAVDRNTGGFKTIF 1
TRAV1-2 TRAJ8 CAAPNTGFQKLVF 1
TRAV21 TRAJ30 CAVLVNRDDKIIF 1
TRAV22 TRAJ9 CAVDRNTGGFKTIF 1
TRAV1-2 TRAJ8 CAAPNTGFQKLVF 1
TRAV21 TRAJ30 CAVLVNRDDKIIF 1
TRAV22 TRAJ9 CAVDRNTGGFKTIF 1













6.2.2 A modified NFAT-luciferase reporter system to clone 
TCRs  
To address the specificity of each dominant pair of TCR clonotypes and investigate the 
possibility that heterologous immunity contributes to abacavir hypersensitivity, a modified 
heterologous T cell receptor reporter assay was developed. This assay was modified from that 
described by Anmole et al. (2015), where separate plasmid DNAs encoding TCRα, TCRβ 
genes, CD8 alpha, and a nuclear factor of activated T cells (NFAT)-luciferase reporter were 
transiently co-transfected in Jurkat “effector” cells. Here, and in order to simplify the TCR 
assay, two plasmids, pAR100 and pAR101, were produced that allowed for the expression of 
all the necessary components (CD8α, luciferase and both TCR chains) within the one plasmid. 
pAR100 allows cloning of TCRs through restriction enzymes (AflII/ApaI and SacII), whilst 
pAR101 permits Gateway® cloning of the TCRαβ chains.  
To create pAR100, CD8 fragment was PCR amplified from pORF9-hCD8Aa plasmid using 
CD8_F and CD8_R primers (Table 2.2; Chapter 2) flanking with AgeI and AflII restriction 
enzyme sites, respectively. The 1.3 kb PCR fragment was digested with AgeI and AflII and 
cloned into a similarly digested pSELECT-GFPzeo-mcs plasmid. The resultant plasmid, 
pIIID_GFP_CD8, was linearized with NheI, dephosphorylated with calf intestinal alkaline 
phosphatase and a multiple cloning site (MCS) I was added. To generate MCSI, forward and 
reverse primers (Table 2.2; Chapter 2) containing AflII, ApaI, AscI, BsiWI, BstZ17I, NruI, 
PstI and SacII flanking with NheI overhangs were designed and annealed. For annealing, 20 
uM of each primer was mixed in the presence of 1× NEB Buffer#2 and annealed at 95oC for 5 
min followed by cooling to room temperature. The resultant annealed MCSI with NheI 
overhangs was ligated into NheI linearized pIIID_GFP_CD8 plasmid to produce 
pIIID_GFP_CD8_MCSI. Similarly, an additional multiple cloning site, MCSII, containing 
KpnI, XbaI, BamHI and SalI flanking with EcoRI overhangs was designed (Table 2.2; Chapter 
2), annealed and ligated into EcoRI linearized pIIID_GFP_CD8_MCSI plasmid to produce 
pIIID_GFP_CD8_MCSI_MCSII. Later, luciferase with the NFAT promoter from pGL3-
NFAT luciferase plasmid was digested with KpnI and SalI and ligated into a similarly digested 
pIIID_GFP_CD8_MCSI_MCSII plasmid. The resultant plasmid was named pAR100 (plasmid 
map and sequence in Appendix C; C.1) 
To create pAR101 which allows Gateway® cloning of TCRs, reading frame cassette A 
(Invitrogen) was PCR amplified from pDONR201 using attR1-KpnI and attR2-EcoRV primers 
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(Table 2.2; Chapter 2) flanking with KpnI and EcoRV respectively. The primer sequences 
were: 5’-taagcaGGTACCAC AAGTTTGTACAAAAAAGCTGAAC -3’ (KpnI underlined) 
and 5’-tgcttaGATATCACCACTTTGTACAAGAAAGCTGAA C -3’ (EcoRV underlined). 
The PCR amplified Reading frame cassette A was digested with KpnI and EcoRV and ligated 
into similarly digested pcDNA3.1(+) plasmid. The resultant plasmid, pcDNA3.1-attR1R2 was 
digested with AflII and ApaI and ligated into similarly digested pAR100. The final plasmid 
was named pAR101 (plasmid map and sequence in Appendix C; C.2).  
 
6.2.3 Cloning of the QSR and VSF specific TCRs 
The TCR sequence analysis identified a dominant TCRα and TCRβ pair sequences specific for QSR 
(TRAV1-2/TRBV6-1) and a dominant TCRα and TCRβ pair for VSF (TRAV12-1/TRBV20-1) 
epitopes. For in vitro reconstitution of these TCRαβ pairs, full length TCR were custom 
synthesized such that two porcine teschovirus-1 (P2A) (Luke et al., 2008) sequences were 
included, one between TCRα and TCRβ and another preceding TCRα, to facilitate stoichiometric 
coordinate expression of CD8α, TCRα and TCRβ under the control of same promoter, EF-
1α/HTLV. The synthesized fragments were cloned into the pAR100 construct and the final plasmids 
were sequenced to ensure that the cloned TCRs were in frame with CD8α. The final plasmid 
contains CD8α, TCRα, TCRβ and NFAT‐luciferase reporter to allow the measurement of TCR‐
mediated activation. The construct was also equipped with EGFP reporter to confirm the 









6.2.4 Reconstitution of the QSR and VSF specific TCRs in 
Jurkat cells 
To assess the utility of the modified reporter assay and characterise the responses of epitope specific 
TCRs, the single plasmids containing either QSR-TCR or VSF-TCR were transiently transfected into 
Jurkat E6.1 cell line. The transfection efficiency of each TCR plasmid was determined by flow 
cytometry based on co-expression of GFP and CD8α. (Fig 6.4) at 24 hours post transfection. The 
surface CD8α expression of the GFP positive Jurkat cells transfected with the QSR TCR plasmid was 
39% of the gated live cells and 20% of the gated live cells for VSF TCR plasmid. This indicated 










Figure 6.4. Flow cytometric determination of transfection efficiency based on GFP and CD8 expression in Jurkat cells  
Flow plots illustrate the expression of GFP and CD8α detected in untransfected (left), cells transfected with QSR-TCR plasmid (middle) and cells transfected 














6.2.5 Reconstituted TCRs can recognise QSR and VSF loaded 
target cells 
To test the hypothesis that EBV-specific T cell receptors cross-recognize abacavir-induced 
altered self, TCRs specific to each EBV epitope were assessed using the in vitro T cell reporter 
assay described above. First, the specificity of each TCR was confirmed. Secondly, the EBV-
specific TCRs were examined for the cross-reactivity to abacavir modified self. 
 
6.2.5.1 Specificity validation of QSR-TCR 
To assess the specificity of QSR-specific TCRαβ pairs (TRAV1-2/TRBV6-1), engineered 
Jurkat cells expressing full length TCRα and β chains at 24 hours post-transfection were co-
cultured with single antigen cell line (K562-B*57:01) pulsed with 10 and 1µg/mL of the QSR 
peptides (Table 6.2). TCR mediated NFAT signalling was quantified by luciferase luminescence as 
described in Chapter 2 (2.2.5.5). The TCR clone pairs displayed dose-dependent responses to the two 
concentrations of the peptide, and the responses were significantly (P<0.05) higher than the negative 
and unstimulated controls (Fig. 6.5A). This indicated that the reporter assay was specific. 
Since the dominant QSR TCR was also identified as subdominant clone with the VSF specific T cell 
pool, the TCR clone pairs (TRAV1-2/TRBV6-1) were assessed for any cross-reactivity to the 
alternate EBV peptide, VSF. The SAL was pulsed with the two concentrations of VSF peptide, 10 and 
1 µg/mL and co-cultured with the QSR-TCR transfected Jurkat cells. As a transfection control in the 
experiment, TCR independent activation of Jurkat cells using phorbol 12-myristate 13-acetate 
(PMA) plus ionomycin was used. The TCR clone pairs (TRAV1-2/TRBV6-1) displayed no 
response to the VSF peptide (Fig. 6.5B). This shows that the clone pair was specific to QSR epitope 
and displayed no cross-reactivity to VSF. Therefore, the appearance of the same clonotypes of QSR 
(TRAV1-2/TRBV6-1) with VSF may be due to index hopping or sequence bleed, which is a 
common issue in the next generation sequencing (NGS) sequencing. 
 
6.2.5.2 Specificity validation of VSF-TCR 
To determine the specificity of the VSF-TCRs (TRAV12-1/TRBV20-1), SAL was pulsed with 
peptide and co-cultured with the TCR+ Jurkat reporter cells. The VSF-TCR+ Jurkat cells specifically 
responded to K562 cells presenting the VSF peptide in the context of HLA-B*57:01. The TCRs 
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responded in a dose-dependent manner to the two doses (10 and 1 µg/mL) of the peptide tested (Fig 
6.6A).  
To confirm the VSF-TCR response was peptide specific, transfected Jurkat cells were 
incubated with the HLA-matched but TCR mismatched alternate peptide, QSR. No significant 
response was detected with the alternate peptide (Fig. 6.6B) and confirmed the VSF-TCRs 
displayed no cross-reactivity to QSR peptide. 
 
6.2.5.3 Validation of TCR cross-reactivity to ABC modified self-
peptide 
Once the specificity of each dominant TCR clone pair was established, the hypothesis, that 
EBV-specific TCR cross-recognises ABC modified self-peptide, was tested. Jurkat cells 
transfected with QSR-TCR were co-cultured with SAL pulsed with abacavir (10 µg/mL). The 
addition of abacavir to K562-B*57:01 did not activate QSR specific T cell clones (Fig. 6.5C), 
indicating no cross-reactivity of the QSR-TCRs to abacavir modified endogenous-peptides 
presented by K562-B*57:01 cells. Similarly, Jurkat cells transfected with VSF-TCR showed 
no cross-reactivity to K562-B*57:01 cells pulsed with abacavir (Fig. 6.6C). Together, this data 
shows that endogenous self-peptides bound to HLA-B*57:01 in the presence of abacavir were 
not cross-reactive with EBV-specific TCR.  
Conversely, the simultaneous pulsing of SAL with abacavir and QSR peptide induced the TCR 
responses, however, the responses were downmodulated compared to the SAL pulsed with 
only QSR (Fig. 6.5C). Similar responses were observed with VSF-TCR stimulated 
simultaneously with abacavir and VSF peptide (Fig. 6.6C). This shows that abacavir likely 





 Table 6.2. Experimental test conditions in Jurkat assay  
Jurkat reporter cells Stimulus Purpose 
QSR-TCR transfected  
Jurkat cells 
Media  Negative control 
PMA 100 ng/mL and Ionomycin 1000 ng/mL  Transfection control 
SAL with no peptide Unstimulated control 
SAL pulsed with 10 µg/mL of QSR peptide Epitope recognition test 
SAL pulsed with 1 µg/mL of QSR peptide Epitope recognition test 
SAL pulsed with 10 µg/mL of VSF peptide Non-cognate test 
SAL pulsed with 1 µg/mL of VSF peptide Non-cognate test 
SAL pulsed with abacavir 10 µg/mL Cross-recognition test 
SAL pulsed with 10 µg/mL of QSR peptide plus 10 µg/mL of abacavir Altered-self test  
SAL pulsed with 1 µg/mL of QSR peptide plus 10 µg/mL of abacavir Altered-self test   
VSF-TCR transfected  
Jurkat cells 
Media  Negative control 
PMA 100 ng/mL and Ionomycin 1000 ng/mL  Transfection control 
SAL with no peptide Unstimulated control 
SAL pulsed with 10 µg/mL of VSF peptide Epitope recognition test 
SAL pulsed with 1 µg/mL of VSF peptide Epitope recognition test 
SAL pulsed with 10 µg/mL of QSR peptide Non-cognate test 
SAL pulsed with 1 µg/mL of QSR peptide Non-cognate test 
SAL pulsed with abacavir 10 µg/mL Cross-recognition test 
SAL pulsed with 10 µg/mL of VSF peptide plus 10 µg/mL of abacavir Altered-self test   
SAL pulsed with 1 µg/mL of VSF peptide plus 10 µg/mL of abacavir Altered-self test   




Figure 6.5. In vitro validation of QSR-TCR mediated effector signalling in Jurkat assay  
QSR-TCR transfected Jurkat cells were co-cultured with SAL pulsed with (A) QSR peptides (10 and 1µg/mL) (B) PMA-Ionomycin and alternate 
peptide (VSF) at 10 and 1µg/mL (C) abacavir (ABC; 10 µg/mL), ABC+QSR peptide (10 and 1µg/mL). Luciferase luminescence activity was 
represented as absolute light units. The results were presented as mean values from 2 replicates and error bars represent standard error mean (SEM) 





Figure 6.6. In vitro validation of VSF-TCR mediated effector signalling in Jurkat assay  
VSF-TCR transfected Jurkat cells were co-cultured with SAL pulsed with (A) VSF peptides (10 and 1µg/mL) (B) PMA-Ionomycin and alternate 
peptide (QSR) at 10 and 1µg/mL (C) abacavir (ABC; 10 µg/mL), ABC+VSF peptide (10 and 1µg/mL). Luciferase luminescence activity was 
represented as absolute light units. The results were presented as mean values from 2 replicates and error bars represent standard error mean (SEM) 




The identification of abacavir-reactive, pre-existing memory CD8+ T cell responses in HLA-
B*57:01-positive abacavir-naïve healthy donor subjects (Chessman et al., 2008; Lucas et al., 
2015), suggests the heterologous immunity is responsible for AHS. The members of HHV 
family such as EBV that persist for a lifetime, are the possible sources of cross-reactive memory 
T cells because they maintain long-lasting sources of T cell populations. Hence, the present 
study was undertaken in order to confirm the specificity of EBV-specific tetramer positive 
TCRs and to determine if these TCRs would cross react with abacavir plus self-peptide and 
lend support for the heterologous immunity model. For this purpose, the TCR repertoire of the 
peptide-MHC class I (pMHC I) complex specific CD8+ T cells, QSR-HLA-B*5701 and VSF-
HLA-B*5701, were investigated based on tetramer staining followed by direct single-cell 
sorting and sequencing. Sequence analysis revealed multiple potential TCR sequences specific 
for each of the two peptides. In each case, the dominant TCRαβ pair was cloned to confirm 
TCR specificity and test the overall hypothesis that AHS is mediated in part at least by cross 
reactivity of anti-viral specific TCR with self-peptides complexed to drugs and HLA 
molecules. 
The introduction of pMHC I tetramers made possible for the detection and isolation of antigen-
specific T cells on the basis of the specificity of their TCR (Altman et al., 1996). Using PE-
conjugated HLA-B*57:01 tetramers complexed with either VSF or QSR peptides, single cells 
were sorted. The high throughput sequencing of single cells specific to each peptide revealed 
various TCR alpha/beta pairs could recognise QSR or VSF (Table 6.1).  
To determine any culture induced differences in the T cell repertoire, the TCR repertoire of 
QSR-specific T cells in PBMC (Fig. 6.2B; QSR-PBMC) was compared with in vitro expanded 
EBV-specific T cell line (Fig. 6.2B; QSR-T cell line). The data indicated that the dominant 
TRAV/TRBV clone pair was similar in both. Moreover, the subdominant clones were also 
shared. This confirms the TCR repertoire in EBV-specific T cell lines represented that the 
initial repertoire in PBMC. 
By using paired single cell TCRαβ analysis, the TCR repertoire of QSR and VSF specific CD8+ 
T cells were analysed and identified the dominant TRAV-TRBV clonotype pairs. However, 
the dominant clonotype pair specific to QSR (TRAV1-2/TRBV6-1) (Fig. 6.2B; QSR-T cell 
line) was detected as a subdominant pair specific to VSF (Fig. 6.2B; VSF-T cell line). While 
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NGS can analyse millions of sequence reads by sample multiplexing, it can lead to data 
integrity issues due to the effects of index switching or swapping (Costello et al., 2018). To 
investigate whether the clonotypes were cross-reactive or NGS issue, the TCRs were further 
analysed by reconstitution in Jurkat cell line and testing the reactivity of TCRs to alternate 
peptide (section 6.2.5.1). No cross-recognition of the TCRs to the alternate peptide was found 
and hence it was considered as NGS issue, where index hopping and sequence bleed is a 
common issue especially in TCR assay with high clonal population and the products are pooled 
prior to library preparation and sequencing.  
Despite the observation that many potential TCRs recognise the same epitope, a clear 
hierarchical structure was apparent in both the QSR specific and VSF specific repertoire, with 
one or two clonotypes dominating the antigen-specific T cell population Fig. 6.2A. Previous 
work has shown that dominant clonotypes exhibit higher avidity for cognate antigen than 
subdominant clonotypes (Price et al., 2005) and the hierarchy of dominance of individual 
clonotypes was preserved during several years in persistent viruses such as EBV, despite 
fluctuations in frequencies of low-dominant clonotypes (Iancu et al., 2013). Thus, in the present 
study, the dominant clonotype pair was selected for further functional characterisation studies. 
The functionality and specificity of the paired TCRαβ genes in vitro have been studied using 
co-transfection of multiple plasmids encoding TCRα and TCRβ genes isolated from a CTL 
clone, CD8α and an NFAT-luciferase reporter vector (Anmole et al., 2015). However, success 
of this approach requires the successful transfection of multiple plasmids into each cell. 
Therefore, the method was modified, and multiple plasmids were consolidated into a single 
plasmid that can accept variable TCRα and TCRβ pairs (section 6.2.2). An advantage of this 
system was that it is also compatible with Gateway cloning (pAR101; C.2; Appendix C), which avoids 
the search of unique restriction enzymes to clone TCRαβ pairs. This one-plasmid reporter system 
quantifies antigen-specific TCR responses based on NFAT driven luciferase signalling.   
The functionality of the TCRs specific to QSR and VSF peptides were validated using the single 
plasmid system and by reconstitution in Jurkat cells (E6.1). Jurkat T cells transfected with the full 
length TCRα and β chains behave essentially like the original CTL clone in terms of ligand binding 
and signalling properties (Aarnoudse et al., 2002). Hence, to test the hypothesis of the study, TCRs 
were tested for their ability to bind the cognate peptide. The TCRs specific to QSR and VSF tested 
with two concentrations of the cognate peptides, showed dose-dependent responses. However, the 
TCRs specific for QSR and VSF epitopes of EBV were not responsive to the abacavir plus 
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self-peptide and were not cross-reactive. This was not due to lack of TCR function as each 
TCR recognised its cognate ligand (QSR or VSF).  
Interestingly, a reduction of TCR signalling was observed with simultaneous stimulation of 
ABC and the EBV-specific peptides, which could be due to drug mediated inhibition of peptide 
specific responses. A previous study using VSF peptide of EBV showed similar results by 
ELISpot (Lucas et al., 2013), suggesting that under controlled conditions, abacavir may inhibit 
host immunity by binding within the class I molecule. 
In summary, this study identified the TCR repertoire specific for VSF and QSR epitopes in a 
healthy EBV+ donor. The single plasmid TCR reporter system confirmed that EBV-specific 
TCR clonotypes were peptide specific and functional. Although these specific TCRs were not 
cross-reactive with abacavir plus self-peptide, this study provided a method that can be applied 
to study heterologous responses of other TCRs.
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7.1 General discussion 
7.1.1 Overview 
HHVs are ubiquitous pathogens and are known for their ability to establish lifelong infection 
and cellular latency. Among HHVs, EBV is a common persistent virus infecting 95% of the 
adult population worldwide. The reactivation of EBV along with the other HHVs such as 
HHV6/7 and CMV and the development of immune-mediated adverse reactions, suggests the 
role of human herpesviruses in drug hypersensitivity (Aihara et al., 2001; Descamps et al., 
2003; Hashizume and Takigawa, 2005; Picard et al., 2010; Tamagawa-Mineoka et al., 2007). 
AHS was shown to be a CD8+ T cell dependent HLA-B*57:01 restricted process. However, 
45% of those carrying HLA-B*57:01 will tolerate abacavir and it is well established that HLA-
B*57:01 is necessary but not sufficient for AHS. Based on previous structural and functional 
studies, it has been hypothesised that cross-reactive T cells, possibly to common viruses such 
as HHV, cross-react with self-peptides complexed to abacavir and HLA-B*57:01 and cause 
AHS (Lucas et al., 2015; White et al., 2015).  
In this thesis, a highly prevalent HHV, EBV was chosen to test the heterologous immunity 
hypothesis by developing a process that allows comprehensive mapping of the CD8+ T cell 
responses to EBV, specifically for those antigens restricted by the relevant risk allele, HLA-
B*57:01. Little is known about the HLA-B*57:01 restricted responses to EBV; no study has 
comprehensively interrogated genome-wide responses to EBV epitopes restricted by this risk 
allele. Therefore, the initial aim of my work was comprehensive mapping of CD8+ T cell 
responses in EBV seropositive HLA-B*57:01 healthy donors to determine host immune 
responses to EBV. This was achieved in Chapter 4 by identifying novel HLA-B*57:01 
restricted responses to EBV. The major finding of this study was that the CD8+ T cell responses 
focussed particularly to 3 antigens, EBNA3B, EBNA3C, and LMP1. The focus of the next aim 
was to identify HLA-B*57:01 restricted epitopes in the candidate antigens that may provide 
insight into heterologous T cell immunity. Chapter 5 demonstrates the screening of HLA-
B*57:01 restricted epitopes. A novel HLA-B*57:01 restricted EBV epitope was identified in 
EBNA3C. The final aim of my work was to sequence and clone EBV-specific T cell receptors 
and determine if these TCRs can cross-recognise self-peptides when presented in the context 
of HLA-B*57:01 plus abacavir. In Chapter 6, a TCR reporter system was developed whereby 
TCR clonotypes specific for EBV epitopes were identified, and a plasmid system was 
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developed to express and study TCR specific responses in Jurkat cells. Although EBV-specific 
TCRs were not cross-reactive with abacavir plus self-peptide, my work has now provided an 
experimental roadmap that can be applied to study heterologous responses of other TCRs. This 
thesis reports a comprehensive study of HLA-B*57:01 restricted CD8+ T cell responses 
towards EBV antigens, revealed a novel immunodominant CD8+ T cell epitope and developed 
a protocol for TCR identification and cloning for use in defining TCR specificity and as a tool 
for investigating heterologous immunity. 
 
7.1.2 Genome-wide mapping of CD8+ T cell responses in EBV 
positive HLA-B*57:01 healthy donors to determine host 
immune responses to EBV 
EBV establishes lifelong latent infection in the majority of the population worldwide. Most of 
the infections are asymptomatic and CD8+ T cells play an important role in controlling EBV 
infection. At the time this research was initiated, there was no comprehensive understanding 
of CD8+ T cell responses towards EBV antigens. Hence, the first aim of the study was a 
genome-wide mapping of CD8+ T cell responses using the viral gene expression library created 
in Chapter 3. Recently, one study explored a proteome-wide analysis of CD8+ T cell responses 
to 70 EBV lytic antigen proteins (Forrest et al., 2018). However, this study explored CD8+ T 
cell responses to EBV, restricted to a range of HLA alleles, but did not include the abacavir 
risk allele, HLA-B*57:01. Therefore, the present study is, so far, the first study to map HLA-
B*57:01 restricted CD8+ T cell responses to the whole genome. 
The common wild type B95-8 strain of EBV was chosen as the source of EBV ORFs and all 
88 ORFs, with the exception of RPMS1, which proved difficult to clone were included in the 
study. From this library, screening of HLA-B*57:01 restricted CD8+ T cell responses to each 
EBV ORF demonstrated T cell responses were focused predominantly towards latent proteins, 
particularly EBNA3B, EBNA3C and LMP1. These data are consistent with other studies 
demonstrating focussed responses to the EBNA3 family (Khanna et al., 1992; Murray et al., 
1992). However, contrary to previous studies, suggesting only occasional responses to LMP1, 
in the present study the responses to LMP1 were frequent, being observed in 6/6 donors tested, 
though the responses were weak in some donors. Interestingly, this pattern was observed only 
with HLA-B*57:01 (Table 4.3; Chapter 4), no response to LMP1 were seen across the other 
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donor HLA class I alleles (Table 4.4; Chapter 4). 
Several novel responses to both latent and lytic phase expressed proteins were also identified. 
Although, the responses to most of the lytic antigens were weak, many CD8+ T cell responses 
were observed towards late antigens in healthy persistent virus carriers, which reconciles with 
the studies of Rhesus lymphocryptovirus, a gamma herpesvirus that naturally infects Rhesus 
macaques, in which the responses to late proteins may develop over time (Orlova et al., 2011). 
In order to effectively map CD8+ T cell responses, development of a robust antigen presentation 
system that stimulates antigen-specific memory T cells was necessary. Four different 
approaches to the production of EBV-specific T cell lines were compared. In most of the 
previous studies, EBV transformed LCLs have been used for the stimulation of EBV-specific 
T cells (Khanna et al., 1992; Murray et al., 1992; Rickinson et al., 1981). However, many 
researchers argue that LCLs focus T cell expansion toward immunodominant EBV antigens 
(Forrest et al., 2018; Subklewe et al., 2001). Hence to present the full spectrum of antigens, 
alternative APC such as lytically infected B cells (Pudney et al., 2005) or antigen loaded DC 
(Forrest et al., 2018; Subklewe et al., 2001) have been employed. It appears that no study to 
date has compared multiple approaches to determine which methods best captures the full 
repertoire of all EBV T cell targets, across all phases of EBV replication. Therefore, to 
stimulate and enrich EBV-specific CD8+ T cells from the blood of healthy virus carriers and to 
screen these T cell lines for reactivity to EBV proteins, 4 different approaches were developed; 
stimulation with cLCLs, stimulation with lytically induced LCLs, stimulation with moDC plus 
cLCLs and stimulation with moDC plus lyLCLs. 
EBV-enriched T cell lines from all the approaches were responsive to both latent and lytic 
antigens with the dominant responses directed toward latent proteins, specifically EBNA3B, 
EBNA3C and LMP1. In total, across all the donors tested, the lines stimulated and expanded 
using cLCLs recognised 5 EBV antigens, 9 EBV antigens were recognised using EBV-enriched 
lyLCL T cell line, 7 using EBV-enriched moDC plus cLCL T cell line, and 10 using EBV-
enriched moDC plus lyLCL T cell line. Whilst, lytic induction in LCLs increased the responses 
towards lytic proteins, the responses to some latent antigens such as EBNA3B, EBNA3C and 
LMP1 were lost in some donors. The addition of moDC to LCLs allowed the detection of weak 
responses, however responses to some ORFs seen with the lines stimulated with LCLs alone 
were lost. For example, the responses to BNRF1 seen with the lines stimulated with cLCLs 
were lost with the lines from moDC+cLCL. Similarly, responses to BBLF2-BBLF3 which 
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were strong in the T cell lines produced by exposure to lytically induced LCL were absent in 
the T cell lines when moDC were added to the lytically induced LCL (Table 4.3). This was 
also observed with other HLA restricted responses in some donors (Table 4.4). The reason why 
responses to specific ORFs were lost with the addition of moDC is not clear but may relate to 
the mode of antigen delivery. The mode of antigen delivery to DCs can impact the antigen 
processing mechanisms and thereby can influence the selection of cross-presented peptides 
(Robson et al., 2010). The approach used in the present study to stimulate EBV-specific CD8+ 
T cell responses was similar to the one used to stimulate CD8+ T cell responses to HSV-1, 
where moDC were loaded with UV irradiated HSV-I infected HeLa cells and co-cultured with 
donor CD8+ T cells for 20 hours. Similarly, in the present study, moDC were cocultured with 
gamma irradiated autologous LCLs and donor’s CD8+ T cells for 20 hours. However, studies 
by Forrest et al., (2018) showed the sorting of activated T cells based on CD137 upregulation 
was optimal on day 3 of coculture, which is longer than the HSV system. In that study, authors 
reasoned the use of cell free extracts as an antigen source compared to the irradiated virus 
infected cells in HSV study delayed the activation. However, in the present study, some 
antigens but not others were cross presented, which implies that different antigens have 
different pathways (Fiebiger et al., 2012). Short lived proteins and defective ribosomal products 
(DRiPs) that are rapidly degraded via proteasome are not efficiently cross-presented; however, 
long-lived proteins or DRiPs that accumulate in autophagosomes could then be delivered to 
DCs for cross-presentation if fusion with lysosomes was blocked (Li et al., 2008). This shows, 
in the present study that the short-lived proteins may be effectively presented by LCLs but not 
cross presented by moDC. However, the reason why antigen was recognised from LCLs alone 
but not after the addition of moDC to LCLs remains unclear. In both the systems LCLs were 
present but the addition of DCs appeared to inhibit the activation of particular T cell clones.  
Overall, this is the first study that surveyed genome wide screening of HLA-B*57:01 restricted 
CD8+ T cell responses to EBV and identified 14 novel antigens along with the 3 previously 
identified antigens. The comparison of approaches that effectively stimulated antigen-specific 
T cells showed the lytic induction in LCLs increased the detection of CD8+ T cell responses to 
lytic proteins, however, responses to latent proteins were lost in some donors. Similarly, whilst 
the addition of moDC to LCLs has allowed the detection of some weak antigens via cross 
presentation, it lost some responses that were seen with LCLs alone. Therefore, it is not clear 
from this study that the cross presentation of moDC significantly improved genome wide 
screening of T cell responses to EBV. 
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7.1.3 Identification of HLA-B*57:01 restricted epitopes in the 
candidate antigens 
Antigenic peptides presented by MHC class I molecules and recognised by virus specific CTLs 
are important tools in studying heterologous immune responses in drug hypersensitivity 
patients. Precise identification of such peptides is a high priority. The second aim of the study 
was to identify HLA-B*57:01 restricted epitopes in the 3 most frequent target antigens 
identified in Chapter 4. 
The ORFeome wide screening of HLA-B*57:01 restricted CD8+ T cell responses to EBV in 
healthy donors identified typically strong responses directed towards 3 EBV genes, EBNA3B, 
EBNA3C and LMP1 in most of the donors tested. Previous studies have identified 
VSFIEFVGW epitope in EBNA3B (Lee et al., 2000) and IALYLQQNW in LMP1 
(Duraiswamy et al., 2003). This study identified a novel epitope, QSRGDENRGW, whose 
optimal length was mapped to amino acid position 60-69 of the nuclear protein, EBNA3C. This 
QSR peptide typically induced robust IFN-γ responses from all T cell lines. These data suggest 
that the precursor frequency of QSR specific memory T cells are high in the blood or had been 
artificially amplified under the culture conditions used. To explore this in more detail, the 
frequency of QSR specific T cells was determined within the PBMCs of healthy EBV+ donors. 
In parallel, precursor frequencies of T cells specific for EBNA3B (VSF), LMP1 (IAL), EBNA2 
(LAS), and EBNA1 (LSR) were also assessed by IFN-γ ELISpot. In each donor, where the 
responses to QSR-epitope were detected, IFN-γ responses were typically higher than that seen 
for other epitopes, suggesting the precursor frequencies for this epitope are high in the blood 
of patients, which was confirmed with the tetramer staining on a single patient. However, not 
all individuals responded to QSR (65%), while responses to the VSF epitope was found in all 
donors. Responses to the IAL epitope were seen in 45% of individuals, 10% of individuals 
made responses to the LSR epitope, T cells specific for the LAS epitope were not identified in 
any patients. These responses were similar to that seen for the full-length antigen-specific 
responses for EBNA3C and EBNA3B using T cell lines by IFN-γ ELISA in Chapter 4. 
However, for LMP1 the responses were detected in all donors using T cell lines but not with 
LMP1 derived IAL epitope in the blood, which suggest low precursor memory T cells and that 




7.1.4 Identification, isolation, and characterisation of EBV-
specific T cell receptors to determine if these TCRs could 
cross-recognise self-peptides when presented in the 
context of HLA-B*57:01 plus abacavir 
CD8+ T cells express αβ TCRs on the cell surface and play a central role in the adaptive immune 
response by recognising peptides bound to MHC class I molecules (Starr et al., 2003). The αβ 
TCR chains are highly variable proteins with the random assembly of V(D)J recombination 
capable of producing hundreds of trillion of unique αβ TCR molecules (Burrows and Miles, 
2013). The mathematical estimated potential TCR diversity is huge compared to the actual size 
of the naïve TCRαβ repertoire (Turner et al., 2006). Hence, to provide sufficient coverage 
against the huge constellation of pMHC complexes with pathogens and environmental 
antigens, TCRs can exhibit a high degree of cross reactivity (Burrows and Miles, 2013). The 
current study was established to explore the hypothesis that cross-reactive anti-viral T cells 
recognise self-peptides complexed to drugs and HLA molecules and drive drug 
hypersensitivity. So, the final aim of the study was the identification, isolation, and 
characterization of epitope specific TCRs to determine if EBV-specific T cell would recognise 
abacavir plus self-peptide (Chapter 6). 
TCR is a critical element that defines antigen recognition, which binds viral peptides presented 
by MHC class I molecules on infected cells. Therefore, the level of TCR focussing to the novel 
epitope in persistent virus carriers was determined. Using tetramer based single cell sorting, 
CD8+ T cells specific for QSR were sorted and sequenced through NGS. The QSR specific T 
cells were sorted from a T cell line and from PBMC, the latter to determine if T cell cloning 
and expansion had altered or skewed the T cell repertoire. There were no obvious differences 
in the TCR repertoires between the expanded T cell lines and PBMC and the dominant 
clonotype pair was similar in both. The TCR repertoire analysis specific to QSR epitope 
demonstrated a dominant TRAV1-2/TRBV6-1 pair along with variable numbers of low 
abundance clonotypes, which is in line with the EBV epitope, GLC-specific CD8+ TCRαβ 
repertoire in healthy donors, the number of unique epitope specific TCRα and TCRβ clonotypes 
ranged from 7-12 per subject (Nguyen et al., 2017). 
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TCR clonotypes may become dominant during T cell differentiation (Iancu et al., 2009) or over 
the course of infection (Annels et al., 2000). The hierarchy of dominance of individual 
clonotypes was preserved during several years in persistent viruses such as EBV, despite 
fluctuations in frequencies of low-dominant clonotypes (Iancu et al., 2013). Therefore, in the 
present study, the dominant clonotype pairs specific to QSR or VSF were selected for further 
functional characterisation studies. 
This study took advantage of the availability of TCR based reporter cell assay by Anmole et 
al. (2015) for functional characterisation of EBV-specific TCRs. In that assay, the authors used 
co-transfection of multiple plasmids encoding TCRα and TCRβ genes isolated from a CTL 
clone, CD8α and an NFAT-luciferase reporter vector. However, the success of the approach 
depends on multiple plasmids successfully transfecting each cell. In the present study, the 
method was modified to allow transfection of a single plasmid expressing all of the required 
components of the previous TCR assay.  
By co-culture of Jurkat cells expressing the full length TCRs in the single plasmid system with 
single antigen line (SAL) expressing HLA-B*57:01 and pulsed with EBV peptides, the TCRs 
were confirmed to be specific to their relevant peptides and functional. The main hypothesis of 
this study was that memory T cells specific for common human pathogens, such as EBV cross 
react with HLA-B*57:01 abacavir plus self-peptide. In 55% of the patients carrying the risk 
allele, HLA-B*57:01, abacavir treatment causes AHS, characterised by fever, malaise, 
gastrointestinal, and/or respiratory symptoms (Mallal et al., 2008). AHS has been explained by 
the altered peptide repertoire model; the drug binds with the F-pocket in the peptide binding 
groove of HLA-B*57:01 altering the chemistry of the binding cleft and thereby the peptide 
specificity. Hence, the peptides presented in this context are recognized as “foreign” by the 
immune system and elicit a T cell response (Illing et al., 2012; Norcross et al., 2012; Ostrov et 
al., 2012). But why some patients carrying a known HLA risk allele tolerate the culprit drug is 
not known. The findings of abacavir reactive CD8+ T cells not only in AHS patients but also 
in abacavir-naïve HLA-B*57:01 positive donors strongly suggest a role for pre-existing 
memory T cells, rather than naïve T cells as a driver of disease (Adam et al., 2014; Chessman 
et al., 2008; Lucas et al., 2015). The heterologous immunity model has been developed to 
explain the hypothesis that cross-reactive T cells, possibly to common viruses such as HHV, 




Two EBV-specific TCRs, specific for QSR and VSF, were tested for recognition of abacavir 
plus self-peptide using K562-B*57:01 SAL. The third peptide, IAL, was excluded in this study 
because abacavir specific CD8+ T cells were not activated by C1R.B57 loaded IAL peptide 
(Chessman et al., 2008). Whilst the QSR and VSF specific TCRs retained specificity for the 
original EBV epitope, they failed to recognise SAL-HLA-B*57:01 plus abacavir. My 
preliminary work suggests that neither of the TCRs tested drive the T cell pathology in AHS 
patients. However, as the TCR repertoire is shaped by the lifelong history of infections in an 
individual, the patterns of cross reactivity may be altered upon sequential infections with 
heterologous viruses (Brehm et al., 2003). Hence, it can be postulated that the pattern of peptide 
recognition may be different and that only some individuals have a T cell clonotype able to 
respond to the neo-antigen. In the present study, EBV-specific TCR repertoire was sequenced 
in a single healthy HLA-B*57:01+ donor, which limits the interpretation of this data. The TCR 
repertoire that recognise EBV-specific epitopes might be different in AHS patients. Therefore, 
sequencing of EBV-specific repertoire in AHS patient samples and testing the predominant 
TCR clonotypes shared by the patients for heterologous immune responses to self-peptide in 
the presence of abacavir might provide further insights.  
 
7.1.5 Conclusions, limitations and future research 
In this thesis, ORFeome wide screening of CD8+ T cell responses to EBV identified several 
novel HLA-B*57:01 restricted antigens and showed that the three latent antigens, EBNA3B, 
EBNA3C, and LMP1 were frequent and dominant targets of the immune response. However, 
the dominance patterns with other HLA class I alleles was different. The responses to EBNA3 
family antigens were detected in at least 1 donor and no responses were detected towards LMP1 
in the donors tested in this thesis. Beyond the context of this study, these findings emphasise 
the importance of selecting the appropriate antigens when developing EBV vaccines to prevent 
primary infection or EBV-associated diseases, or therapeutic vaccines to treat EBV 
malignancies. Furthermore, this data will add value to the current knowledge of CD8+ T cell 
responses to EBV in donors carrying the HLA-B*57:01 risk allele. This study also detected a 
novel HLA-B*57:01 restricted epitope in an immunodominant antigen, EBNA3C. 
The comparison of four different approaches to the production of EBV-specific T cell lines 
detected distinct patterns of CD8+ T cell responses to EBV ORFs. The approach that used 
lytically induced LCLs increased the detection of CD8+ T cell responses to lytic proteins, 
162 
 
however, responses to latent proteins were lost in some donors. Similarly, the addition of 
moDC to LCLs allowed the detection of weak responses, nonetheless, some responses that 
were seen with LCLs alone were lost. In both the systems LCLs were present and the reason 
why the responses were lost with the addition of moDC remains unclear. Further studies should 
be done to understand the processing of antigen and what inhibits the activation of particular T 
cell clones with the addition of moDC. 
Preliminary experiments conducted with the single plasmid TCR reporter system developed in 
this study confirmed that two EBV-specific TCR clonotypes retained specificity for the original 
EBV epitope. However, these EBV specific TCRs failed to cross recognise self-peptide in the 
presence of abacavir. It is noteworthy that the TCR was isolated from a single healthy donor. 
Further studies with a larger EBV+ cohort will help to define the heterogeneity of the EBV 
specific TCRs. Importantly, it will be necessary to determine if the repertoire of EBV-specific 
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Appendix A Supplementary data of Chapter 3 
A.1 List of ORFs cloned into an expression vector, 
pDEST103 
Table App A.1. A list of 88 EBV ORFs used in the present study.  
  EBV ORF start (AA) end (AA) length (AA) FL (AA) Class 
1 LMP2A 1 497 497 497 Latent 
2 LMP2B 1 378 378 378 Latent 
3 BNRF1 1 1318 1318 1318 Late 
4 BCRF1 1 170 170 170 Late 
5/6 BCRF2/BWRF1 1 383 383 383 Unknown 
7 EBNA-LP 1 236 236 506 Latent 
8 BYRF1/EBNA2 1 487 487 487 Latent 
9 BHLF1 1 660 660 660 Early 
10 BHRF1 1 191 191 191 Early 
11 BFLF2 1 318 318 318 Early 
12 BFLF1 1 525 525 525 Early 
13 BFRF0.5/BFRF1A 1 135 135 135 Unknown 
14 BFRF1 1 336 336 336 Early 
15 BFRF2 1 591 591 591 Early 
16 BFRF3 1 176 176 176 Late 
17 
BPLF1_D10  1  1000  1000  3149 
Late 
BPLF1_D7 501   1500  1000  3149 
BPLF1_D8 1001 2000 1000 3149 
BPLF1_D9 1501 2500 1000 3149 
BPLF1_A5 2001 3000 1000 3149 
BPLF1_A1 2491 3149 659 3149 
18 
BOLF1_F1 1 400 400 1239 
Late BOLF1_F2 201 600 400 1239 
BOLF1_E4 573 1239 667 1239 
19 BORF1 1 364 364 364 Late 
20 BORF2 1 826 826 826 Early 
21 BaRF1 1 302 302 302 Early 
22 BMRF1 1 404 404 404 Early 
23 BMRF2 1 357 357 357 Late 
24 BMLF1 42 479 438 479 Early 
25 BSLF2+BMLF1 1 479 479 479 Early 
26 BSLF1 1 874 874 874 Early 
27 BSRF1 1 218 218 218 Late 
175 
28 BLLF3 1 278 278 278 Early 
29 BLRF1 1 102 102 102 Late 
30 BLRF2 1 162 162 162 Late 
31 BLLF2 1 148 148 148 Early 
32 BLLF1 1 907 907 907 Late 
33 EBNA3A 1 944 944 944 Latent 
34 EBNA3B 1 938 938 938 Latent 
35 EBNA3C 1 992 992 992 Latent 
36 BZLF2 1 223 223 223 Late 
37 BZLF1 1 245 245 245 IE 
38 BRLF1 1 605 605 605 IE 
39 BRRF1 1 310 310 310 Early 
40 BRRF2 1 537 537 537 Late 
41 
BKRF1_D4/EBNA1 1 89 89 641 Latent 
BKRF1_C8/EBNA1 379 641 263 641 Latent 
42 BKRF2 1 137 137 137 Late 
43 BKRF3 1 255 255 255 Early 
44 BKRF4 1 217 217 217 Late 
45 BBLF4 1 809 809 809 Early 
46 BBRF1 1 613 613 613 Late 
47 BBRF2 1 278 278 278 Late 
48 BBLF2-BBLF3 1 723 723 723 Early 
49 BBRF3 1 405 405 405 Late 
50 BBLF1 1 75 75 75 Late 
51 BGLF5 1 470 470 470 Early 
52 BGLF4 1 429 429 429 Early 
53 BGLF3.5 1 153 153 153 Early 
54 BGLF3 1 332 332 332 Early 
55 BGLF2 1 336 336 336 Late 
56 BGLF1 1 507 507 507 Late 
57 BDLF4 1 225 225 225 Early 
58 BGRF1 1 312 312 690 Late 
59 BDRF1 1 378 378 690 Late 
60 BDLF3 1 234 234 234 Late 
61 BDLF2 1 420 420 420 Late 
62 BDLF1 1 301 301 301 Late 
63 BcLF1 1 1381 1381 1381 Late 
64 BcRF1 1 750 750 750 Early 
65 BTRF1 1 404 404 404 Late 
66 BXLF2 1 706 706 706 Late 
67 BXLF1 1 607 607 607 Early 
68 BXRF1 1 248 248 248 Late 
69 BVRF1 1 570 570 570 Late 
176 
70 BVLF1 1 272 272 272 Early 
71 BVRF2 1 605 605 605 Late 
72 BdRF1 1 345 345 345 Late 
73 BILF2 1 248 248 248 Late 
74 LF3 1 142 142 924 Early 
75 LF2 1 429 429 429 Early 
76 LF1 1 469 469 469 Late 
77 BILF1 1 312 312 312 Late 
78 BALF5 1 1015 1015 1015 Early 
79 BALF4 1 857 857 857 Late 
80 A73 1 126 126 126 Unknown 
81 BALF3 1 789 789 789 Early 
82 BARF0 1 471 471 471 Unknown 
83 BALF2 1 1128 1128 1128 Early 
84 BALF1 1 220 220 220 Early 
85 BARF1 1 221 221 221 Early 
86 BNLF2b 1 98 98 98 Early 
87 BNLF2a 1 60 60 60 Early 
88 LMP1 1 386 386 386 Latent 
Highlighted panels indicate expression vectors for those ORFs were newly generated in 
this study. Start and end represents the starting and end amino acids of each ORF or ORF 
fragment cloned into an expression vector respectively. Length represents the length of 
the ORF or ORF fragment. The actual full length and the gene class of each ORF where 
clearly established is also listed. FL, full length; AA, amino acid 
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A.2 EBV ORF clones confirmed through Sanger sequencing 
Table App A.2. The protein sequences of 88 EBV ORFs cloned into an expression vector and confirmed through Sanger sequencing  




















































































































































































































































































































































GA repeat region (Excluded this region) 
BKRF1 329-378 



























































































































































































































































































The length of amino acid sequence of each ORF cloned into an expression vector and the translated Sanger sequences of each ORF was listed. AA – amino acid. 
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Appendix B Supplementary data of Chapter 4 
B.1 Representative IFN-γ standard curve measured at 
450nM wavelength using DTX 880 multimode 
detector 
The relationship between absorbance and serial dilutions of the human recombinant IFN-
γ ELISA standard starting from 800 pg/mL down to 12.5 pg/mL were plotted on 
standard IFN-γ curve after subtracting the mean absorbance value of the blank wells. 
The sample concentrations were calculated using the standard curves in GraphPad 
Prism® Version 5 Software GraphPad. 
 
Figure App B.1. Representative IFN-γ standard curve. The standard curve was plotted 
with serial dilutions of the human recombinant IFN-γ ELISA standard starting from 
800 pg/mL down to 12.5 pg/mL. The sample absorbance was translated into 
concentrations by the use of standard curves in GraphPad Prism® Version 5 
Software (GraphPad Software Inc., San Diego, Calif, U.S.A.).























IFN-γ standard concentration (pg/mL)
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B.2 Reactivity of each EBV-enriched T cell line and their controls with autologous LCLs by IFN-
γ intracellular staining (six pages) 
 
                                              
 
 
Figure App B.2. (A) Gating strategy of CD8+ polyclonal population by ICS. The gating strategy involved first identifying the lymphocyte population 



























































Figure App B.2. (B) IFNγ+ expression of CD8+ polyclonal population by ICS (Six pages). Dot plots of intracellular IFNγ+ expression of CD8+ 
polyclonal population after exposure to autologous LCLs. These data are the basis for Table 4.2. Each page shows results from a distinct participant from 
Table 2.3; Chapter 2. Each dot-plot shows expression of CD8+ and intracellular IFN-γ. The numbers in the upper right quadrants of each dot-plot are the 
percentages of cells.
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B.3 IFN-γ release by EBV-enriched cLCL line in 
Donor4 
No CD8+ reactivity to EBV ORFs was observed with the EBV-enriched cLCL line of 
Donor 4. Therefore, the line was tested with other donor HLA alleles to confirm the line 
was functional. The IFN-γ secretion measured after co-culture of polyclonal CD8+ T cells 
with Cos7 cells individually expressing each EBV ORF in combination with HLA-




Figure App B.3. IFNγ release by EBV-specific line stimulated and expanded with conventional LCLs in Donor 4.  
 
 
IFN-γ secretion was measured after co-culture of polyclonal CD8+ T cells with Cos7 cells individually expressing each EBV ORF in combination with HLA-A*01:01 or HLA-B*07:02 alleles. 
EBV ORFs were arrayed along the x-axis in the order of their location on the EBV genetic map. IFN-γ release in pg/mL was extrapolated from standard curves as described in Chapter 2 
(section 2.2.3.12). The IFN-γ release less than the lowest IFN-γ standard used in the study, 12.5pg/mL, was graphed at 0. Blue and green bars represent IFN-γ release from each duplicate 
transfection.  
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Appendix C Supplementary data of Chapter 6 
C.1 pAR100 map and sequence 
C.1.1 pAR100 map 
 
 




















































































































C.2 pAR101 map and sequence 
C.2.1 pAR101 map 
 
 




C.2.2 pAR101 sequence 
AATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCAT
AGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCC
CAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAAT
AATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCC
AGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTTAGTCCT
GTTCCTCAGCTACAAAATGGACACAATTTCCAGCAGGGTCTCTGAGGGCAAATTCCCTTCCCCAAGGTTGTTCACCAATTTCT
GTCATGGCTGGGCCAGAGGCATCCCTGAAATTTGTGCTGACTACTTCTGACCATTCTGCATAAAGCTCATCTAGGCCTCTGAC
CCAGACCCAAGCAAGGGTGTTGTCAGGGACAACTTGGTCCTGAACTGCTGAGATGAAGAGGGTGACATCATCTCTGACAACA
CCAGCAAAATCATCTTCAACAAAGTCTCTGGAGAATCCTAATCTGTCAGTCCAGAACTCTACAGCCCCTGCAACATCCCTTGC
TGTGAGGACTGGGACTGCAGAAGTGAGTTTGGCCATGATGGCTCCTCCTGTCAGGAGAGGAAAGAGAAGAAGGTTAGTACA
ATTGCTATAGTGAGTTGTATTATACTATGCTTATGATTAATTGTCAAACTAGTGGGTTCATAGTGCCACTTTTCCTGCACTGCC
CCATCTCCTGCCCACCCTTTCCCAGGCATAGACAGTCAGTGACTTACCCTTGTACAGCTCATCCATTCCCAGAGTAATTCCTG
CTGCTGTCACAAACTCCAGGAGGACCATGTGGTCTCTTTTCTCATTAGGGTCTTTGGACAGAGCAGATTGAGTGCTGAGATAG
TGATTATCTGGGAGGAGAACTGGGCCATCACCAATAGGGGTGTTCTGCTGGTAATGGTCTGCCAGTTGGACAGATCCATCCT
CAATGTTGTGTCTAATCTTGAAATTAGCCTTAATTCCATTCCTCTGCTTATCTGCCATAATGTAAACATTGTGAGAATTATAGT
TGTACTCCAGCTTGTGACCCAGAATGTTTCCATCTTCCTTAAAATCAATGCCTTTCAGCTCAATTCTGTTAACCAGTGTATCAC
CTTCAAACTTCACTTCTGCCCTTGTCTTATAATTTCCATCATCCTTAAAGAAGATTGTCCTCTCCTGAACATAACCTTCTGGCA
TTGCAGATTTAAAGAAGTCATGCTGCTTCATGTGGTCAGGGTATCTGCTGAAACATTGAACACCATAAGTCAGGGTGGTCAC
CAGAGTTGGCCAAGGCACTGGCAGCTTTCCTGTTGTACAAATGAACTTCAGAGTCAGCTTTCCATAAGTTGCATCTCCTTCAC
CTTCACCAGACACAGAGAATTTGTGGCCATTCACATCACCATCCAGCTCAACCAGAATTGGGACAACACCAGTAAAGAGTTC
TTCTCCCTTAGAAACCATGGTGGCTTGGATCTGTAACGGCGCAGAACAGAAAACGAAACAAAGACGTAGAGTTGAGCAAGC
AGGGTCAGGCAAAGCGTGGAGAGCCGGCTGAGTCTAGGTAGGCTCCAAGGGAGCGCCGGACAAAGGCCCGGTCTCGACCTG
AGCTTTAAACTTACCTAGACGGCGGACGCAGTTCAGGAGGCACCACAGGCGGGAGGCGGCAGAACGCGACTCAACCGGCGT
GGATGGCGGCCTCAGGTAGGGCGGCGGGCGCGTGAAGGAGAGATGCGAGCCCCTCGAAGCTGATCTGACGGTTCACTAAAC
GAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGA
AAGTCCCGTTGATTTACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACC
GCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGT
AGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTT
GGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTAT
TGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACC
GTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCG
CGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCC
GACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT
ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTC
GCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAAC
CCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACA
GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATT
ACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTT
AAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTG
TTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGT
CCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGC
ACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAAC
TGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGA
ACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGC
CCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCA
CGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGG
206 
CGCCTACCTGAGATCACCGGTCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCA
GGCCGAGCCAGTTCCGGGTGTCGCCGCTGGATCGGACCTGGAACCTGGGCGAGACAGTGGAGCTGAAGTGCCAGGTGCTGC
TGTCCAACCCGACGTCGGGCTGCTCGTGGCTCTTCCAGCCGCGCGGCGCCGCCGCCAGTCCCACCTTCCTCCTATACCTCTCC
CAAAACAAGCCCAAGGCGGCCGAGGGGCTGGACACCCAGCGGTTCTCGGGCAAGAGGTTGGGGGACACCTTCGTCCTCACC
CTGAGCGACTTCCGCCGAGAGAACGAGGGCTACTATTTCTGCTCGGCCCTGAGCAACTCCATCATGTACTTCAGCCACTTCGT
GCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCC
CTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCT
ACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACCGA
AGACGTGTTTGCAAATGTCCCCGGCCTGTGGTCAAATCGGGAGACAAGCCCAGCCTTTCGGCGAGATACGTCCTTAAGCTTG
GTACCACAAGTTTGTACAAAAAAGCTGAACGAGAAACGTAAAATGATATAAATATCAATATATTAAATTAGATTTTGCATAA
AAAACAGACTACATAATACTGTAAAACACAACATATCCAGTCACTATGGCGGCCGCTAAGTTGGCAGCATCACCCGACGCAC
TTTGCGCCGAATAAATACCTGTGACGGAAGATCACTTCGCAGAATAAATAAATCCTGGTGTCCCTGTTGATACCGGGAAGCC
CTGGGCCAACTTTTGGCGAAAATGAGACGTTGATCGGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTA
CCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCG
TTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAG
CTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCT
GATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACC
GTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTC
GCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATC
CCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATAT
TATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTCTGTGATGGCTTCCATGTCGGCAGAA
TGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAACGCGTGGATCCGGCTTACTAAAAGCCAGAT
AACAGTATGCGTATTTGCGCGCTGATTTTTGCGGTATAAGAATATATACTGATATGTATACCCGAAGTATGTCAAAAAGAGG
TGTGCTATGAAGCAGCGTATTACAGTGACAGTTGACAGCGACAGCTATCAGTTGCTCAAGGCATATATGATGTCAATATCTC
CGGTCTGGTAAGCACAACCATGCAGAATGAAGCCCGTCGTCTGCGTGCCGAACGCTGGAAAGCGGAAAATCAGGAAGGGAT
GGCTGAGGTCGCCCGGTTTATTGAAATGAACGGCTCTTTTGCTGACGAGAACAGGGACTGGTGAAATGCAGTTTAAGGTTTA
CACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCCGGGCGACGGATGGTG
ATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCT
GGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCAGCCACCGCGAAAA
TGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCTCCCTTATACACAGCCAGTCTGCAGGTCGA
CCATAGTGACTGGATATGTTGTGTTTTACAGTATTATGTAGTCTGTTTTTTATGCAAAATCTAATTTAATATATTGATATTTAT
ATCATTTTACGTTTCTCGTTCAGCTTTCTTGTACAAAGTGGTGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCC
GGCGCGCCCGTACGGTATACTCGCGACTGCAGCCGCGGTAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAG
TGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAA
CAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTG
GTATGGAATTCGGTACCGAGCTCTTACGCGTGCTAGCGGAGGAAAAACTGTTTCATACAGAAGGCGTAGATCTAGACTCTAG
AGGGTATATAATGGAAGCTCGAATTCCAGCTTGGCATTCCGGTACTGTTGGTAAAAAGCTTGGCATTCCGGTACTGTTGGTAA
AGCCACCATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTGGAAGATGGAACCGCTGGAGAGCA
ACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGGACATCACT
TACGCTGAGTACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAATCGTCG
TATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGAC
ATTTATAATGAACGTGAATTGCTCAACAGTATGGGCATTTCGCAGCCTACCGTGGTGTTCGTTTCCAAAAAGGGGTTGCAAA
AAATTTTGAACGTGCAAAAAAAGCTCCCAATCATCCAAAAAATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCA
GTCGATGTACACGTTCGTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTGCCAGAGTCCTTCGATAGGGACA
AGACAATTGCACTGATCATGAACTCCTCTGGATCTACTGGTCTGCCTAAAGGTGTCGCTCTGCCTCATAGAACTGCCTGCGTG
AGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGGATACTGCGATTTTAAGTGTTGTTCCATTCCATCAC
GGTTTTGGAATGTTTACTACACTCGGATATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTT
TCTGAGGAGCCTTCAGGATTACAAGATTCAAAGTGCGCTGCTGGTGCCAACCCTATTCTCCTTCTTCGCCAAAAGCACTCTGA
TTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGGTGGCGCTCCCCTCTCTAAGGAAGTCGGGGAAGCGGTTGCC
AAGAGGTTCCATCTGCCAGGTATCAGGCAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAGGGGG
207 
ATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTGTGGATCTGGATACCGGGAAAACGCTGGG
CGTTAATCAAAGAGGCGAACTGTGTGTGAGAGGTCCTATGATTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCC
TTGATTGACAAGGATGGATGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCATCGTTGACCGCC
TGAAGTCTCTGATTAAGTACAAAGGCTATCAGGTGGCTCCCGCTGAATTGGAATCCATCTTGCTCCAACACCCCAACATCTTC
GACGCAGGTGTCGCAGGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGA
TGACGGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGG
ACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGA
AAGATCGCCGTGTAATTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAA
CCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGC
AATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGT
AAAACCTCTACAAATGTGGTAAAATCGATAAGGATCCGTCGACG 
 
 
 
